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Transition metal complexes have played a critical role in antitumor therapy with many 
complexes incorporating platinum, ruthenium, and lanthanum having been investigated in 
preclinical and clinical trials. The best known transition metal therapeutic is cisplatin, which is 
utilized in nearly 50% of all cancer therapies, despite its significant toxic side effects. The toxic 
side effects of current FDA approved platinum-based chemotherapeutics are often overlooked due 
to the “special status” granted to these drugs due to their ability to fight, what is often considered 
an incurable disease with life expectancies often measured in months. Oncology drug development 
has therefore now focused on developing new complexes with less toxicity and which inhibit 
cancer cell growth by different mechanisms of action when compared with platinum-based 
therapeutics.  
Understanding exactly how a biological agent elicits its observed activity is perhaps the 
most critical step in drug discovery and is a question left unanswered by many. Take for instance 
NAMI-A and KP1019, both Ru(II)-based chemotherapeutics currently in clinical trials, despite 
their unsolved mechanisms of action. Detailed mechanistic investigations have the potential to 
inform the design of next generation chemotherapeutics. Therefore, in the first half of this thesis, 
we investigated the mechanisms of actions of some transition metal complexes incorporating 
Co(III), Ru(II), and/or V(IV) metal centers. Utilizing spectroscopic, biophysical, and molecular 





calorimetry, and flow cytometry, we investigated the ability of these unique transition metal 
complexes to interact with CT DNA, inhibit cellular proliferation in mammary breast cancer cells, 
and modify cell signaling pathways. This information provides valuable insight into the potential 
mechanism of action of these compounds, which is expected to be different for each unique 
molecular structure. Additionally, a novel localized ablation technique involving a transition metal 
therapeutic and nanosecond pulsed electric field technology was developed and investigated. In 
the second half of this thesis, we focused attention on the development of new ligands and 
complexes which can be screened for their potential chemotherapeutic activity. Using simple, 
clean, and efficient organic and inorganic reactions small libraries of molecules were synthesized 
and characterized using a variety of spectroscopic techniques including: 1H, 13C, and 19F NMR 
spectroscopy, high resolution mass spectroscopy, and X-ray crystallography, where appropriate. 
From this work a new potential lead molecule(s) may be identified which may show enhanced 
chemotherapeutic activity. Additionally, structurally similar ligands and complexes will lead to 
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Δm    mitochondrial membrane potential  
Ac-DEVD-AMC N-Acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin 
CHCl3   chloroform 
CT DNA  calf thymus DNA 
DMEM  Dulbecco’s modified eagle’s medium 
DMF   dimethylformamide 
DMSO   dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
EB   ethidium bromide 
ECT   electrochemotherapy 
EDTA   ethylenediamine tetracetic acid 
EF50   half maximal inhibitory electric field 
EtOH   ethanol 
ESI MS  electrospray ionization mass spectroscopy 
FBS   fetal bovine serum 
FT IR   Fourier transform infrared resonance spectroscopy 
H2AX   histone 2.AX 
HCl   hydrochloric acid 
IC50   half maximal inhibitory concentration 
ITC   isothermal titration calorimetry 
IRE   irreversible electroporation 
Kapp    binding constant 





Kq    quenching constant  
MeATSC  9-anthracenethiosemicarbazone 
MeCN   acetonitrile 
MeOH   methanol 
MHz   megahertz 
NMR   nuclear magnetic resonance 
ns   nanosecond 
nsPEF   nanosecond pulse electric field 
PBS   phosphate buffered saline 
PCA   pyridine-2-thiocarboxamide 
PDT   photodynamic therapy  
phen   1,10-phenanthroline 
oda   2,2’-oxydiacetate  
RBF   round bottom flask 
RCD   regulated cell death 
RNA   ribonucleic acid 
sal-L-tryp   N-salicylidene-L-tryptophanate 
TLC   thin layer chromatography  
TMRE   tetramethylrhodamine methyl ester 
TSC   thiosemicarbazone 
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BIOINORGANIC CHEMISTRY: METALS IN MEDICINE 
Metal ions play pivotal roles in a plethora of biological processes,1and the study of the 
roles of these metal ions in biological systems falls into the rapidly developing interdisciplinary 
field known as bioinorganic chemistry. When compared to other branches of natural sciences, 
bioinorganic chemistry seems to be a young discipline, however, there is a copious amount of 
information on the effects of metals on biological systems. For instance, the hazardous toxicities 
of metal ions such as mercury, lead and chromium on the environment have been well publicized.1 
While on the other hand, it is know that some metals such as iron, copper and zinc are absolutely 
required to support life as we know it.2, 3 Scientists in this field are exploiting the unique properties 
of “toxic” metals such as arsenic, gadolinium, platinum, and technetium, to develop metal 
complexes that can be employed as therapeutic and diagnostic agents.3, 4 The introduction of metal 
ions into a biological system for the treatment or diagnosis of diseases is just one of the many 
subdivisions within the field of bioinorganic chemistry.  
While the field of bioinorganic chemistry is considered by many to be a relatively new 
field, this is contrary to historical fact, which has shown that metals were used in potions which 
trace back to the ancient civilizations of Mesopotamia, Egypt, India, and China.5-8 Many of the 
inorganic compounds utilized in these times were used in an empirical way with little attempt to 
design the compounds, and with little to no understanding of the molecular basis of their 
mechanism of action. As science has evolved, so too have the uses of the metals and the methods 
                                                          





experimentalists utilize to intentionally introduce these complexes into the human biological 
system. Figure 1 and table 1 present selected examples of successful therapeutic and diagnostic 
agents. Magnevist and Cardiolite, GdIII and 99mTcI complexes, respectively, have drastically 
increased our understanding and detection of diseases through imaging of living tissues using 
single photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI) 
scans.9 Thanks to these diagnostic methods, malignant growth, cardiologic diseases, and 
atherosclerosis in patients can be detected early; furthermore, such imaging agents enhance 
research as they, for example, enable researchers to visualize the activity of the brain in vivo. 
 
 





The applications of various metal centers utilized as therapeutics reaches as far as the 
imagination of the scientist who envision them. One of the first reported metallodrugs, salvarsan 
(also known under its working name Ehrlich 606, as it was the 606th compound tested by Ehrlich 
and colleagues), was reported by German  Nobel Laureate Paul Ehrlich in 1912.10 The compound 
is an organoarsenic based antimicrobial agent used specifically for the treatment of syphilis 
(caused by spirochete Treponema pallidum). While the origins of the compound can be further 
traced to Pierre Bechamp in 1863 (famous for the Bechamp process for the production of aniline) 
the exact composition of the complex remains elusive. It is hypothesized that the compound exists 
as a mixture of 3-amino-4-hydroxyphenyl-arsenic(III) compounds, however, computational 
structural models have failed to determine the exact chemical composition.11 Salvarsan in 
combination with mercury and bismuth was the standard treatment regime for syphilis until World 
War II, when it was finally replaced by penicillin. Salvarsan provided an effective demonstration 
for Ehrlich’s belief that it is possible to fight infectious diseases through a systematic search for 






Table 1. Some metal compounds in clinical use 
Compound Example (Brand name) Function Comment 
Active Complexes   
   cis-[PtIICl2(NH3)2 (cisplatin) Anti-cancer Trans-isomer inactive 
   
   [GdIII(DTPA)(H2O)]
2- (Magnevist) Extracellular contrast agent for MRI Low toxicity 
   [99mTcI(CNCH2C(CH3)2OCH3)6]
+ (Cardiolite) Myocardial imaging Positively charge complex 
taken up by the heart 
   Vitamin B12
 Coenzyme Deficiency causes pernicious 
anemia 
Active metals   
   Li2CO3 Prophylaxis for bipolar disorders Li forms weak complexes, 
labile 
   [AuI(thiomalate)] (myocrisin) Antirheumatoid arthritic Facile thiol exchange on AuI 
   Ammonium potassium BiIII citrate (De-Nol) Antibacterial, antiulcer Strong binding of Bi to thiols, 
facile exchange 
   Na2[Fe
II(CN)5(NO)]·2H2O (Nipride) Hypotensive Releases NO, vasodilator 
   (Bleomycin) Anticancer Requires Fe for DNA attack 
   p-xylyl-bicylam-8HCl (AMD3100) Anti-HIV, stem cell mobilization May bind to metals in vivo 
   CaCO3, Mg(OH)2 Antacid Slow release of alkali 
   
   La2





CANCER AND CHEMOTHERAPEUTIC AGENTS 
 Cancer (or neoplasm), is a term used to describe over two hundred diseases which can 
affect various tissues, organs, and organ systems throughout the body. One hallmark of cancer is 
the uncontrolled autonomous growth of tissue beyond normal boundaries, which allows for the 
formation of tumors (neoplasms).12, 13 There can be two major forms of neoplasms: encapsulated 
or nonencapsulated. Encapsulated benign tumors facilitate the invasion and destruction of adjacent 
tissue; whereas nonencapsulated malignant tumors grow rapidly, and spread to various regions of 
the body and metastasize. These metastases (or secondary growths) are the cause of over 90% of 
cancer related deaths.14-16 
Cancer is an incredibly complex disease.17-20 There is an inherent connection between 
genotype (characteristics arising from genetic coding) and phenotype (characteristics expressed by 
the organism) but the correlations are often weak. Genetic abnormalities occur on the way to 
tumorigenesis as there must be a successive accumulation in mutations in proto-oncogenes and 
suppressor genes which deregulate the cell cycle. Key events in this progression are single point 
mutations in the DNA, chromosomal aberrations such as translocations or deletions, and changes 
that affect chromatin structure such as methylation of DNA or acetylation of histone. The multitude 
of influential factors in cancer inception and progression make it very difficult to predict its 
occurrence. Additionally, the presence of highly controversial and highly resistant “cancer stem 
cells” further compounds the complexity of the disease.17, 21, 22 
Despite extensive research and various treatment regimens cancer remains among the 
leading causes of death worldwide and is the 2nd leading cause of death in the U.S.A., with 14.1 
million new cases and 8.2 million deaths in 2012 alone.23-25 In the United States, one in three 





the changes in death rates related to major disease in the U.S.A. have dropped considerably, except 
from those deaths related to cancer. The global burden of disease study commissioned in 1990 (as 
a collaborative effort between the World Health Organization, Harvard School of Public Health, 
the University of Auckland, the Institute for Health Metrics and Evaluation, and the World Bank) 
reported updates in 2004 and 2010 which projects the incidence of cancer death to increase to 12 
million by 2030.26-29  
 
Cancer Chemotherapy 
Common cancer therapies include surgery, radiotherapy, and chemotherapy. Combinations 
of the three are commonly utilized and are based on the location of the cancer, potential for 
successful outcome, and various other risk factors.30, 31 Chemotherapeutic (or neoplastic) drugs 
aim to selectively kill malignant tumor cells. Current therapies are divided into categories based 
on their mechanisms of actions and usually include categories such as: alkylating agents, 
antimetabolites, anthracyclines, plant alkaloids, and topoisomerase inhibitors. Common examples 
of antimetabolites: mercaptopurine and 5-fluorouracil are DNA base pair analogues which are 
utilized to enzymatically inhibit DNA replication in acute leukemia and colorectal/pancreatic 
cancer, respectively.  
While there have been significant advances in the development of chemotherapeutic 
agents, serious problems lies within their narrow margin of safety (i.e., therapeutic index 
TD50/LD50). The positive effects of the agents are often hindered by nonspecific adverse effects. 
Nonselective biodistribution often means large doses are required in order to obtain high local 
concentrations within the tumor cells. The emergence of targeted therapies has drastically reduced 





32 This approach has been utilized extensively by exploiting some of the unique properties of tumor 
cells such as hypoxia, specific enzymatic profiles, and low pH values.  
The emergence of targeted therapies has reduced non-selective effects from 
chemotherapeutic agents but drug resistance remains a major problem.33 Even more prevalent 
today is the emergence of multidrug resistance (MDR), which occurs when cancer cells develop 
cross-resistance to structurally similar drugs. The pathways and mechanisms that lead to MDR 
often include drug modification or inactivation (as is the case with cisplatin by glutathione), 
decreases permeability or increases drug effects by MDR pumps. 
The 1965, Rosenburg and coworkers serendipitously discovered the star of the anticancer 
chemotherapeutic world, cisplatin, (cis-diamine-dichloroplatinum(II), cis-[PtCl2(NH3)2])  
(Platinol), a square planar Pt2+ complex.34 While the complex was first shown to inhibit cell growth 
in the bacterium Escherichia coli, today approximately 50% of all patients undergoing 
chemotherapy are treated with this alkylating agent. Cisplatin was the first metal based medicinal 
agent to enter into worldwide clinical trials and gained FDA approval 1978 for the treatment of 
genitourinary tumors and is generally combined with one or multiple organic anticancer drugs, 
such as 5-fluorouracil, cyclophosphamide, or gemcitabine.35-38 After the initial surgical removal 
of malignant tissue, the patient undergoes cycles of intravenous injections of cisplatin. The 
mechanism of action has been intensively studied and is facilitated by the diffusion of cisplatin 
into cells in its chloride form (due to variance in intra- and extra-cellular [Cl-]). The Pt2+ of the 
[Pt(NH3)2(OH2)Cl]
+ (obtained following an intracellular aquation event) unit binds covalently to 
deoxyribonucleic acid  (DNA), more specifically, to the N-7 of either guanine (G) or adenine (A) 
in the dinucleotide sequences GG and AG to form interstrand cross-links and 1,2- or 1,3-





in response to cisplatin, lead to expression of p53, replication arrest,  transcription inhibition, cell-
cycle arrests, DNA repair, and apoptosis.40 
 
 
Figure 2. Mechanism of action of cisplatin. 
 
While cisplatin remains one of the most widely prescribed anticancer drugs to date, side 
effects including nephrotoxicity (kidney poisoning), ototoxicity (loss of high frequency hearing), 
peripheral neuropathy and the emergence of cisplatin-resistant cancers decrease it effectiveness.38, 
41, 42 As previously stated, MDR resistance to cisplatin is often facilitated by its’ inactivation due 
to glutathione or other sulfur rich proteins. The sulfur groups provide good ligands for coordination 
to the platinum metal center according to Person’s hard/soft acid-base theory, thereby not allowing 
the complex to reach its intended molecular target. There have also been reports of enhanced levels 
of other sulfur rich detoxification agents such as metallothioneins in cells which are insensitive to 





DNA damage mechanism but were designed with the focus of lowering the levels of other 
unwarranted side effects caused by cisplatin.  
 
Metal complexes as chemotherapeutic agents 
While small organic molecules have and continue to dominate the pharmaceutical industry, 
the near number of infinite possible metal-ligand combinations and complexes makes metal-based 
therapeutic agents an interesting area of study with many potential benefits. Such organic 
molecules are limited in terms of geometry due to the hybridization of carbon to sp (linear), sp2 
(trigonal-planar) and sp3 (tetrahedral). Besides these shapes, geometries of pyramidal, triagonal 
bipyramidal and octahedral can be obtained with metals (higher coordination numbers and 
geometries with even larger metal ions can also be achieved). Additionally, these higher 
coordination number and non-limitations to low hybridization options allows for a variety of 
substituents (ligands), to coordinate around the metal leading to various stereoisomers and 
stereochemical flexibility.45 Furthermore, modifications can be made to the ligands to tailor them 
to a specific function or target.46 Additionally, most metal-based complexes have been reported to 
mitigate the side effects of the organic parent molecule (a ligand) while increasing their biological 
activity. 
Despite the earlier report of Ehrlich’s chemotherapeutic agent, salvarsan, the discovery of 
cisplatin is often regarded as the birth of metal based chemotherapy; and ultimately sparked the 
rise to investigate metal based anticancer agents. Prior to this, it was thought that heavy metals 
could not be utilized due to their inherent toxicities. One notable exception is Fowler’s solution 
(1% KAsO2), which gave rise to popular arsenotherapies utilized until the late 1950s.





In the 1930s,49 Collier and Krauss reported the first ever structure activity relationship 
study on metal complexes, introducing a rationale which stated that: “The effect of a heavy metal 
on experimental murine cancer is not only due to the metal alone but also to the structure of the 
compound and the type of compound.” This is the single most important concept when it comes 
to the design of metal based anticancer agents! Take for instance cisplatin, it was first actually 
described in 1844 by Peyrone as Peyrone’s chloride. Initial experiments in the 1960s by Rosenberg 
and coworkers failed to produce a compound with viable biological activity, until it was discovered 
that the compound exists in two isomeric forms, cis and trans. The latter, transplatin is more stable 
and is inactive. Biological studies conducted after this discovery lead to the confirmation that the 
active isomer, cisplatin, possessed potent anticancer activity in sarcoma-180 cells.50, 51 Therefore, 
the structure of the compound plays a pivotal role on the observed biological activity, and by 
extension so do the ligands bound to the metal center.  
After the booming success of cisplatin, many other metal complexes were quickly 
investigated for their anticancer potential due to their unique chemical reactivities.52, 53 The d block 
metals (transition metals), in particular, have been extensively researched and many have been 
found to possess good cytotoxic potential. There are many examples of complexes which possess 
photochemical, anticancer, or both of these activities in a variety of cell lines. These metals offer 
a variety of coordination geometries which allows for the synthesis of compounds with various 
stereochemistries that are not obtainable via conventional organic molecules. There are a number 
of critical factors which can be modified using coordination complexes: geometry, 
stereochemistry, ligand binding affinity, ligand shapes, counter ions, etc. Given the volume of 





increase the number of therapeutic metal complexes, however, they still remain a minority of all 
therapeutics on the market to date.    
 
Development of new metal based anticancer agents 
 Drug discovery is a long multi-stage process which includes: synthesis, characterization, 
proof of biological activity, as well as pre-clinical and clinical screening. Testing for the biological 
activity requires intense measurements of the effects in vitro (in multiple cancer cell lines) and in 
vivo (in animals). With the majority of successful pharmaceuticals originating in university 
settings, a large amount of ground work is done in research labs across the world. There are three 
main strategies to the development of new tumor-inhibiting complexes: (1) synthesis of classical 
and non-classical derivatives of cisplatin; (2) synthesis of non-platinum based complexes; or (3) 
synthesis of platinum complexes linked to a carrier system.  
 The first seems the least attractive as this will lead to drugs with a similar chemistry (and 
therefore side effects) to that of cisplatin. However, mitigation of some of these side effects can 
be accomplished as demonstrated by carboplatin and oxaliplatin, respectively. The second 
approach is perhaps the riskiest (but most attractive) as it seeks to utilize central metal atoms other 
that platinum. While there are a plethora of transition metals to try, each possesses its own wide 
range of activity, oxidation state, coordination geometries, and chemical properties which have to 
be considered. With so many possibilities producing a lead molecule from this group may be 
difficult but the window for breakthrough is greater. Lastly, linking platinum complexes to carrier 
molecules has long been known by the concept of drug targeting. Drugs produced from this 





work on this idea by specifically targeting mitochondrial DNA, by utilizing mitochondrial-
penetrating sequences covalently bound to cisplatin.54 
 There are two main issues with anticancer drug development: time and variance. With 
many of the potential leads for pharmaceutical companies coming from individual research labs 
time is precious. It often take up to  6 years to take one target molecular from conceptualization to 
conclusion of preclinical trials.55 Additionally another major problem is the leap between the 
preclinical in vitro and in vivo studies to clinical trials. It is at this step that major differences 
between the animal models utilized begin to differ significantly from the treatment of actual human 
patient tumors.56  
 
NON-PLATINUM BASED CHEMOTHERAPEUTIC AGENTS 
Despite the toxicity and side effects of cisplatin and its many derivatives they remained the 
gold standard in the treatment of many varieties of cancer since FDA approval dating back to 1978. 
Due to the inherent limits of cisplatin and other platinum based chemotherapeutics there has been 
extensive research on the use of other metals in medicine. As discussed in previous sections, 




Ruthenium based compounds have arguably emerged as the best candidates for a viable 
alternative to platinum-based drugs in cancer therapy. There are three main properties that make 
ruthenium compounds well suited for medicinal applications: (i) rate of ligand exchange, (ii) the 





certain biological molecules.57 Many ruthenium complexes have been evaluated for clinical 
applications, particularly in the treatment of cancer, due in part, to Ru(II) and Ru(III) complexes 
having similar ligand exchange kinetics to those of Pt(II) complexes and cellular division rates.58 
Ligand exchange is an important determinant of biological activity, as very few metal-based drugs 
reach the biological target without being modified.59 
Ruthenium is unique amongst the platinum group metals in that each of its common 
oxidation states Ru(II), Ru(III) and Ru(IV) are all readily accessible under physiological 
conditions. In a biological environment glutathione, ascorbate and single electron transfer proteins 
can be used to reduce Ru(III) and Ru(IV), while molecular oxygen and cytochrome oxidase readily 
oxidize Ru(II).59 In these oxidation states the ruthenium center is predominantly hexacoordinate 
with octahedral geometry, and Ru(II) complexes tend to be more biologically inert than related 
Ru(III) and Ru(IV) complexes. Coordinatively saturated and substitutionally inert polypyridyl 
Ru(II) compounds have cytotoxic effect which are partially attributed to noncovalent interactions 
with nucleic acids, particularly DNA.60-62 Recently several studies have shown that other factors 
such as modification of cell membrane and cell adhesion properties, topoisomerase I and II 
inhibition,63 or mitochondrial-mediated apoptosis,61 could be responsible for cytotoxicity.  
The low toxicity of ruthenium drugs is derived from the fact that ruthenium can mimic iron 
in biological systems. This fact allows it to bind to many biomolecules, including serum transferrin 
and albumin.64 These two proteins are used by mammals to solubilize and transport iron; as such 
ruthenium possesses natural advantages over Pt-based drugs. Since rapidly dividing cells, for 
example cancer cells, have a greater requirement for iron, they increase the number of transferrin 







Anticancer Ruthenium Agents 
The potential anti-cancer activity of ruthenium compounds were first examined by Clarke 
and co-workers who studied chloro-ammino derivatives of the general formula [Ru(NH3)6-
xClx]
Y+.66-68 The compounds were chosen due to similarities with cisplatin to allow for binding of 
the complexes with nucleic acids.  [RuII(NH3)5Cl]
+ and its aqua analog [RuII(NH3)5H2O]
2+ have 
been extensively studied and show rapid binding to DNA with an affinity constant of 
approximately 5000 M-1 (Figure 3 a).  The hypothesized binding product of the complex with DNA 
involves substitution of the chloride/aqua ligand and coordination to N7 nitrogen of guanine in the 
DNA major groove.  Despite strong binding to N7 of guanine, similar to cisplatin, penta-
ammineruthenium complexes do not show efficient anti-cancer activity. In contrast, cis-
[RuIII(NH3)4Cl2]
+ and fac-[RuIII(NH3)3Cl3] shown in figure 3 B and C, respectively, have been 
tested against multiple tumor cells and show comparable in vivo activity to cisplatin.69-71 Clarke 
and co-workers have rationalized that the in vivo tumor environment reduces the inactive Ru(III) 
complex to the corresponding active Ru(II) drug which is able to substitute its chlorido ligands 
much more rapidly and bind to DNA.72 Unfortunately many of these complexes are far too 
insoluble for pharmaceutical use.70  
 
 
Figure 3.  Some chloro-ammino ruthenium derivatives. (a) [RuII(NH3)5Cl]
+, (b) cis-
[RuIII(NH3)4Cl2]






                          
Figure 4.  Dimethyl-sulfoxide containing ruthenium complexes. (a) cis-[RuII(DMSO)4Cl2] and the 
corresponding aqua species, (b) trans-[RuII(DMSO)4Cl2] and the corresponding aqua species.  
 
The initial solubility issues can be highly improved by coordinating a DMSO molecule as 
opposed to the previously utilized NH3 ligands as shown in figure 4.  Mestroni, Alessio and co-
workers conducted in vitro and in vivo studies on cis- and trans-[RuII(DMSO)4Cl2] complexes.
73 
Monoadduct formation was observed for the cis-isomer, whereas the trans-complex, similar to 
cisplatin, showed the ability to form DNA biadducts leading to both intra- and inter-strand cross-
links.73 Both isomers coordinate the N7 position of guanine residues in DNA, however the trans 
isomer has been shown bind more rapidly and is almost sixteen (16) times more active than the cis 
isomer in P388 leukemia cells.74  The encouraging results obtained with trans-[RuII(DMSO)4Cl2] 
are at the epicenter of the search for other trans-DMSO ruthenium complexes as anti-cancer 
agents. Na[trans-[RuIII(DMSO)(Im)Cl4]] (where Im = imidazole) (NAMI) and its imidazolium salt 
NAMI-A represents the greatest achievements in this area as it was the first Ru compound to enter 





noncytotoxic in common cancer cell lines but has turned out to be a specifically anti-metastatic 
drug. The mechanism by which NAMI-A exerts its anti-metastatic activity is not yet completely 
elucidated. As with many other ruthenium complexes it is thought that both of its chlorido ligands 
are lost though aquation before it binds with biomolecules such as DNA. NAMI inhibits the actions 
of DNA and RNA polymerases, but does not form significant DNA interstrand cross-linking.76 
Thus, it is hypothesized that the anti-metastatic activity of NAMI arises from a mechanism 
different than that of cisplatin, such as protein-DNA cross-links.77   
 
Scheme 1. Structural representation of KP1019 and NAMI-A. 
 
 
KP1019 (trans-[tetrachlorobis(1H-indazole)ruthenate(III) was the second Ru complex to 
enter clinical trials in 2003 and represents one of the most successful complexes in terms of 
anticancer ruthenium complexes as it reduces tumor sizes in rats and triggers apoptosis in vitro.78 
Despites KP1019s success, its mechanism of action remains up for debate. For example, KP1019 
has been shown to bind transferrin, and transferrin receptor-mediated endocytosis has been 
implicated as a mechanism of drug internalization.79, 80 However, drug uptake occurs in the absence 





mechanism by which the drug exits the endosomes and gains access to intracellular targets remains 
unclear.   
 
 
Figure 5.  Ruthenium complexes with chloride and/or heterocyclic ligands.   
 
While ruthenium complexes with coordinated chloride ligands served as a strong starting 
point, additional and extensive research has focused on the coordination of polypyridyl ligands to 
the ruthenium metal center. The first report by Dwyer and co-workers in the early 1950s,81-83 
showed a family of tris(polypyridyl) complexes had bacteriostatic and antiviral activities (in some 
instances, the growth of Gram-positive bacteria was inhibited at  a concentration of 1 mM for 
[Ru(phen)3](ClO4)2 (where phen = 1,10 phenanthroline).
81  Figure 5 shows a few examples of such 





that have been prepared and are being investigated for their anti-tumor properties.  One of the first 
studied complexes cis-[RuII(bpy)2Cl2] (where bpy = 2,2’-bipyridine) has been tested against many 
cell lines but is mostly inactive as an anti-tumor agent.84  In contrast, Reedijk and co-workers have 
shown that one isomer of cis-[RuII(azpy)2Cl2] (where azpy = 2-phenylazopyridine) exhibits high 
toxicity comparable to that of cisplatin against a series of cell lines.84-86  Barbec and co-workers 
reported high cytotoxicity comparable to that of cisplatin and carboplatin with their complex mer-
[RuII(tpy)Cl3]
- which contains a tridentate terpyridine ligand.87 This complex similar to cisplatin 
was shown to form a high number of interstand cross-links.87 Bouwan and co-workers have shown 
a novel complex [RuIII(PAn3)P(An)(phenolate)2Cl] shows toxicity similar to cisplatin, and 
enhanced toxicity in cisplatin-resistant cell lines.88  Tan et al.89 reported a series of ruthenium-
norharman complexes which are highly cytotoxic to a variety of cancer cell lines with IC50 values 
well below those of cisplatin and NAMI-A.  Lakomska et al.90 have developed two Ru(III) 
complexes based on triazolopyrimidine ligands.  The bulky substituents in the heterocyclic ligands 
significantly enhance the cytotoxicity of both complexes which is attributed to high lipophilicity 
which facilitates high cellular uptake. Both show much higher cytotoxicity than cisplatin against 
human lung carcinoma A-549 and T47D breast carcinoma cell lines with IC50 values in the range 
of 0.02-2.4 µM.90  
Arenes are known to stabilize ruthenium(II) complexes and provides a hydrophobic face 
which may facilitate biomoelcular recognition and transportation of ruthenium through cell 
membranes; thus the potential uses of ruthenium-arene complexes are gaining much attention in 
literature.91-95 The “half-sandwich” Ru(II) mono-arene complexes often possess good aqueous 
stability and the arene ligand is relatively inert towards displacement under physiological 





dichloride [Ti(Cp)2Cl2] Cp = η
5-C5H5) into clinical trials as an anticancer drug, Dyson and his co-
workers have conducted much work on ruthenium-arene complexes specifically as it related to 
highly cytotoxic RAPTA (Ruthenium Arene PTA) complexes, [(η6-arene)Ru(pta)(Cl)2] (where pta 
= 1,3,5-triaza-7-phosphatricyclo[3.3.1.13.7]decane) (Figure 6).96-98 Protonation of pta ligands 
influences the solubility properties of the complex and at physiological pH environments the 
predominant species carries no charge and can thus be easily transported across the lipid membrane 
and move freely into and within the cells.96  
 
 
Figure 6.  Aquation and protonation of RAPTA-C complex prior to DNA damage. Adapted from 
Scolaro et al.98 
 
The RAPTA complexes have been extensively studied since their inception and 
interestingly in gel shift assays it selectively binds to DNA at pH values close to or lower than its 
pKa value.
98 The attractiveness of this series of complexes is that they select target cells which 
possess metabolic activity, similar to those associated with increase or accelerated cell division. In 
vivo biological screening of a series of nine complexes of the generic formula [(η6-





dimethylimidazolium tetrafluoroborate, ethyl benzene, hexamethylbezene) synthesized by Dyson 
et al.98 failed to produce a complex with IC50 comparable to cisplatin, however [(η
6-
arene)Ru(pta)(Cl)2] did reduce the number and weight of metastasis cells similar to NAMI-A with 
a higher system clearance rate.98 A related compound prepared by Maysinger and co-workers 
showed the synergistic effect which can be obtained from pairing a ruthenium(II)-arene complex 
with a known chemotherapeutic agent: letrozole. The ruthenium(II)-letrozole complex, shown in 
figure 7,  was shown  to exhibit significantly higher activity towards cancer cells line when 




Figure 7.  Ruthenium-letrozole complex as by Castonguay et al.99 
 
Sadler and co-workers have also conducted extensive work on ruthenium-arene complexes 
for similar applications. Cytotoxicities obtained for a series of complexes with the generic formula 
[(η6-arene)Ru(en)(Cl)]+ indicated that the cytotoxic behavior increased as a function of the size of 
the coordinated arene (benzene < p-cymene < biphenyl < dihydroanthracene < 
tetrahydroanthracene), such that in wild and cisplatin resistant A2780 human ovarian cancer cells, 
the biphenyl complex showed similar toxicity to carboplatin and the tetrahydroanthracene complex 





that single ligand exchange (presence of bidentate ligand) facilitates high cytotoxicity.  Binding 
studies indicate the formation of monoadducts with N7 of guanine similar to results observed with 
other ruthenium complexes.100, 101  
Beckford and co-workers are conducting work in the synthesis of ruthenium-arene 
complexes containing thiosemicarbazone (TSC) ligands.102, 103 TSCs possess a broad range of 
medicinal application including antitumor, antibacterial, and antiviral properties all of which can 
be modified and enhanced by coordination to a metal ion. A series of complexes as shown in figure 
9 of the general formula [(η6-p-cymene)Ru(TSC)(Cl)]Cl were recently reported and their 
biological properties were studied.102, 103 Studies indicate in vitro activity as anticancer agents 
against human colon cancer cell lines, with a moderate DNA interaction. Complexes showed 
comparable anticancer activity to cisplatin and other similar ruthenium-arene complexes currently 
under investigation; however, no complex provided activity similar to etoposide (an anticancer 
drug belonging to the topoisomerase inhibitor class). Two of the complexes ([(η6-p-
cymene)Ru(pEtTSC)Cl]Cl and [(η6-p-cymene)Ru(pPhTSC)Cl]Cl showed a modest capability of 
inhibiting topoisomerase II enzymes at low concentrations which may still give these complexes 
applications in anticancer drug development.103 This highlights the ability of Ru(II)-complexes to 
increase the bioactivity of parent ligands, while increasing bioavailability. 
 
 







Figure 9.  Heteronuclear arene ruthenium complexes containing a ferrocene (A) and titanocene (B) 
moiety.   
 
Similar to binuclear and multinuclear ruthenium complexes, strategies have been employed 
in synthesizing multinuclear and heteronuclear ruthenium-arene complexes which modify the 
mode of action of the metal based drug.  Two heteronuclear complexes containing ruthenium(II)-
arenes with ferrocene and titanocene were recently prepared and are shown in in figure 10.104, 105 
In vitro studies demonstrate the cytotoxicities correlate with the lipophilicity and water solubility 
of the complexes similar to other ruthenium(II) complexes.  Dinuclear, trinuclear, tetranuclear, 
hexanuclear, and octanuclear systems can all be found in literature, with each system showing a 
different level of activity and degree of selectivity towards certain cancer cell lines. Dinuclear 
complexes containing pyridone linkers have provided insight into the correlation present between 
the spacer length and cytotoxicity (Figure 10 A),106, 107 while the thiophenolato-bridged p-cymene 
ruthenium complex [(piPrC6H4Me)2Ru2(µ2SC6H5)3]Cl shows activity against human ovarian 
cancer cell lines in the nanomolar range (Figure 10 B).108 A dinuclear (η6-arene)ruthenium(II) 
benzaldehyde TSC complex as shown in figure 10 C was shown to exhibit moderate in vitro 








Figure 10.  Selected example of multinuclear arene ruthenium complexes. Bridging ligands 
include: pyridone (A),106, 107 thiophenolato (B),108 thiosemicarbazone (C),109 Trinuclear metalla-
cycle (D),110 tetranuclear arene ruthenium complex (E).111 
 
More complex ruthenium containing metallocycles, such as those shown in figure 10 D, 
have also been investigated for their anticancer potential.110  The tri-ruthenium metallocycle 
remains stable under neutral pH, however under the reduced pH environment within cancer cells 
the trimeric structure is converted to the activated monomeric species.110  Rectangular shaped 
metalla-cycles of the general formula [(arene)4Ru4(ox)2(N-N)2]
4+  as shown in figure 10 E (arene 
= p-cymene, hexamethylbenzene; ox = oxalato, oxamido, 1,4-benzoquinonato-2,5-dilato, 3,6-
dichloro-1,4-benzoquinonato; N-N = pyrazine, 4,4’-bipyridine, 1,2-bis(pyridyl)ethylene, 1,2-
bis(4-pyridyl)ethane) have been tested against multiple cancer cell lines.111 The activity of these 





excellent activity, depending on the size of the linker utilized, in some cases IC50 values as low as 
4 µM were obtained.  Similarly, metalla-assemblies containing polypyridyl-porphyrin derivatives 
and dinuclear ruthenium complexes have been reported.112  
  
Ruthenium photodynamic therapeutic agents 
One of the other major themes in the evolving world of ruthenium chemotherapeutics is 
the utilization of polypyridyl ligand architectures for photodynamic therapy (PDT).113, 114 Due to 
the attractive photophysical properties and site specific DNA binding, much research has focused 
on these complexes. As the rules that govern the cellular uptake and cellular localization of these 
systems are determined numerous applications ranging from cellular imaging to therapeutics are 
rising.58, 115  
Polyazaaromatic ruthenium(II) complexes are generally well suited for use as 
photosensitizers and are an integral portion of PDT.116 The properties of such complexes can be 
varied by varying the ligands chelated to the metal center as shown by their different photophysical 
and photochemical behaviors in the presence and absence of DNA.116 Ruthenium(II) complexes 
are capable of interacting with DNA forming three distinct interaction geometries: (1) the complex 
be can externally associated in the electrostatic environment of the DNA double helix, (2) it can 
be absorbed into the DNA grooves, or (3) it can intercalate between two DNA bases pairs via one 
of its ligands.  Barton et al.117 have confirmed many of these binding modes showing [Ru(bpy)3]
2+ 
shows a weak interaction with DNA either by intercalation or electrostatic interaction; while in 
contrast [Ru(phen)3]
2+ and [Ru(DIP)3]
2+ (where DIP = 4,7-diphenyl-1,10-phenanthroline) show 





Hundreds of molecules have already been shown to photosensitize singlet oxygen 
production, many of which are polypyridyl Ru(II) complexes due to their large absorbance spectra 




2+ shown in figure 11, induces the production of singlet oxygen and 
DNA single strand breaks.117 High quantum yields of singlet oxygen productions from (0.1 to 1.0 
depending on the complex and solvent) have been determined for a variety of Ru(II) complexes.118 
Photoinduced ligand substitution is also possible whereby a metal complex would either release a 
biologically active molecule or bind to nucleic acids or protein active sites.   
 
 





Improving the selectivity of anticancer drugs towards cancer cells is the main goal of drug 
optimization; thus a prodrug strategy offers significant promise. Light-triggered prodrugs provide 
an efficient approach for controlling the localization of cytotoxicity. One example of this concept 
of localized activation was reported by Gasser and co-workers using, [Ru(dppz)2(CppH)]
2+ (where 
CppH=2-(2-pyridyl)pyrimidine-4-carboxylic acid). The complex localized with the mitochondria 





cells. A photolabile functionality, 3-(4,5-dimethoxy-2-nitrophenyl)-2-butyl ester (DMNPB), 
makes the active [Ru(dppz)2(CppH)]
2+ (where dppz = dipyrido[3,2-a:2’,3’-c]phenazine) moiety 
within [Ru(dppz)2(Cpp-ODMPNB)]
2+ innocuous to both cancerous (HeLa and U2OS) and non-
cancerous (MRC-5) cells (IC50  > 100 µM).
120 Irradiation at 350 nm releases the photolabile 
DMNPB ester forming the active complex [Ru(dppz)2(CppH)]
2+
  as shown in figure 12 below. IC50 
values obtained before irradiation (> 100 µM) indicate nontoxic behavior of the complexes 
containing the DMNPB ester; while after irradiation values (17.5 and 17.2 µM) are comparable 
with those of cisplatin 12.0 and 32.6 µM in HeLa and U2OS, respectively.120 Though still in the 
prototype stage, light triggered prodrugs hold potential for designing sophisticated properties well-
suited for controllable cytotoxic action under physiological conditions.   
 
 
Figure 12.  Photocleavage of DMNPB ester moiety to form active [Ru(dppz)2(CppH)]
2+.120 
 
As the search for adequate PDT agents continues to evolve the systems being utilized are 
also constantly evolving.  The above discussion describes examples of systems containing 
mononuclear/multinuclear ruthenium complexes and some PDT-active complexes.121-124 





to show greater specificity, however their applications as potential DNA-binding agents remains 
largely unexplored. Mixed metal dinuclear complexes offer even more advantages over ruthenium-
ruthenium dinuclear complexes as the second metal utilized may possess its own biological 
application making for dual-application complexes or enhanced biological function.  Sakai and co-
workers have tethered a tris(bpy)ruthenium(II) derivative to a cis-PtCl2(amine)2 moiety to 
incorporate a known DNA intercalating unit with a known DNA binding unit.125 The complex 
[{Ru(bpy)2µ-bpy(CONH(CH2)3NH2)2}PtCl2](PF6)2·3H2O shows efficient cleavage of PBR322 
DNA to nicked and linearized forms only following irradiation (λirr = 470 ± 10 nm) at atmospheric 
conditions.125 Liang et al.126 reported biological application of  
[(phen)2Ru(bpibH2)Co(phen)2](ClO4)5·2H2O (where bpibH2 = 1,4-bis([1,10]phebanthroline-[5,6-
d]imidazol-2-yl)-benzene) which includes Ru(II)-Co(III) metal centers.  During this present study 
the system does not show cytotoxic behavior comparable to cisplatin, however, information from 
this study can enhance the understanding of the mechanism for the binding of metal polypyridyl 
complexes to nucleic acid.126 
 Holder et al.127 reported the synthesis, characterization and biological properties of two 
ruthenium(II)-vanadium(IV) complexes: [Ru(pbt)2(tpphz)VO(sal-L-tryp)](PF6)2·6H2O (where pbt 
= 2-(2’-pyridyl)benzothiazole), tpphz = tetrapyrido[3,2-a:2‘,3‘-c:3‘‘,2‘‘-h:2‘‘‘,3‘‘‘-j]phenazine , 
and sal-L-tryp = N-salicylidene-L-tryptophanate)  and [Ru(pbt)2(phen2DTT)VO(sal-L-
tryp)](PF6)2·5H2O (where phen2DTT =  1,4-bis(1,10-phenanthrolin-5-ylsulfanyl)butane-2,3-diol), 
the structures of which are shown in figure 13.237  Biological screenings showed the monomer 
[VO(sal-L-tryp)(phen)]·H2O and [Ru(pbt)2(tpphz)VO(sal-L-tryp)]Cl2 were the most active against 
A431 carcinoma cells with IC50 values comparable to those obtained for cisplatin as shown in table 





This qualitative study gives indication that mixed-metal ruthenium(II)-vanadium(IV) complexes 
may be good PDT agents.   
 
 
Figure 13.  [Ru(pbt)2(tpphz)VO(sal-L-tryp)]Cl2 and [Ru(pbt)2(phen2DTT)VO(sal-L-tryp)]Cl2.
127 
 
Table 2.  Anti-proliferative data obtained from complexes by Holder et al.  Data expresses as IC50 
value in µM. (Reprinted with permission)127 
 IC50 / [µM] 
Species A431 HFF 
[Ru(pbt)2(tpphz)VO(sal-L-tryp)]Cl2 41.3 ± 7.6 100.7 ± 17.7 
[Ru(pbt)2(phen2DTT)VO(sal-L-tryp)]Cl2 48.6 ± 13.1 41.3 ± 7.6 
[VO(sal-L-tryp)(phen)]·H2O 41.3 ± 7.6 41.3 ± 7.6 
Cisplatin 41.3 ± 7.6 41.3 ± 7.6 
 
 
Arguably one of the greatest contributors to the field of mixed-metal Ru(II)-PDT agents, 
Karen Brewer, has reported multiple supramolecular complexes, which possess at least two Ru(II) 
metal centers and one Pt(II) binding site. In a landmark report, 





of molecular oxygen, thereby showing singlet oxygen generation to not be the only method of 
facilitating DNA damage. This discovery, along with subsequent investigations has lead the 
convention of both type I and type II PS.128 
 
Scheme 2. [{bpy)2Ru(dpp)}2Ru(dpp)PtCl2]
6+ as by Brewer and co-workers.128 
 
 
Utilizing known drug molecules, such as Ru(II) incorporating chloride ligands, is often a 
good starting point for the development of novel drugs. In a similar fashion much research in PDT-
Ru(II) PS development has focused on mimicking Photofrin. Photofrin, a FDA approved 
porphyrin-based photosensitizer,129, 130 has been shown to generate singlet oxygen through an 
energy transfer upon photoexcitation in the visible region causing cell death.  While 
photoexcitation leads to cell death, Photofrin also suffers from dark toxicity and purification 
difficulties, thus it is imperative to find alternatives to eliminate negative attributes.130 Masico first 
reported on the use of tetraruthenated porphyrins as potential photosensitizers for photodynamic 
therapy in the late 1990s.131 Polypyridyl ruthenium(II) substituents covalently linked to porphyrins 
offer enhanced water solubility while maintaining the intercalation properties of the ruthenium 
metal center.132, 133  Swavey and co-workers have combined the properties of fluorinated porphyins 





photodynamic therapy. An example structure is shown below of a ruthenium porphyrin complex 
[cis-H2(DPDPFPP)Ru2(bpy)4Cl2(PF6)2] (where DPDPFPP = 5,15-(4-pyridyl)-10,20-
(pentafluorophenyl)porphyrin), exhibits the ability to bind and photocleave supercoiled DNA 
when irradiated with low-energy light.134 Cell studies indicate a low dark toxicity of the complex 
towards both melanoma and normal cells, however, under visible light melanoma cells reveal 
extensive apoptosis.134 
 
Scheme 3. Example ruthenium-porphyrin complex 
 
 
In another study a new porphyrin 5,15-(4-pyridyl)-10,20-(pentafluorophenyl)porphyrin 
(H2DPDPFPP) and its diruthenium(II) analogue ([trans-H2(DPDPFPP)Ru2(bpy)4Cl2(PF6)2]) were 
examined for their interaction with linearized pUC18 plasmid (Figure 14).135 Gel electrophoresis 
studies showed interactions between the metallated porphyrin and DNA which was confirmed by 
UV-visible spectroscopic titrations with CTDNA which resulted in a binding constant of 105 M-
1.135 More recent studies by Swavey and co-workers have found that multi-nuclear porphyrin 






Figure 14.  Structure of metallophorphyrin complexes as by Swavey and co-workers.135, 136 
 
As with conventional ruthenium complexes, arenes stabilizing face caps have also found 
applications in porphyrin based Ru-PDT systems. Dyson and co-workers recently reported the first 
conjugation between a porphyrin and arene-ruthenium system and evaluated its biological 
applications in against human melanoma cells.137 Five 5,10,15,20-tetra(4-pyridyl)porphyrin (TPP) 
areneruthenium(II) derivatives were prepared and characterized as potential photosensitizing 
chemotherapeutic agents as shown in figure 15.  Cellular uptake and localization microscopy 
studies of [Ru4-(η
6-C6H5CH3)4(TPP)Cl8] and [Rh4(η
5-C5Me5)4(TPP)Cl8] revealed that they 
accumulated in the melanoma cell cytoplasm in granular structures different from lysosomes. 
Thus, the porphyrin arene-ruthenium(II) derivatives represent a promising new class of 
organometallic photosensitizers able to combine chemotherapeutic activity with the photodynamic 







Figure 15. 5,10,15,20-tetra(4-pyridyl)porphyrin (TPP) arene-ruthenium(II) complex prepared by 
Dyson and coworkers.137  
 
Cobalt 
Cobalt is an essential trace element found in all animal species. It is one of the most 
important trace metals and in the form of vitamin B12 (cobalamin) the metal plays a number of 
critical roles in multiple biological functions including DNA synthesis, formations of red blood 
cells, maintenance of the nervous system, and in growth and development.138 The metal also plays 
a role in a least eight cobalt dependent proteins. Within cobalamin, cobalt exists in the +1 oxidation 
state (although it can undergo oxidation to the +2 and +3 states) and adopts an octahedral geometry. 
The cobalt(I) ion is equatorially coordinated to four nitrogen atoms of a corrin ring, and axially to 
5.6-dimethylbenzimidazoled and either cyanide, hydroxide, methyl, or 5’-deoxyadenosy 
groups.139 The cobalamins themselves are utilized as pharmaceutical agents in the treatment of 
hypocobalaminemia.140 
 Despite their well-known versatility, cobalt derivatives have not been explored extensively 





genotoxic and mutagenic rates at high concentrations. In fact the most significant medical 
advancement in terms of cobalt compounds is the clinical development of Doxovir (CTC-96) for 
Herpes labialis (or herpes simplex virus 1).141 The first reported bioactive complexes were reported 
in the 1950s,142 and since then there has been significant interest in cobalt(III) complexes of 
bidentate mustards,143, 144 which appear to act selectively on hypoxic tumor cells. Interestingly, 
these complexes show activity against leukemia and lymphoma cells as well as various bacterial 
strains. Cobalt complexes are also reported to possess various other activities including insulin-
mimetic properties, antifungal, and antioxidant activity.145, 146  
 
Cobalt Anticancer Agents 
Given the prominent role of cobalt in biological processes, humans have evolved 
mechanisms to overcome cobalt overload. Due to this fact, cobalt is viewed as less toxic to humans 
than non-essential metals such as platinum. This fact has prompted many researchers to investigate 
cobalt-containing compounds as less toxic alternatives to platinum-based anticancer drugs. The 
first biological study of these complexes was conducted by Dwyer et al.147 in the 1950s. The 
toxicity of tris-acetylacetane cobalt(III), tris-ethylenediamine cobalt(III) nitrate isomers, 1,8-
bis(salicylideneamino)-3-,6-dithiaocatance cobalt(III) chloride, 1,10-bis(salicyclindeneamino)-
4,7-dithiadecane cobalt(III) iodide, and tris-glycine cobalt(III) were investigated in mice after 
intraperitoneal injection (shown in figure 16). The doses required to induce death were reasonably 
high for all cobalt complexes tested (ranging from 75-165 mg kg-1), highlighting the low systemic 
toxicity of cobalt. While the anticancer properties of these complexes were never investigated 
these studies did contribute to the realization that cobalt-containing complexes possess vast 






Figure 16. Chemical structures of cobalt(III) coordination complexes used in early biological 
studies. 
 
Cobalamin bioconjugates for targeted delivery 
One attractive exploit of cobalt based drugs is to utilize the fact that rapidly proliferative 
cells have higher requirement for cobalamin than non-transformed or normal cells. Therefore, this 
dependence can be exploited by preparing cobalamin-drug bioconjugates to exploit this 
dependence with selectivity for cancer cells (select examples shown in figure 17). In general, the 
bioconjugate consists of a cytotoxic drug tethered to a cobalamin via the -axial position (through 
the Co-C bond). Grissom et al.149 developed a cobalamin-chloroambucil bioconjugated which was 
capable of killing leukemia cells to the same extent of free chlorambucil. The bioconjugate was 
shown to be extracellularly inert, but once internalized via receptor mediated endocytosis, was 
activated via b-axial bond cleavage, thereby releasing the drug in its active form. Toxicity can be 
attenuated in the presence of excess cobalamin, proving the cobalamin moiety is responsible for 





cisplatin to breast and ovarian cancer cells.150, 151 The platinum compound was fused to 
cyanocobalamin through a Pt-cyanide bond, however, biological studies have shown this treatment 
to be less effective than free cisplatin.150 One highlight of this class of compounds are 
nitrosylcobalamins, which possess a NO moiety in the -axial position.152 Mechanistic studies 
have shown that nitrosylcobalamins release NO upon cell entry leading to metabolism inhibition, 
DNA damage and apoptosis with selectivity for cancer cells over normal cells. In vivo studies 
conducted in dogs showed tumor reduction ranging from 43 – 77%, with one case showing 
complete remission following treatment for six months.153 Given these encouraging resulting it is 
expected that this class of drugs will shortly enter into human trials.  
 
Figure 17. Chemical structures of cobalamin–drug bioconjugates.  
 
Cobalt carbonyl-nonsteroidal anti-inflammatory drugs (NSAIDs) conjugates 
Cobalt(III) complexes have also been proposed as alternatives to platinum based anticancer 
agents. The first report appeared in 1956,142 where it was shown that cobalt(III) complexes could 





growth of murine leukemia cells. Some of the most famous Co(III) complex are those that fall into 
the category of cobalt-alkyne analogues such as those which incorporate dicobalt hexacarbonyl. 
Initially these complexes were utilized as labelling agents, for instance ethinylestradiol was 
tethered to [Co2(CO)6] and were used to monitor the binding of steroids to estrogen receptors in 
breast cancer cells.155 Jung156 and then Ott and Gust et al.157 investigated the anticancer properties 
of these [Co2(CO)6]-acetylene complexes and found the complexes had the ability to inhibit cancer 
cell proliferations and this was strongly dependent on the chemical nature of the acetylene moiety. 
The most active drug in the series showed that a Co-alkyne complexes bearing an acetylsalicylic 
acid derivative was the most potent (figure 18). This evolving class of compounds is labelled as 
cobalt-carbonyl-nonsteroidal anti-inflammatory drugs (NSAID) conjugates; they are highly active 
against breast cancer cell lines, owing to their increased intracellular levels due in part to their 
lipophilic characteristic when compared with their free ligands.156, 157 Recent studies have 
indicated that the potent activity of this class of compound is multifactorial and may be due to 
COX inhibition, caspase-3 cleavage, and matrix metalloproteinase dysfunction.154, 156, 158 Despite 
not knowing the exact mode of action of these compounds, they are often combined with other 
cytostatic agents such as imatinib, a tyrosine kinase inhibitor, which elicits an additive or 
syngergistic effect on the proliferation inhibition of acute and chronic myeloid leukemia cells (HL-
60, LAMA-84), and CML-T1).  
 
 






Given the success of cobalt-carbonyl complexes many small molecules and biomolecules 
containing dicobalt-carbonyl moieties have been prepared, however, overall these studies have 
proved somewhat disappointing. Fructopyranose derivatives coupled to [Co2(CO)6] through an 
alkyne functionality, similar to auranofin (a gold-based NSAID) displayed modest activity (IC50 > 
20 µM), against MCF-7 breast cancer cells.159 Attachment of dicobalt octacarbonyl to 
deoxyuridines has improved antiproliferative activity (IC50 = 5 – 50 µM in MCF-7 and MDA-MB-
231 cells.160 In contrast the conjugation of [Co2(CO)6] into the scaffold of a targeting peptide, 
leucine enkphalin (primary amino acid sequence Tyr-Gly-Gly-Phen-Leu), produced the first 
organometallic peptide bioconjugate to show significant toxicity against multiple tumor cell lines 
including HeLa and HepG2.161 More recently, a number of cobalt(II) complexes attached to 
NSAIDs, such as mefenamic acid, naproxen, and tolfenamic acid have been prepared and shown 
to interacted with duplex DNA and HSA with high antioxidant activity (high scavenging efficacy 
against hydroxyl and superoxide radicals).162, 163 Unfortunately, the anticancer potential for these 
complexes has yet to be explored.  
 
Hypoxia activated cobalt(III) prodrugs 
A popular strategy with cobalt drugs, similar to many other metal therapeutics, is to employ 
a cobalt(III) prodrug which is reduced in vitro to a more reactive Co(II) species in the harsh tumor 
microenvironment.164 This selective localized reduction event often prompts Co(III) prodrugs to 
be identified as hypoxia selective antitumor agents. The aforementioned cobalt(III) nitrogen 
mustards are selective in this manner as shown below in figure 19. Another example in this strategy 





report involved the linking of matrix metalloproteinase inhibitor (MMP), marimastat, with a 
Co(III)-tris(2-methylpyridyl)amine (TPA) chaperone to inhibit overexpressed metalloproteinases 
in tumor patients.165 The Co(III)-TPA chaperone transports the drug and is reduced in the tumor 
environment to a Co(II) species resulting in the release of the inhibitor intracellularly. This prodrug 
strategy is often utilized, however, it was noted that in this case both the prodrug and the free 
inhibitor promote and potentiate metastasis.165  
 
 
Figure 19. Examples of Co(III)-nitrogen and Co(III)-marimastat complexes 
 
Apart from TPA, other tetradentate ligand systems have also been used as chaperones for 
Co(III) agents. Ware et al showed that Co(III)1,4,7,10-tetraazacyclododecane (cyclen) complex 
were effective chaperones for toxins such as 8-hydroxyquinoline (8-HQ) and 
azachloromethylbenindoline (azaCBI, a DNA minor groove binder).166 These complexes showed  
20-fold increase in selective potency toward colorectal and adenocarcinoma cells in hypoxic vs 
oxic conditions. Larger macrocyclic ligands such as 1,4,8,11-tetraazacyclotetradecane (cyclam), 
have also been utilized to chaperones for azaCBI. Among this series the most effective complex 
displayed 81 – 212-fold greater toxicity under hypoxia than 20% oxygen against a panel of human 





electron reductase, NADPH or cytochrome P450 oxidoreductase which are known initiators of 
hypoxia activated prodrugs.167 
While typically less utilized due to their enhanced reactivity (leading to more unwarranted 
side effects), Co(II) complex have also seen some applications as anticancer drugs.148, 168-171 One 
such study reported on a series of salen complexes which stated that the associated anti-
proliferation activity was dependent on both the type and position of the substituents on the 
aromatic rings (figure 20).172 Additionally, there have been reports of 2-substituted benimidazoles 
possessing good antitumor activity against HeLa and HCT-115 cell lines.  
 
 
Figure 20. Example of a Co(II)-salen complex 
  
FINDING THE TARGET 
All of the above discussed examples represent the new era in drug discovery – gone are the 
days of serendipity and welcomed are the days of rational design. The rational design process of 
metallodrugs does not differ much from the process of designing a new organically based drug 
molecule. While rationally designed metallodrugs dominate current literature there is still a lack 
of studies working to elucidate the exact mechanism behind the observed bioactivity of these 
complexes. The critical first steps of this process involve the identification of the target associated 





In the world of traditional medicinal chemistry, the identification of these targets is often 
facilitated through the use of genomics and proteomics. A medicinal inorganic chemist involved 
in similar research would be classified under the emerging field of “metallomics”, which supports 
target validation. Metallomics is the full characterization of the metal or metalloid species present 
in a cell of tissue type, inclusive of their interaction with the genome, transcriptome, proteome, 
and metabolome.173 Research in this field is broadly tasked with comprehensively and completely 
understanding the metal uptake, trafficking, biological function, and excretion of these 
compounds.140  
Biological targets of metallodrugs have been comprehensively reviewed and critically 
evaluated quite recently,174, 175 and often a logical starting point for many researchers is to use what 
is already present within the body, as these systems work with these existing building blocks. 
Seven of the 21 naturally occurring amino acids, the building blocks for proteins, possess donor 
atoms (N, O, or S) which may allow for coordination or affiliation with a metallodrug. More 
specifically, metal-binding sites exist at the N-terminus of many naturally occurring proteins, such 
as the N-terminus of the Cu(II) and Ni(II) binding ATCUN motif, which possess three site for 
interaction with a metal.176, 177 Therefore, many metallodrugs possess a natural target in proteins 
as they may be able to alter the protein structure. Other proteins, such has metalloenzymes, require 
the presence of a metal center to be functional. If a chelating agent is administered that can strongly 
bind the metal ion, the target metalloenzyme may become inactivated.178  
Another popular target for metallodrugs is DNA, whether it be nuclear or mitochondrial. 
All base pairs possess the necessary atoms (N, O) which can be bound by a metal ion. Of particular 
importance is the binding interaction which take place at the N7 position of adenine and guanine 





covalently bind to form both intra- and inter-strand cross links. Additionally, the incorporation of 
planar hydrophobic groups which can insert between the base pairs in a process known as 
intercalation, facilitated by noncovalent forces can occur increasing binding strength. These, so-
called dual mode DNA binding metallodrugs not only bind covalently to the DNA but additionally 
intercalate as well, while other metallodrugs selectively target a specific sequence.  
Biophysical chemists are increasingly investigating the factors which promote metabolism 
of metals within the human body, as well as potential pharmacological effects. This has given rise 
to a number of bioanalytical chemists who are now studying the mode of action of metallodrugs 
by identifying their specific molecular targets.179 These studies now aim to utilize a variety of 
analytical techniques such as mass spectrometry,180, 181 capillary electrophoresis and a variety of 
other hyphenated techniques to probe the interactions of metal ions with proteins.182,183  
In drug development, it is critical to gain as much detailed information about the target of 
the molecule as possible. This information can then be further utilized to rationally design next 
generation drug molecules, which have a better fit (binding affinity) for the target as opposed to 
other competitive binding sites, resulting in a decrease in side effects. On the other hand, a 
simplistic one molecule-one target approach can pigeonhole the application of a drug molecule, 
making it difficult to treat complex diseases such as Alzheimer’s disease(AD) or Parkinson’s, for 
which more radical multifaceted targeting molecules are needed.184 
A 2005 study by the US National Cancer Institute (NCI) highlighted the diversity of metal 
complex being investigated in anticancer research, including approximately 1000 metal-containing 
compounds in a study.185 The main aim was to establish correlations between observed 
cytotoxicity and the gene expression profiles of various cell lines. While the study confirmed that 





fundamental classes were identified: (i) binding to sulfydryl groups, (ii) chelation, (iii) generation 
of ROSs, and (iv) production of lipophilic ions.185 These categories demonstrate the broad array 
of mechanisms and potential targets of metallodrugs. Similarly, while one metallodrug may act in 
different ways it may also be active against a variety of diseases. For instance, gold(I) compounds 
(i.e. auranofin) were traditionally employed to treat rheumatic arthritis but are slowly being 
integrating into anticancer clinic studies as well.  
As opposed to high-throughput screening or brute force searching for potentially active 
complexes it is becoming more popular, with the assistance of computational methods,186 to study 
the binding pocket of proteins and tailor molecules to nicely docks onto the protein. For example, 
PIM kinases are enzymes located on the proviral insertion site of the moloney murine leukemia 
virus that can be selectively inhibited by inert half-sandwich ruthenium-indolocarbazole 
complexes (i.e. NP309 and its derivatives) such as those developed by Meggers et al.187 These 
organoruthenium complexes have demonstrated an extremely good fit in the ATP binding pockets 
of PIM1 and PIM2 inactivating these PIM kinases, which in return leads to restored apoptosis in 








While the fit of a drug is fundamentally important, it cannot be overshadowed that the 
molecule must be able to reach its cellular target. Since many metallodrugs are injected into the 
blood steam or muscle, the molecule will contact many other biological substances which may 
alter its composition, for example cisplatin’s reaction with sulfur rich cysteine residues.  The most 
common substrate for metallodrugs is human serum albumin (HSA, 0.65 mM),183 which may act 
as a reservoir or transport vehicles in the case of ruthenium drugs due to iron mimetic properties. 
This substrate can also be exploited as HSA has been shown to accumulate in tumor cells due to 
increased demand for iron.189, 190 Another common protein which may interact with metal ions is 
apo-transferrin (Tf), which normally binds iron(III) but can also interact with main group,191 
transition metal,192 and lanthanide metal ions.193  
While metal centers have been the focus of many researchers the ligands bound to the metal 
center also play a critical role in the bio-activity of complexes. Ligands are most often, but not 
limited to, organic compounds that bind to metal ions, thus modifying the physical and chemical 
properties of the ion(s). Ligands can be introduced to the system to limit the adverse effects of 





of the aforementioned effects include modifying reactivity and lipophilicity, stabilizing specific 
oxidation states, and contributing to substitution inertness; however purposeful design today can 
go way beyond these effects. Tailored, multifunctional ligands for metal-based medicinal agents 
offer many exciting possibilities, and can play an integral role in muting the potential toxicity of a 
metallodrug to have a positive impact in areas of diagnosis and therapy. 
It is important to ask which parts of the active compound are essential for activity: the 
metal itself, the ligands, or the intact complex of metal plus, at least, some of the ligands? Many 
metallodrugs are “pro-drugs”, and undergo ligand substitution and/or redox reactions before they 
reach the target site. Thus, a rational design of potential therapeutic/diagnostic agents is needed to 
achieve specific targeting features and to control toxicity (side-effects), by controlling 
thermodynamic and kinetic processes of metal complexes. Tailored, multifunctional ligands for 
metal-based medicinal drugs offer many exciting possibilities, including targeting specific tissues, 
membrane receptors, or endogenous molecules, and can play an integral role in modulating the 
potential toxicity of a metallodrug to achieve success in areas of diagnosis and therapy. 
Additionally, with the diverse and infinite number of mechanisms of these metallodrugs there is 
renewed hope that they can overcome developed resistance;194 examples of overcome drug 
resistance from malaria research and cancer research suggest this hope may not be in vain.195, 196 
 
RESEARCH GOALS 
  Although there are numerous known, effective metal complexes employed as agents 
against a variety of human diseases, there is still need to improve and search for potentially more 
effective drugs. The mechanisms of action of many current transition metal therapeutics also 





metal complexes and conduct structure activity relationship (SAR) studies, it is critical to fully 
elucidate these mechanisms of actions. Therefore, the aims of this thesis are twofold: (1) to conduct 
preliminary mechanistic studies on the bioactivity of transition metal complexes and (2) to design 
and synthesize novel ligands and complexes for future mechanistic and structure activity 
relationship studies. In part 1 (Chapters 2 and 3) a variety of cell-free and cell-based assays are 
utilized to investigate the mechanism of action of various transition metal complexes; while part 
2 (Chapters 4 and 5) focuses on the development of small libraries of molecules for future SAR 
studies. 
In chapter 2, a Co(III) complex, [Co(phen)2(MeATSC)](NO3)3·2.5H2O·EtOH,
 was tested 
for its chemotherapeutic potential against a model metastatic breast cancer system, as well as for 
its interaction with CT DNA in order to mimic cellular DNA. After revealing the complexes ability 
to induce apoptosis further studies believed to be critical to its ability to inhibit cancer cell growth 
are discussed. In addition, nanosecond pulse electric field (nsPEF) technology was combined with 
[Co(phen)2(MeATSC)](NO3)3·2.5H2O·EtOH in hopes of developing a novel localized ablation 
therapy. Synergistic studies were conducted and the observed effects of this novel locoregional 
ablation treatment therapy are discussed. 
In chapter 3, to further work previously conducted within our lab, a oxidovanadium(IV) 
complex was synthesized and characterized via conventional spectroscopic techniques and X-ray 
crystallography. In addition, a novel binuclear Ru(II)-V(IV) complex, 
[Ru(pbt)2(phen2DTT)VO(oda)](PF6)2•2.0H2O•0.5C2H5OH, was synthesized, characterization and 
studied for its binding interactions with CT DNA. In this chapter we discuss the utility of 
isothermal titration calorimetery (ITC) as a method for determining binding and thermodynamic 





conducted in collaboration with Ms. Kathy Currie (Undergraduate Student, ODU) on the synthesis 
and binding interactions of the complexes presented. Comments on the antimetastatic potential of 
the complexes will also be made.  
In chapter 4, the synthesis and characterization of a novel series of N,S coordinating ligands 
and subsequent complexes is discussed. Utilizing a one-pot synthetic scheme analytically pure 
pyridine-2-thiocarboamides (PCAs) were prepared in a single step reaction. The molecular 
structure was confirmed using a variety of spectroscopic techniques, to include in one case X-ray 
crystallography, confirming the utility of the modified Willgernot-Kindler reaction scheme 
utilized. Analytically pure ligands were complexed with either Co(III) or Ru(II) precursor 
molecules and the characterization of these coordination complexes is discussed as well. Finally, 
in chapter 5, the synthesis and characterization of a library of novel thiadiazol and 
triazolothiadiazol containing ligands will be discussed. The compounds prepared represent a proof 
of concept model for the synthetic procedure and will be further investigated for their biological 





CHAPTER 2  
PRELIMINARY MECHANISTIC STUDIES OF A Co(III)-COMPLEX AND NSPEFs: A 
POTENTIAL LOCOREGIONAL ABLATION TECHNIQUE FOR TREATMENT OF 
METASTATIC BREAST CANCER 
 
INTRODUCTION 
Metastatic breast cancer is the most common malignant disease in western women, with 
approximately 1.7 million new breast cancer diagnoses in 2014.15, 197 In many patients, it is not the 
primary tumor, but the metastases at distant sites that are the main cause of death. While rates of 
metastasis and mortality have slightly decreased over the last two decades, the disease is still 
considered incurable even with advances in early detection and systemic adjuvant therapies.198 
Chemotherapy only increases the 15 year survival rate of women under 50 by 10%; in elderly 
women this increase is only 3%.199, 200 Currently, no technology exists for the accurate prediction 
of metastasis and therefore patients are subjected to the toxic side effects of classic chemotherapy 
which substantially affect the patients’ quality of life.201-203   
Advances in genomics and cell biology have increased the opportunity for rational design 
of targeted drugs and therapies to inhibit the function of specific molecules, including those 
contributing to the proliferation of cancer cells.204-207 Although, targeted therapies may offer 
enhanced efficacy and improved selectivity (and therefore less nonspecific toxicity), most often 
their effects are not durable when they are used alone. Cellular pathways operate in vast 
interconnected webs as opposed to information superhighways, therefore with multiple 
redundancies, alternative pathways may be activated in response to inhibition of a specific 





pressure of the targeting agent, resulting in drug resistance.33 For this reason, combination 
therapies are often needed to effectively treat many tumors and infectious diseases.33, 208  
As discussed in chapter 1, following the widespread success of cisplatin, a variety of 
transition metal coordination compounds have been extensively studied for their biological 
properties.209, 210 Specifically, polypyridyl coordination complexes have been extensively 
investigated due to their unusual binding properties and general photoactivity; these coordination 
compounds have been shown to be suitable candidates as DNA secondary structure probes, 
photocleavers, and antitumoral drugs.211, 212 The effects of size, shape, hydrophobicity, and the 
charge on the binding of the complex to DNA have been studied by changing the type of 
heteroaromatic ligands or metal center.213, 214 The vast majority of such studies have been focused 
on complexes of Ru(II),215-217 but to a far lesser extent, on other metal complexes. For instance, 
Barton et al.214 has reported that chiral phenanthroline–cobalt(III) complexes recognize different 
local structures of DNA.  
To date, the only cobalt-based therapeutic that has reached clinical trials is Doxovir (CTC-
96), a Co(III) Schiff base complex effective against drug-resistant herpes simplex virus 1 
(HSV1).141 The mechanism of action of Doxovir, however, is not fully understood. A substantial 
amount of literature on bioactive cobalt derivatives has been published in the last decade, 
demonstrating their rich potential in medicinal applications.164, 218 However, the rationale behind 
the design and mechanisms of many of these agents has not been clearly elucidated. An 
understanding of how the unique properties of cobalt complexes interplay with biology to elicit 
therapeutic effects is clearly necessary for the development of cobalt-based drugs. 
For many years, thiosemicarbazones and their metal complexes have been found to exhibit 





pharmacology to nuclear medicine.219-223 In 1994,224 and more recently, cobalt(III) complexes with 
TSCs and methyl substituted phenanthroline ligands have been reported as anti-cancer agents as 
they inhibit cell growth of several cancer cell lines.225-229 230  The present level of interest in metal 
complexes of TSCs stems from the fact that the inherent biological activity of the organic ligand 
is enhanced upon coordination to the metal center.231 
While extensive research has been conducted on chemotherapeutic drugs, many effectively 
target specific molecular processes such as DNA replication which is not unique to cancerous cells 
leading to unwarranted side effects. Therefore, in attempts to mitigate harmful side effects low 
dose chemotherapeutic drugs are often combined with alternative treatments such as: targeted,232 
immuno-,233 and radiation-therapies.234 In particular, electrochemotherapy (ECT) which utilizes 
conventional electroporation with electric fields in the micro- to milli-second range has found 
widespread success.235-238 ECT cause large pores or defects to form in the plasma membrane, 
thereby allowing for the entry of poorly permeable drugs such as bleomycin to ablated tumors.239 
Concepts from this conventional electroporation techniques have been further exploited and now 
extended to irreversible electroporation (IRE), which uses stronger electric fields to destroy plasma 
membranes entirely causing tumor necrosis without the utilization of drugs.240 Although ECT and 
IRE are not generally utilized in the United States, both have found widespread application in 
Europe for the treatment of cancer.241 
As opposed to these conventional electroporation techniques, nanosecond pulsed electric 
fields (nsPEFs) are an emerging alternative novel treatment for cancer.242, 243 While nsPEFs can 
be regarded as an extension of conventional electroporation, generally, pulse duration of only 10 
ns to several hundred ns, and electric field intensities of 10 kV/cm to several hundred kV/cm are 





in sub-microsecond bursts also known as “pulsed power”.244, 245 For comprehension of the “pulsed 
power” concept consider the release of one joule of energy in one second versus releasing the same 
energy over one nanosecond. If the stored energy was release over one second the peak power 
would be only 1 watt, not even enough energy to power a light bulb, however, if released over one 
nanosecond the peak power would be one gigawatt (109), a billion times greater. This energy could 
light an entire medium sized city for that nanosecond.  
Due to these ultrashort pulse durations, nsPEFs have been shown to induce a specific series 
of unique biological effects such as apoptosis,246-249 calcium fluctuation and phosphatidylserine 
translocation,250-252 with little hyperthermal effects. Researchers in this area typically fall into a 
newly emerging field known as bioelectrics (coined by Dr. Karl Schoenbach – Frank Reidy Center 
for Bioelectrics) and are concerned with investigating the effects of short burst electrical stimuli 
on cells and tissue for various basic science and therapeutic applications. Despite the relatively 
new evolution of this field, there has been extensive modeling253, 254 and experimental studies249, 
255-259 which detail effects on plasma membranes and intracellular membrane such as the 
endoplasmic reticulum,250, 260-262 mitochondria,251, 255, 263, 264  and the nucleus/DNA. Given the 
broad-based effects of nsPEFs on cellular structure and function it is unsurprising that there are 
also reports on the utility of this technique for cancer ablation.259, 265, 266 Recently it was reported 
that µS- and ns-PEFs can be utilized as a locoregional minimally invasive treatment for 
hepatocellular carcinoma.259, 265, 266 Additionally, nsPEF have been shown to induce apoptosis in a 
variety of cell types, including pancreatic cancer, melanoma and HeLa cells.246, 267, 268  NsPEFs 






Herein we present our efforts to study the mechanism by which, a non-platinum complex, 
[Co(phen)2(MeATSC)]·2.5H2O·C2H5OH (1),
273 inhibits breast cancer cell growth. In this study, a 
highly metastatic 4T1-luc mouse mammary cancer cell line was utilized to mimic tumor growth 
and metastasis in its human counterpart.274-276 Due to these properties we have set out to test the 
efficacy of the complex in inhibiting their proliferation, as well as discern the mechanism of action 
in cell-free and cell-based assays. While utility of nsPEF has been proven in vivo as a drug free 
therapy for the treatment of breast cancer,277 no such investigation has been conducted where a 
transition metal chemotherapeutic agent is combined with nsPEF technology. As such, a novel 
combination therapy involving treatment of cells with nsPEFs and a Co(III) transition metal agent 
will be explored.   
 
 




[Co(phen)2(MeATSC)](NO3)3·2.5H2O·C2H5OH (1) was provided by Dr. A.A. Holder and 





solutions were prepared with doubly-distilled water from a Milli-Q system. Fetal bovine serum 
(FBS) and DMEM were obtained from Mediatech, Inc. (Manassas, VA). CellTiter 96® 
AQueous One Solution Cell Proliferation Assay (MTS), and Caspase-3/7 Glo kits were purchased 
from Promega Corporation (Madison, WI). CT DNA was purchased from Sigma (St. Louis, MO). 
Stability of 1 in PBS buffer 
The stability of 1 in PBS buffer was examined by UV-visible spectrometry using a Cary 
5000 UV-2450 spectrophotometer. Spectra were collected from samples dissolved in a PBS 
solution containing: NaCl (137 mM), KCl (2.7 mM), Na2HPO4 anhydrous (10 mM), and KH2PO4 
(2 mM), pH 7.4, with the solutions having 5 % DMSO added to aid in solubility. Spectra (240 nm 
- 1000 nm) were recorded every ten minutes over twenty-four hours. Data was fit utilizing Agilent 
UV-Vis ChemStation software.  
DNA binding UV-visible titration studies 
Electronic absorption titration experiments were conducted on a Agilent 453 diode array 
spectrophotometer at room temperature. Electronic absorption titration experiments were 
performed with a fixed concentration of 1 (10 μM) but variable nucleotide concentration ranging 
from 0 to 100 μM. 3 mL solutions of the blank PBS and the Co(III) complex were placed in two 1 
cm pathlength curvettes. Then aliquots of buffered CT DNA solution were added to each to 
eliminate background absorbance from DNA itself. Before each spectra was recorded, the Co(III)-
CT DNA solutions were allowed to equilibrate at room temperature for 5 min. Data was fit utilizing 
Agilent UV-Vis ChemStation software.  
Competitive fluorescence binding studies 
The relative binding of 1 to CT DNA was determined with ethidium bromide (EB)-bound 





Spectrophotometer with a Peltier 4 position multi-cell holder and temperature probe accessories. 
In displacement experiments a solution containing 10 µM DNA and 0.33 µM EB (saturated 
binding conditions), was titrated with concentrated solution of 1 to generate solutions with various 
mole ratios of complex to CT DNA. The influence of the addition of complex to the EB-DNA 
complex was obtained by recording the variations in the fluorescence emission spectra with 
excitation at 525 nm and emission at 605 nm with slit widths of 5 nm at various temperatures. 
Cell culture 
4T1 cells (mouse mammary breast cancer) were obtained from American Type Culture 
Collection (ATCC). 4T1 cells were transformed with pGL4.50luc2/CMV/Hygro. 4T1-luc cells were 
maintained in the logarithmic stage of growth in high glucose DMEM (Dulbecco’s Modified 
Eagle’s Medium) supplemented with 10% fetal bovine serum (FBS), 1% non-essential amino acids 
(NEAA) and 1% antibiotics (100 units/mL penicillin and 100 µg/mL streptomycin) at 37 °C in a 
humidified atmosphere containing 5% CO2 and were used at passages 3 to 25. Except where 
indicated, analyses were performed on same passage cells within two weeks after thawing. Cell 
line used in these studies was tested and shown to be free of mycoplasma and viral contamination.  
Preparation of stock solutions of complex 1 
An 80 mM stock solution of complex 1 was prepared by dissolving 39.6 mg of complex in 
500 µL of DMSO. All other stock solutions were diluted to the desired concentration using 
complete media along with the respective vehicle control (DMSO) ≥0.5%.  
Cytotoxicity studies 
Cell viability following exposure to complex 1 was assessed via the CellTiter 96® 
AQueous One Solution Cell Proliferation (MTS) Assay (Promega, Madison, WI). Briefly, cells were 





Following incubation, fresh solutions containing complex 1 at various concentrations were 
prepared in complete medium. Seeding media was removed and cells were then treated with 100 
µL of 1 in complete media at various concentrations (0 – 200 µM) and incubated for 24 hours at 
37 °C in 5% CO2. After 24 hours incubation, the cells were treated with 20 µL of the CellTiter 
96® AQueous One Solution Reagent containing [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and phenazine ethosulfate. 
Following one hour incubation, the absorbance was measured at 492 nm using either a µQuant™ 
Microplate spectrophotometer or VersaMax ELISA Microplate reader. To block autophagy, cells 
were preincubated at 37 °C for four hours with 600 nM necrostatin-1 (Sigma-Aldrich, St. Louis, 
MO) prior to the addition of complex 1. To inhibit caspase activity, cells were preincubated with 
10 mM benzyloxycarbonyl-Val-Ala-Asp-(O-methyl)-fluoromehylketone (z-VAD-FMK) for four 
hours prior to the addition of complex 1. The compound as well as all positive and negative 
controls were tested in triplicate on cells at various passage numbers. 
Caspase 3/7 Activity 
Caspase 3/7 activity was determined by Caspase-Glo 3/7 kit using tripeptide substrate 
sequences Ac-DEVD-AMC (Promega, Madison, WI). According to manufacturer’s instruction, 
for each analysis, cells were plated in triplicate on 96-well plates (2.5 x 104 cells per well) in the 
presence or absence of pan caspase inhibitor z-VAD-FMK for four hours. Seeding media was 
removed and cells were then treated with 100 µL of complex 1 in complete media at different 
concentrations and incubated for 24 hours at 37 °C in 5% CO2. After twenty four hour incubation, 
plates were equilibrated to room temperature for 30 minutes and 100 µL of Caspase-Glo 3/7 
reagent was added to each well and the contents were gently mixed using a plate shaker at 300 





Labtech), after thirty-five minute incubation at room temperature, which measured linear catalytic 
rate for the substrate. Increase in activity was calculated based on activity of control (sham-treated) 
cells.  
Analysis of autophagy by flow cytometry 
Autophagy was detected using Cyto-ID® autophagy detection kit (Enzo Life Science, 
Farmingdale, NY) using Cyto-ID™ green autophagy detection reagent, which selectively labels 
green vacuoles associated with the autophagic pathway, with minimal background lysosomal 
staining. Briefly, cells were harvested from culture and plated on a 24 well plate (7.0 x 104 cells 
per well) for four hours in the presence or absence of 600 nM necrostatin-1. After incubation, the 
supernatant was discarded and cells were treated with 100 µL of complex 1 in complete media at 
different concentrations (0 – 80 µM) and incubated for various times (1 – 24 h) at 37 °C in 5% 
CO2. After incubation, cells were washed with twice with PBS, centrifuged (1000 rpm for 5 
minutes), and the supernatant was discarded. The cells were resuspended in 250 µL fresh indicator 
free DMEM containing 5% FBS. The staining solution was prepared by diluting 1 µL of Cyto-
ID® green detection reagent to 1 mL with indicator free DMEM containing 5% FBS. Then 250 
µL of the staining solution was added to the cell suspension and each vial was gently vortexed. 
The samples were then incubated for 30 minutes at 37 °C, centrifuged, washed with 1X assay 
buffer (500 µL) and resuspended in 1X assay buffer. The cell samples were then analyzed on a 
Becton Dickinson FACSAria flow cytometer in the FL-1 and FL-2 channels for 10,000 events. 
Autophagic activity was estimated measuring the mean fluorescence intensity (MFI) value. 
Positive controls for inducing autophagy included: Rapamycin (500 nM), Chloroquine (120 µM), 
and starvation (DMEM - FBS). Results shown are representative of multiple experiments 





Flow cytometric analysis of calcium flux and mitochondrial membrane potential (Δm) 
The levels of intracellular calcium were determined using Fluo-4 Direct (Molecular Probes, 
Eugene, OR) and depolarization of the m was detected using tetramethylrhodamine ethyl ester 
(TMRE) (Immunochemistry Technologies LLC, Bloomington, MN). Briefly, cells were seeded on 
a 24 well plate (7.0x104 cells per well) for four hours. After four hour incubation, media was 
removed and cells were then treated with 500 µL of complex 1 in complete media at different 
concentrations for either 2, 4, or 6 hours at 37 °C in 5% CO2. At the specified time points (2, 4, 
and 6 h) cells were then harvested using 150 µL trypsin-EDTA 1X (ThermoFisher Scientific, 
Waltham, MA), pelleted and the supernant was removed. Cells were then preincubated with 1x 
Fluo-4 Direct calcium reagent loading solution for 60 min at 37 °C. During the last 15 min of Fluo-
4 incubation, 200 nM TMRE was added to the solution. At the end of incubation, cells were washed 
2x with PBS and resuspended in culture media (500 µL) and analyzed on a Becton Dickinson 
FACSAria flow cytometer. The average red fluorescence intensity (10,000 cells) was analyzed on 
the FL-2 channel and green fluorescence was read on the FITC channel. The green emission of 
Fluo-4 increases when calcium increases and TMRE red emissions decreases when m 
decreases. Data was analyzed using FlowJo_V10 software. 
Flow cytometric analysis of histone 2.AX (H2AX) phosphorylation 
Cells were harvested and plated on a 24 well plate (1.0 x 105 cells per well) for 3 hours. 
After three hours, media was removed and cells were treated with 500 µL of complex 1 in complete 
media at different concentrations and incubated for various 18 hours at 37 °C in 5% CO2. After 
eighteen hour incubation cells were washed, harvested via trypsinization, and resuspended in 
fixation/permeabilization solution (BD Cytofix/Cytoperm™, BD Biosciences) for 20 min at 4°C. 





γH2AX (Ser139) (Cell Signaling Technology) for 1 hr at 37°C and followed by incubation with a 
secondary Alexa 488-conjugated goat anti-rabbit IgG for 45 min at room temperature (Molecular 
Probes, Invitrogen). After washing twice in BD Perm/Wash buffer, the fluorescence of 10,000 
cells was analyzed using a Becton Dickinson FacsAria flow cytometer (488nm, FL-1). Positive 
control for inducing DNA damage included incubation of cells with 16.5 µM cisplatin for 2 hours 
prior to fixation. 
Determination of cellular viability following exposure to nsPEFs 
Cells were harvested from culture via trypsinization and resuspended in the fresh cell 
culture medium at a density of 3.2 x105 cells/ml. 130 µL of cell suspension was placed in a 0.1-
cm gap-width cuvette (Biosmith, San Diego, CA) and exposed to nsPEFs. 4T1-luc cells were 
exposed one, five, or ten pulses with duration of 60 ns and electric field strength ranging from 0 
to 60 kV/cm. Cells where then plated on a 96 well plate (2.5x104 cells per well). Cellular viability 
was assessed after 24 hours using the CellTiter 96® AQueous One Solution Cell Proliferation (MTS) 
Assay as describe above.  
The 60 ns pulses were produced by a Blumlein circuit switched by a pressurized spark 
gap.278 The Blumlein circuit consisted of two 50 Ω coaxial cables, which gave a total impedance 
of 100 Ω. This value was chosen to match the impedance of the cable, Z, to the resistance of the 
cell suspension between the two electrodes, R. In this case, the energy stored in the cables is 
transferred into the load in the form of a rectangular power pulse, with the pulse duration 
determined by the length of the cable and the speed of electromagnetic waves in the dielectric of 
the cable.279 For the cables used in this device, the dielectric constant is ɛr = 2.25, producing a 
wave velocity v = c/(εr)
1/2 of 2 × 108 m/s with c being the speed of light in a vacuum. The total 





as T = l/ν. The rise time of the pulse (e.g., the time to reach a steady state mode with a current 
of I = Vo/Z) is determined by the closing switch, where Vo is the value of the applied voltage. In 
this device, a spark gap with a closing time of less than 10 ns was used to produce 60 ns and 300 
ns pulses with amplitude jitter of less than 5%. Since the amplitude of the voltage applied is below 
1 kV for pulses with duration in excess of 1 μs, a pulse generator using MOS field effect transistors 
(BIMOSFET; IXBH 40N160, IXYS Corporation, Santa Clara, CA) could be used. The rise time 
of these pulses is ∼50 ns, which is short compared to the pulse duration. The maximum voltage of 
the long pulse was 1.6 kV, limited by the maximum operating voltage of the BIMOSFET; the 
maximum voltage of the short pulses was 5 kV, limited by the hold-off voltage of the cable 
connectors. 
Determination of cellular viability following exposure to both 1 and nsPEFs 
     Cell viability following exposure to both complex 1 and nsPEF was assessed via the CellTiter 
96® AQueous One Solution Cell Proliferation (MTS) Assay similar to above describe procedures. 
Briefly, cells were seeded on a 24 well plate (5.0 x 104 cells/well) in 500 µL of medium and 
incubated for 4 hours. Cells were then treated with 500 µL of complex 1 in complete media at 
different concentrations and incubated for 24 hours at 37 °C in 5% CO2. After twenty four hour 
incubation, the cells were washed twice with PBS, harvested, pelleted and resuspended in culture 
medium. 130 µL of cell suspension (3.2 x 104 cells) was placed in a 0.1-cm gap-width cuvette 
(Biosmith, San Diego, CA) and exposed to ten pulses with duration of 60 ns and electric field 
strength ranging from 0 to 60 kV/cm. 100 µL of cell suspension (100 µL ≈ 2.4 x 104 cells) where 
then plated on a 96 well plate and cellular viability was assessed after 24 hours using the CellTiter 






RESULTS AND DISCUSSION  
The electronic absorption spectra of complex 1 consists of three well-resolved bands in the 
range of 200–450 nm, specifically with ε = 19 x 103 M-1 cm-1, 9.1 x 103 M-1 cm-1, and 9.6 x 103 M-
1 cm-1 at 294, 378 (shoulder), and 392 nm, respectively.273 The high energy absorption bands in 
the spectra of 1, below 300 nm are assigned to π → π∗ intra-ligand charge transfer transitions and 
the band found around 400 nm is assigned to ligand-to-metal charge transfer (LMCT). Kinetic 
experiments were conducted monitoring any changes in the high energy absorption bands over 
twenty-four hours, in PBS to ensure inertness in buffered conditions. As shown in figure 21 there 
are only minimal changes (<0.005 absorbance units) in the electronic absorbance spectrum over 
the time period, confirming the complex is inert in the selected buffered solution, with the complex 
never reaching one half-life over the course of the experiment. Upon the addition of DNA, the 
above bands exhibited slight hypochromism accompanied with a slight blue shift. Hypochromisim 
and bathochromism in the UV absorption spectrum following addition of DNA, indicates the 
complex can interact with DNA, most likely through stacking interactions between an aromatic 
ring and the base pairs of DNA.280  The extent of hypochromism exhibit is often an indicator of 
the strength of intercalation, as shown in figure 22, only slight hypochromism exist indicating the 







Figure 21. Absorbance vs Time plot of complex 1 in PBS (pH = 7.4). Cycle Time: 900 s, 
Temperature: 25 °C, [Complex] = 24 µM.   
 
For metal complexes, DNA binding can occur via a variety of mechanisms including base 
pair intercalation, groove binding, and electrostatic binding.281 In order to quantitatively determine 
the binding strength of complex 1 to DNA, the intrinsic binding constants (Kb) were obtained by 
monitoring the changes in lower energy bands of complex 1, with increasing concentration of 
DNA using the equation282: 
 
           [DNA]/[ɛa−ɛf] = [DNA]/[ɛb−ɛf] + 1/Kb[ɛb−ɛf] (1) 
 
where: [DNA] is the concentration of DNA in base pairs, the apparent absorption 





in free solution, and the extinction coefficient for the complex in the fully bound form, 
respectively. A plot of [DNA]/[ɛb−ɛf] vs [DNA] gave a slope and the intercept which are equal to 
1/[ɛa−ɛf] and (1/Kb)/[ɛb−ɛf], respectively; Kb is the ratio of the slope to the intercept. The magnitude 
of Kb was calculated to be 6.69 × 10
4 M-1. The observed Kb value revealed that complex 1 binds 
weakly with CT DNA. The nature of the results suggest that the complex interacts weakly with 
DNA via an intercalation mechanism. It is however, possible that the cationic nature of the 
complex could provide for electrostatic interactions.  
 













































Figure 22. UV-visible spectral changes observed during titration of complex 1 with CT DNA. [Co] 
= 50 µM, [DNA] = 0 - 200 µM, buffer PBS (pH = 7.4). Arrow indicates the change upon increasing 






Steady-state competitive binding experiments using complex 1 as a quencher were 
undertaken to get further determine if complex 1 interacts with DNA via and intercalative fashion, 
similar to other metallointercallators. Ethidium bromide (EB) is a planar cationic dye which is 
widely utilized as a sensitive fluorescence probe for native DNA as it intercalates well through 
interactions with the minor groove.283 EB emits an intense fluorescent signal at ≈600 nm (λex = 
525 nm) in the presence of DNA due to its strong intercalation between the adjacent DNA base 
pairs, however, the addition of a competitive substrate which also binds to DNA drastically reduces 
the observed fluorescent intensity due to displacement and subsequent quenching of the EB 
molecules in aqueous solution.284, 285 As the concentration of the competitive substrate increases, 
the fluorescence spectra shows a significant shift (red) in wavelength with a reduction in the 
fluorescence intensity clearly indicating that the EB molecules are displaced from their DNA 
binding sites and are replaced by the substrate under investigation.286  
The fluorescence quenching spectra of DNA-bound EB by complex 1 is shown in figure 
23 (and supporting figure 1) and illustrates that the quenching of EB bound to DNA 1 is in good 








The Stern-Volmer quenching constant (Ksv) obtained by taking the ratio of the slope to the 
intercept (obtained by plotting F0/F vs [Q]) yielded a value of 3.46 × 10
4 M−1. This values 
suggested that the complex 1 shows high quenching efficiency. Furthermore, the apparent binding 
strength (Kapp) values obtained for the complex using the equation: KEB [EB] = Kapp [complex] 





of EB and KEB = 1.2 × 10
6 M−1, ([EB] = 4 μM)) was 3.2 × 105 M−1, which suggest moderate 
binding strength. An alternative calculation of the binding constant (Kb) value obtained from a plot 
of log[(F0−F)/F] vs log [Q] were found to be 1.68 × 10
5 M−1 as shown in figure 24, confirming the 
moderate binding ability. A typical DNA intercalator like EB has a binding constant of 3.0 x 106 
M-1.283, 289 Given that the Kapp from the competition experiments are an order of magnitude less 









Figure 23. Fluorescence spectra of competition of EB and complex 1 binding with CT DNA. ex = 520 nm, [EB] = 0.33 µM, [DNA] = 






Figure 24. A plot of (Fo-F)
-1 vs. [Complex]-1 obtained from the fluorescence titration of complex 
1. 
 
The quenching of the fluorescence can occur via two mechanisms – dynamic and static 
quenching.287 It is proposed that in the reaction here, predominantly static mechanism is operating. 
In this scenario a quencher-fluorphore complex is formed. This is inferred from the bimolecular 
quenching constant (Kq) calculated using 0 = 22 ns for the EB-DNA complex. Keq for the reactions 
are on the order of 1012 M-1s-1 which are two orders of magnitude larger than the limiting value of 
1010 M-1 s-1 considered the largest possible value in aqueous solution. 
The typical thermodynamic parameters for a reaction can be calculated from the obtained 























Table 3. Binding constants and thermodynamic parameter for interactions of complex 1 with the 
EB-DNA complex 
T/K K (10-4)/ (M-1) R2 G° / kJ mol-1 H° / kJ mol-1 S° / J mol-1 K-1 
298 12 0.9899 -30.8 40 237 
304 16.5 0.9942 -32.4   
 
  
The values obtained are given in table 3. There are several intermolecular forces at play 
when a small molecule binds to a macromolecule. Both the Hº and Sº are positive which suggest 
that the major force in the action is hydrophobic in nature. This is most likely attributed the water 
molecules around the DNA being displaced upon binding to the compound and the whole system 
acquiring a more random configuration.  
The cytotoxicity of complex 1 against a model metastatic breast cancer cell line was 
measure by means of the MTS (colorometric) assay, which serves as an index of cell viability by 
detecting the reduction of a tetrazolium compound to purple formazan product in the presents of 
NADPH or NADH produced by dehydrogenase enzymes in metabolically active cells. As shown 
in figure 25, the compound exhibited a concentration-dependent decrease in cell viability after a 
24 h treatment. An IC50 value of 34.4 ± 5.2 µM was calculated indicating moderate anti-cancer 
activity for complex 1. Additionally, the precursor [Co(phen)2(OH2)2](NO3)3 has previously been 
shown to be non-toxic in multiple cell lines therefore the observed activity by this complex 1, must 
be derived from the biological activity of this specific architecture, and not simply from the 
chaperoning of “free” Co(III) into cells by the ligand. The inhibition of cancer cell proliferation 





or cell cycle arrest, or a combination of these two modes.290, 291 Due to the many potential cellular 
targets (i.e. nuclear DNA, mitochondria, etc.) as well as potential background absorbance of the 
complex confirmation of the calculated IC50 values were attempted utilizing two other assays 
which measure different cellular function, specifically lactate dehydrogenase and ATP activity, 
however protocols were never fully optimized for these methods. 
 
Figure 25. 4T1-luc cellular viability following exposure to complex 1. Graphs represent minimum 
(n = 3) replicates of data with plates being 1 h post incubation with MTS reagent. Data was fit 
using an exponential function using Origin 8 software. IC50 value = 34 ± 3.5 µM 
 
Apoptosis can be initiated by two main mechanisms, extrinsic (death receptor) and intrinsic 
(mitochondrial) pathways. Caspases, members of the cysteine acid proteases family, are known 
effectors in both the mitochondrial and receptor mediated apoptotic pathways.292, 293 The roles of 
known caspases are outline in table 4. To determine the molecular events initiated by complex 1, 





Monitoring the activity of this effector proteins would discern whether cell-death induced by 
complexes was due to apoptosis or other biological factors. Figure 26 shows the complex 1 induces 
increases in caspase-3/7 cleavage in a concentration dependent manner over a five hour time 
period, with peak activity occurring at 4 hours. Additionally, the preincubation of a common pan 
caspase inhibitor z-VAD-fmk completely inhibits caspase cleavage in all concentrations. 
Following this observation, the effect of inhibiting the caspase cascade on cellular viability was 
investigated. As shown in figure 27, the presence of z-VAD-fmk, shifted the calculated IC50 value 
to the higher concentrations with the calculated IC50 value for the complex almost doubling to ≈ 
64.6 ± 4.7 µM. This data indicated that complex 1 induces a caspase dependent, apoptotic cell 
death, which is the proposed major mechanism of cell death in response to this complex. However, 
without monitoring other upstream effector caspases (i.e. caspases-8,-9) and proteins (i.e. BAX, 
Bcl-2, BAD, BID, and PKB) it is impossible to determine whether the observed apoptotic event 
stems from either the extrinsic or intrinsic pathways. However, given the data obtained from the 
UV-vis and fluorescence binding assays previously discussed, which indicate DNA 
intercalation/interaction, it is hypothesize that the apoptotic event is initiated after DNA damage 
which would activate the intrinsic (mitochondrial) pathway. However, further experimentation 








Table 4. Role of caspases 
Caspase Conventional Role Other Roles 
Caspase-1 Inflammatory Response Unknown 
Caspase-2 Apoptosis (Initiator) DNA damage response 
Caspase-3 Apoptosis (Executioner) Cell differentiation 
Caspase-4 Unknown, presumed inflammatory response  
Caspase-5 Inflammatory Response Possible tumor suppressor 
Caspase-6 Apoptosis (Initiator) Unknown 
Caspase-7 Apoptosis (Executioner) Unknown 
Caspase-8 Apoptosis (Executioner) Embryonic development, motility, tumor metastasis, 
T cell proliferation, cell cycle regulation, bacterial 
infection response 
Caspase-9 Apoptosis (Initiator) Differentiation of cell type 
Caspase-10 Apoptosis (Initiator) Immune response to dsRNA, possible tumor 
suppressor 
Caspase-11 Inflammatory Response Cell migration 
Caspase-12 Inflammatory Response Unknown 
Caspase-14 Keratinocyte differentiation  Unknown 
Caspase-15 Apoptosis (Initiator) Unknown 
Caspase-16 Unknown, phylogenetic association with caspase-
14 
Unknown 
Caspase-17 Unknown, phylogenetic association with caspase-3 Unknown 









Figure 26. Complex 1 induces increase in cleavage of caspase 3/7 in 4T1-luc cells in a concentration dependent manner. 4T1-luc cells 
were preincubated in the presence or absence of 10 µM pan caspase inhibitor z-VAD-fmk for four hours followed by exposure to 1 for 
various time: 1 h (red), 3 h (blue), 5 h (cyan). ║ indicate cells pre-incubated with zVAD-fmk for 4 hours. The activity of caspase-3/7 







Figure 27. Determination of effect of inhibition of caspase cleavage on cell death in 4T1-luc cells 
following exposure to complex 1. Absence (black line) or presence (red line) of z-VAD-fmk. 
Values from each point were normalized to control values. Values represent the mean ± SE (n=3). 
 
 The mitochondria is often described as an essential target for cancer chemotherapy as it 
plays a critical role in the regulation of cell fate by integrating the apoptotic signals which originate 
both from intrinsic and extrinsic pathways.294-296 Disruptions in mitochondrial-mediated events 
often lead to increases in caspase-3 activity.297 The mitochondrial pathway is activated by BH3-
only subset of Bcl-2 family proteins (BID and BIM) which subsequently activated multidomain 
BH123 proteins (BAX and BAK), the latter of which permeabilize the mitochondrial membrane. 
Due to the increases in caspase-3 activity, the ability of complex 1 to modulate the mitochondrial 





tetramethylrhodamine methyl ester (TMRE). As observed in figure 28A there are two distinct cell 
populations prior to treatment with approximately 83% of cells exhibiting a higher membrane 
potential (upper left quadrant) and 17% with a lower membrane potential (lower left quadrant). 
After two hours of incubation with complex 1, there is a concentration-dependent increase in the 
number of cells with a low membrane potential beginning at 40 µM and a maximum of 47% of 
cells exhibiting with a lower membrane potential at the highest concentration tested (Figure 28B-
F). Table 4 further shows a concentration dependent modulation in the m beginning at 
approximately the IC50 for 1 (A2 – A5). While there do not appear to be many clear trends based 
on the data in table 5, a few conclusion can be drawn. Low concentration of complex 1 seem 
incapable of inducing an effect on the m after 2 h of incubation, however at 4 h a concentration 
dependent increase in low membrane potential cells is observed, indicating it takes longer for low 
concentrations to affect the mitochondria. At the 4 h time point, effects on m at higher 
concentration of the complex showed that populations of cell remaining at that time had a m 
like cells of the original control levels. However, at 6 h the higher complex concentrations now 
indicated populations of cells that again exhibited lower m values, while lower complex 
concentrations exhibited lesser effects on the remaining populations after effects observed at 4 h. 
This interpretation is consistent with effects on cells at intermediate complex concentrations, 
where 40 µM had effects at all three time points. This indicates that the 4T1 cells have different 
levels of sensitivity to complex 1 with higher concentration affecting some cells rapidly (2 h) and 
affecting a more resistant population later (6 h). These results are, however, consistent with the 
increase in caspase activity observed with the fluorogenic assays, therefore further validating the 









Figure 28. Representative contour plots of fluorescence resulting from m after two hours  (FL2-H, Y-axis) and FSC-H (Y-axis).A) 0 





Table 5. Percentage of cell population positive and negative for TMRE 
Complex (µM) 2 hours  4 hours  6 hours 
 - +  - +  - + 
0 17.05 80.83  24.92 73.21  16.96 78.88 
5 18.08 81.23  36.63 60.72  14.16 79.37 
20 13.07 85.42  48.76 49.73  31.86 61.65 
40 27.02 71.90  42.35 55.63  50.11 46.01 
60 26.50 71.41  39.93 58.44  52.42 45.26 
80 47.41 52.03  17.33 80.58  45.21 53.42 
 
 
With another potential molecular target identified in the mitochondria, further investigation 
into other regulated cell death (RCD) mechanisms were undertaken to discern other molecular 
events initiated in response to complex 1. Autophagy is a conserved process of cellular 
degeneration in eukaryotic cells, in which unfolded, aggregated, or long-lived cytoplasmic proteins 
are delivered to the lysosome for degradation.298 Under “normal” conditions, autophagy remains 
at low levels for maintenance of cellular homeostatis, however, autophagy can be readily induced 
in response to nutrient deprivation, metabolic stress, radiation, anticancer drugs, endoplastic 
reticulum (ER) stress, and reactive oxygen species.299 The ability of the complex 1 to induce 
autophagy was monitored using flow cytometric methods and is shown in figure 29 to determine 
if the complex can induce activation of other RCD pathways. As shown in figure 29 after 24 hour 
treatment with complex 1, the mean fluorescent intensity of cells treated with 5 µM (cyan) and 10 
µM (yellow/orange) are significantly increased (shifted right) compared to unstained (red) and 





the autophagasome and other organelles associated with the induction of the autophagy process. 
Conversely, in high dose treatments there is a decrease in the mean fluorescence intensity (left 
shift) indicative of the absence of the organelles associated with autophagy, which is likely 
attributed to the movement of cells from the initial stages of autophagy to cell death. However, as 
evident in figure 30C/D high concentrations of complex 1 also induce autophagy, however, the 
effect is only observable at shorten time periods (1-7 hours vs 24 hours). This finding is not 
uncommon as it is known that autophagy can be induced as a protective mechanism depending on 
the extent and duration of the treatment. The induction of autophagy in a time dependent manner 
also could explain the observed increase in cellular viability at early time points in low doses in a 










Figure 29. Complex 1 induced autophagic flux after 24 hour treatment. A) Representative histograms are shown of fluorescence resulting 
from autophagic flux (FL2-H, X-axis) and cell counts (Y-axis). B) Plot of the RFUs vs [Complex]. Red – unstained cells, dark green – 









Figure 30. Time course induction of autophagic process following exposure to complex 1, upper and lower rows indicate treatment with 
5 and 80 µM complex 1, respectively. A/C) Representative histograms are shown of fluorescence resulting from autophagic flux (FL1-










Figure 31. Necrostatin-1 inhibits autophagy induced by complex 1 in concentration dependent manner.  A) Representative histograms 
are shown of fluorescence resulting from autophagic flux (FL2-H, X-axis) and cell counts (Y-axis). Red – unstained cells, dark green – 







Although autophagy can be often viewed as a protective mechanism, it can also lead to 
post-autophagic death after autophagic cell protection has failed. Thus the appearance of large 
scale cell death in a time- and concentration-dependent manner in figures 29 and 30. The regulatory 
events that facilitate the switch from a “protective” event to autophagic death mechanism are 
poorly defined.299-301 In order to determine the role of autophagic death in the overall regulated 
cell death processes following exposure to complex 1, viability was determined in the presence 
and absence of necrostatin-1. Necrostatin-1 is commonly utilized as a necroptosis inhibitor, 
although, it has recently been shown to be an applicable inhibitor of autophagy and minimally 
apoptosis.302, 303 As shown in figure 31 it is possible to inhibit the autophagy process by utilizing 
necrostatin-1, however, eventually the protective nature of this event is overcome at concentrations 
greater than the IC50 (>40 µM, complex 1). A comparison of the IC50 values in the absence or 
presence of the inhibitor shows only a slight difference (figure 32), of approximately 10 µM. This 
shift is most likely attributed to the loss of the initial “protection” afforded to the cells by the 
activation of the aautophagic pathway. Unlike the effect observed with caspase inhibition this shift 






Figure 32. Cell viability graphs following treatment of 4T1-luc cells with complex 1 in the 
presence or absence of necrostatin-1. Cells were seeded at 2.5 x 104 cells per well for 24 h prior to 
addition to treatment. Graphs represent n = 3 replicates of data with plates being 1 h post incubation 
with MTS reagent. Data was fit using an exponential function using Origin 8 software.  
 
Nanosecond pulsed electric fields (nsPEFs) are an emerging bioelectrical technology that 
has showed its potential in cancer therapy.304, 305 NsPEFs can generate pulsed high voltage electric 
field in ultra-short nanosecond duration to produce immediate power, which could ablate targeted 
tumor.306-308 NsPEFs mediates cell destruction by multiple mechanisms.255, 256, 309 The nanosecond 
pulses with a high intensity electric field changes the permeability and change the electric 
properties of the plasma membrane and intracellular organelle membrane, which results in 





or chemical ablation, thus producing a lower risk of local complications, such as thermal or 
chemical injuries.257, 264, 309 
Prior to determining if an inherent synergy exists between the use of transition metal 
complexes and nsPEF, we must first investigate the effect of applying nsPEFs to 4T1-luc cells. To 
complement the experimental data on complex 1 (i.e. IC50 values) we first set to determine the 
effect of modulating the pulse electric field strength and number on 4T1-luc cells to determine an 
EF50 value. The effect of nsPEF on cellular viability 24 hours post treatment is shown in figure 33 
as determined by the MTS assay. It is clear that nsPEFs produced a dramatic decreased on in vitro 
cell survival with increases in pulse number and electric field strength. Surprisingly, there is little 
effect on viability from variable pulse numbers (1 – 10 pulses). In a manner similar to complex 1, 
this information allowed for the calculation of EF50 following treatment which was calculated at 







Figure 33. 4T1-luc cellular viability following exposure to nsPEFs utilizing various pulse strength 
at a 60 ns pulse duration. Cells were seeded at 2.5 x 104 cells per well for 12 hours. Graphs represent 
n = 3 replicates of data with plates being 1 h post incubation with MTS reagent.  
 
 It was previously observed a synergistic effect exist between a chemotherapeutic small 
organic molecule 4-amino-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin-
2(1H)-on (gemcitabine) and low dose nsPEF technology in human oral squamous cell and breast 
cancer carcinoma due to increases in intracellular calcium levels following nsPEF treatment.310 It 
is important to note that while nsPEFs induce formation of nanopores in plasma membranes, these 
pulses do not enhance delivery of drugs to cells as has been observed with ECT.311-313 We therefore 
set out to determine whether a similar underlying synergistic effect exists between complex 1 and 





of complex 1 (5 or 7.5 µM) for 24 hours and then were exposed to 60 nsPEFs of varying pulse 
numbers, with cellular viability being determined 24 hours post pulsing. Low dose treatments are 
required for both treatments in order for a synergism quotient to be calculated. Initially strictly 
synergism studies where carried out utilizing the IC15 and EF10 of the individual treatments (7.5 
µM and 20 kV/cm, respectively), which would result in a 10 – 15 % decrease in cellular viability, 
individually. If a synergism were to exist a killing efficiency >25%, should be observed. However, 
as shown in figure 34 dual treated cells receiving either 1 or 5 20 kV/cm pulses and 7.5 µM 
complex 1 showed a slight increase in cellular viability as shown by the increase in the absorbance 
reading compared with the untreated control cells the opposite of the predicted effect.  
 
 
Figure 34. Viability of 4T1-luc cells following dual treatment with complex 1 and nsPEFs (60 ns 
pulse duration). 
  
Following initial experiments a protocol similar to that reported by Wang et al.310 was 





employed. In these studies, electric field strengths were varied from 0 to 60 kV/cm following 
incubation with complex 1 at 7.5 µM. Similar to figure 33, in figure 35A/B an electric field strength 
dependent decrease in cellular viability in cells only exposed to nsPEF was observed, however, in 
pulse strengths greater than 20 kV/cm there appears to be a protective event in cells preincubated 
with 1 prior to exposure to nsPEFs which seemingly negates the effect of the nsPEF. In the high 
dose electric field, ≥40 kV/cm, the protective effect observed increases cellular viability 2-fold 
greater than when nsPEFs are utilized alone. As previously shown, low concentration dose 
treatments with complex 1 leads to the induction of autophagy which could potentially place the 
cells within a heighten protective state and lead to increased cell survival. As previously shown 
for this cell line autophagy can be inhibited by the addition of necrostatin-1 and therefore, 
preincubating the cells with necrostatin-1 would negate any protective event occurring from the 
induction of autophagy. As shown in figure 35, the addition of necrostatin-1 to inhibit the 
autophagic process showed minimal differences on cellular viability when compared to cells not 
exposed to necrostatin-1, indicating that autophagy is not the cause of the protective event 
observed. While both treatments were shown to be effective inhibitors of cell grown individually, 










Figure 35. 4T1-luc viability following exposure to complex 1, nsPEFs (60 ns duration), or a combination. A) Plot of absorbance vs 





While there have been no previous reports of a combination therapy involving a transition 
metal complex and nsPEFs, previous studies by Pakhomov and coworkers,314, 315 reported that 
lanthanide ions (Gd3+ and La3+) could block plasma membrane electropermeabilization induced 
by nsPEFs thereby reducing cell death. Permeabilization of both the plasma membrane and 
mitochondrial membrane have be implicated to be important in cell death in treatment of various 
cancers.255, 316-318 Furthermore, while the application of transition metal complexes is increasing in 
frequency for chemotherapeutic purposes, little mechanistic knowledge is reported on cobalt drugs 
specifically, with the exception of studies involving DNA intercalation and in vitro toxicity.158, 168, 
319, 320 While it is interesting to speculate on the hypothesis that a synergism must exists between 
1 and nsPEFs, extensive studies are needed to further elucidate the mechanism of action of both 
techniques individually prior to offering an explanation on the nature of the observed protective 
effects.   
 
CONCLUSION 
In conclusion, preliminary mechanistic investigations of the potential mechanism of action 
of a cobalt(III) complexes beating a thiosemiacarboazone ligand (MeATSC) were presented. Our 
data indicates that complex 1, similar to many other polypridyl transition metal complexes, binds 
and interacts to DNA in an intercalative manner albeit in a weak fashion. Competition assays 
conducted with EB calculate a Kapp value of 3.2 × 10
5 M−1 making the complex a weak to moderate 
metallointercallator, an unsurprising finding given not only the heteroaromatic ligands but 
additionally the large anthracene moiety present which may stack between DNA base pairs. In 
vitro analysis of the complex indicates the complex 1 is moderately toxic (IC50 ≈ 34 µM) to the 
model metastatic breast cancer cell line, with the most significant contribution to cell dearth arising 





activity and dissipation of the m. Additionally, the complex was also shown to induce autophagy 
in both a concentration- and time-dependent manner. While the results of H2AX were inconclusive 
(due to lack of optimization of protocol), it can be most likely concluded from the caspase, 
mitochondrial, and spectroscopic studies that the complex induces apoptosis through a 
mitochondrial mediate (intrinsic) pathway stemming from DNA damage, however, more intensive 
and localized mechanistic studies will be necessary to confirm.  
Additionally, a potentially novel dual mode treatment therapy for cancer was discussed 
involving nsPEFs and transition metal chemotherapeutics. Following exploration of the effect of 
nsPEFs on the model breast cancer cell line, synergistic studies were undertaken to explore the 
effect of “sensitizing” cells to the nsPEFs. Contradictory to the hypothesized synergistic killing 
effect, a protective effect was observed in cells which were treated with both complex 1 and 
nsPEFs. Inhibiting the “protective” autophagic process yielded little to no change on cell survival 
following dual treatment illustrating autophagy is not the reason for the observed protective effect. 
A previous study with “free” Gd3+ ions hypothesized that the uncoordinated metal could stabilize 
or revert electropermeablization of the plasma membrane thereby inhibiting the effect of the 
nsPEF.314 Future studies will focus on the effect of the nanosecond pulses on the intact Co(III) 
complex in both cell-free and cell-based environments.   
These findings provide valuable insight into the mechanism of action of Co(III)-containing 
metallodrugs. Mechanistic insights into the bioactivity of such materials may inform the design of 
drugs which are better suited and selective towards target molecules and pathways. To further 
elucidate the mechanism or to guide the addition of an adjuvant treatment more intensive 
mechanistic investigations must be conducted on both Co(III)-based therapeutics and nsPEFs 





CHAPTER 3  
SYNTHESIS, CHARACTERIZATION, AND IN VITRO ACTIVITY OF V(IV) AND 




With the recent emergence of photoactivated chemotherapy (PACT), or more commonly 
photodynamic therapy (PDT), as a non-invasive therapeutic treatment of cancer, comes the 
important challenge of designing new anticancer agents that show both nucleolytic and anti-
metastatic activity selectively in cancer cells. As previously discussed, coordination complexes 
containing d6 metal centers and polypyridyl ligand architectures have been developed as structure- 
and site-specific DNA binding agents.113, 114 Due to the attractive photophysical properties, much 
research has focused on complexes containing d6 ruthenium metal centers. As previously discussed 
in chapter 1, many examples exist of ruthenium(II) complexes which have been utilized as PDT 
metallodrugs with low toxicity and good selectively for tumor cells.321 
As the search for adequate photodynamic therapeutic agents continues to evolve the 
systems being utilized are also constantly evolving. While DNA interactions with mononuclear 
ruthenium complexes have flooded literature recently,322-325 similar interaction are possible with 
dinuclear ruthenium-containing species,326-332 however their applications as potential DNA-
binding agents remains largely unexplored. Dinuclear complexes offer increased variation in shape 
and size and have the potential to show greater specificity. Mixed metal dinuclear complexes offer 





utilized can possess its own unique biological application making for dual-application complexes 
or enhanced biological function. 
Vanadium is a widespread element in the environment and an ultra-trace element in 
biological systems.333, 334 The current interest in the chemistry of oxovanadium complexes has 
grown exponentially in recent years due in part to the resurgence in research that has shown that 
vanadium plays a large role in several biological processes,335, 336 such as the regulation of 
carbohydrate metabolism.337, 338 As early as the 19th century the insulin-mimetic properties of 
vanadium substrates have been reported.339 Unsurprisingly, there are many reports of vanadium 
compounds displaying interesting effects at pharmacological doses both in vivo and in vitro 
systems.340, 341 As an early first row d-block metal vanadium is capable of exhibiting a wide range 
or oxidation states, the most relevant valences of vanadium are +3, +4, and +5. Vanadium(III) and 
Vanadium(V) are unstable at physiological pH and in the presence of oxygen, however, the 
stability of V(IV) coordination compounds is strongly impacted by the ligands coordinated to the 
metal center.342, 343 For instance, an example of a particularly stable V(IV) compound is the 
complex formed by V(IV)O with transferrin.344 Additionally, while vanadium(III) complexes are 
rare, a recent study has shown that an organovanadium(III) compound, VC-III,345 can mitigate 
cisplatin-induced genotoxocity and myelosuppression in mice.346 
While the mechanism of vanadium toxicity are poorly understood, it has been reported that 
vanadium compounds can behave as growth factors which regulate cell growth.347, 348 These 
mimetic properties allow vanadium agents to exert action upon signal transduction pathways and 
promote morphological changes in cells.349-351 In some cases this has be extended to induction of 
anti-metastatic behavior, decreasing cell spreading and adhesion to the extracellular matrix as well 





compounds induce the generation of reactive oxygen species (ROSs) to produce adverse biological 
effect including: modulation of signaling pathway and DNA photocleavage.354-359 On the other 
hand, other studies have reported that vanadium compounds promote apoptosis and convey the 
cells to death through the increasing of ROS levels and disturbance of the redox status, especially 
by alteration of mitochondria functions in the cells.360, 361 
More recently, mechanistic investigations have focused on gaining deeper insights into the 
presumptive mechanism of action of vanadium derivatives. It has been shown that organically 
chelated vanadium compounds facilitate more pharmacological potency when compared with 
simple vanadium salts.362 This facet can be attributed to the poor absorption of some vanadium 
species in the gastrointestinal tract, thereby increasing the effective dose of vanadium required to 
produce the pharmacological effect.363, 364 Studies with oxidovanadium(IV) complexes, 
specifically, have demonstrated that some compounds cause substantial single strand breaks in 
DNA and produce lipid peroxidation.359, 365 In this sense, the synthesis of vanadium complexes 
with ligands that hold multiple donor atoms is of considerable interest in vanadium biochemistry 
and in relation to their potential therapeutic applications.366 
As previously stated, d1-V(IV) complexes have been shown to photocleave DNA via 
generation of ROS, albeit with limited specificity.367 As part of a continuing project related to 
vanadium compounds with potential pharmacological applications, the present study deals with 
the effects of an oxidovanadium(IV) complexes ([VO(oda)(phen)]·1.5H2O or [VO(sal-L-
tryp)(phen)]·H2O), as well as binuclear Ru(II)-V(IV) species structurally similar to those reported 
by Holder et al.127 on a mouse breast cancer cell line (4T1-luc). It is envisioned that these 
compounds will serve as photodynamic therapeutic agents as they possess a Ru(II) 





investigated the interactions of these compounds with CT DNA as a model for the interactions of 
these compounds with cellular DNA. Understanding how both the mononuclear and binuclear 
species interact with DNA is pivotal to discerning the mechanism of action of these compounds. 
Increased understanding into the mechanism can also inform the rational design of future 
photodynamic therapeutic agents.  
 
EXPERIMENTAL 
General and Instrumentation 
All reagents used in the syntheses, if not specified, were obtained from either Sigma-
Aldrich (St. Louis, MO, USA) or VWR International (Radnor, PA, USA) and were used without 
further purification. [Ru(pbt)2(phen2DTT)](PF6)2•1.5H2O and [VO(oda)(H2O)2] were previously 
prepared by Holder et al.127 and were utilized without further purification. [VO(sal-L-
tryp)(phen)]•H2O was synthesized using the procedure by Sasmal et al.
368 
The reagents utilized for the MTS assays were purchased from Promega Corporation 
(Madison, WI, USA). Microanalyses (C, H, N) were performed by Intertek Pharmaceutical 
Services, P.O. Box 470, Salem Industrial Park Bldg. #5, Whitehouse, NJ 08888. FT IR and ATR 
data was obtained using a Nicolet AVATAR 370 DTGS spectrophotometer. Ultraviolet absorption 
spectra were obtained using an Agilent 8453 diode array system. X-ray crystallography studies 
were conducted by Dr. Colin McMillen Director of the Molecular Structure Center, Department 
of Chemistry of the Clemson University (Clemson, SC, USA). ITC studies were performed 







Synthesis of phen•HCl•H2O 
1,10-phenanthroline (2.00 g, 11.10 mmol) was dissolved in concentrated HCl (50 mL, 2.04 
mol) in a 100 mL beaker. The resulting solution was transferred to a porcelain evaporating dish 
and evaporated over a steam bath. Upon drying an off-white crystalline power was obtained. Yield 
= 2.60 g (100 %). FT IR (KBr) cm-1: 3094 (H2O, s), 1406 (C=N, s).  
Synthesis of complexes 
Synthesis of [VO(acac)2] 
V2O5 (5.00 g, 27.5 mmol) was dissolved in H2O (12 mL) H2SO4 (9 mL), and EtOH (25 
mL) in a 250 mL round bottom flask and was placed in a boiling water bath. The reaction was 
stirred continuously for 30 minutes and the color changed from orange, to dark green to dark blue. 
After 30 minutes H2O (20 mL) was added and the filtrate was collected in a 600 mL beaker. 2,4-
pentanedione (13 mL, 126.3 mmol) was added the solution was stirred for 10 minutes. The solution 
was neutralized via the dropwise addition of aqueous sodium carbonate (20 g in 120 mL H2O). 
The precipitate was collected by filtration and was recrystallized from chloroform to yield a blue 
powder. Yield (4.24 g, 60%). FT IR (KBr) cm-1: 1529.35 (C=C=C, vs), 1373.14 (C=O, s.br), 
997.07 (V=O, vs).  
Synthesis of [VO(oda)(phen)]•1.5 H2O (1) as by Álvarez et al.369 
[VO(oda)(OH2)] (0.1803 g, 0.8 mmol) was dissolved in H2O (20 mL) in a 50 mL round 
bottom flask. Then solid o-phenanthroline (0.1607 g, 0.8 mmol) was added to the flask and it was 
stoppered and allowed to stand at room temperature of four days. After four days the solid green 
crystals in the reaction flask were collected by vacuum filtration. Yield = 0.2571 g (85%). FT IR 
(KBr) cm-1: 3401.98 (OH, s,br), 1677.86 (COO asym, vs), 1143.64 (C-O-C, m), 1000.93 (V=O, 





Synthesis of [VO(oda)(phen)]•1.5 H2O 
[VO(oda)(OH2)] (0.1803 g, 0.8 mmol) was dissolved in H2O (20 mL) in a 50 mL round 
bottom flask. Then solid o-phenanthroline (0.1607 g, 0.8 mmol) was added to the flask and the 
contents were thoroughly mixed resulting in an opaque green solution, which was allowed to stand 
for at room temperature of four days. After four days the solution was filtered to afford a green 
powder. Yield = 0.2366 g (78%). FT IR (KBr) cm-1: 3401.98 (OH, s,br), 1677.86 (COO asym, vs), 
1143.64 (C-O-C, m), 1000.93 (V=O, vs), 451.28 (V-O, s). 
Synthesis of [VO(oda)(phen)]•1.5 H2O as by Del Rio et al.370 
[VO(oda)(OH2)] (0.1803 g, 0.8 mmol) was dissolved in H2O (20 mL) in a 50 mL round 
bottom flask. Then solid freshly prepared phen•HCl (0.185 g, 0.8 mmol) was added to the flask 
and it was stoppered and allowed to stand at room temperature of four days. After four days the 
solid green crystals in the reaction flask were collected by vacuum filtration. Yield = 0.1041 g 
(34%). FT IR (KBr) cm-1: 3401.98 (OH, s,br), 1677.86 (COO asym, vs), 1143.64 (C-O-C, m), 
1000.93 (V=O, vs), 451.28 (V-O, s). 
Synthesis of [Ru(pbt)2(phen2DTT)VO(oda)](PF6)2•2.0H2O•0.5C2H5OH (2). NOTE: The 
synthesis of this compound was carried out by Ms. Kathy Currie and Dr. Alvin Holder. 
[Ru(pbt)2(phen2DTT)](PF6)2•1.5H2O (0.100 g, 0.074 mmol) and [VO(oda)(H2O)2] (0.0174 
g, 0.074 mmol), were dissolved in a 2:1 ethanol/acetonitrile mixture (78 mL) in a 100 mL round 
bottom flask, and the reaction mixture was refluxed for three hours with stirring under argon at 
110 °C. The reaction mixture was rotary evaporated to dryness, and the product was washed with 
ether and collected. Yield = 0.0993 g (85%). Calc. for C57H49F12N8O10.5P2RuS4V, C, 43.21; H, 
3.12; N, 7.07. Found: C, 43.24; H, 3.04; N, 6.66. FT IR (ν/cm-1): 3421 (O-H, br, s), 1643 (C=O, 





Preparation of buffers 
The phosphate buffered saline (PBS) buffer was prepared by adding NaCl (8.004 g), KCl 
(0.2001 g), Na2HPO4 (1.7520 g), and K2PO4 (0.2003 g) to a 1000 mL volumetric flask and diluted 
with water. The 50 mM Tris-HCl buffer pH 8.0 was prepared by dissolving tris (6.057 g, 0.05 mol) 
in H2O (700 mL) in a 1 L volumetric flask. Then 1 N HCl (8.98 mL of HCl conc. diluted to 100 
mL with H2O) (29.2 mL) was added to the volumetric flask and the solution was diluted to the 
mark. The pH of the solution was checked using a pH meter (8.01). The 5 mM Tris, 25 mM NaCl 
buffer pH 7.0 was prepared by dissolving tris (0.6057, 5 mmol) and NaCl (1.460 g, 25 mmol) in 
H2O (700 mL) in a 1000 mL beaker. The pH of the solution was then adjusted to 7 via slow 
dropwise addition of concentrated HCl and was monitored via a pH meter. The solution was then 
transferred to a 1 L volumetric flask and was diluted with water.  
Preparation of CT DNA stock solutions in various buffers 
Stock solutions of CT DNA were prepared in each of the three buffers prepared above 
(PBS, 50 mM Tris-HCl pH = 8.0, 5 mM Tris/25mM NaCl pH = 7.0) by dissolving CT DNA (9 
mg) in 25 mL of buffer in a 50 mL conical tube. The solutions were places in the refrigerator at 4 
°C for twenty-four hours prior to use. Prior to each use of the stock solution the [CT DNA] was 
checked spectrophotometrically in a 0.2 cm quartz curvette using a ε260 = 6600 M
- cm-. Dilutions 
were made quantitatively using the appropriate buffer and [CT DNA] was recalculated based on 
electronic absorbance spectrum. All solutions were used within four days of preparation. 
Preparation of Ethidium Bromide stock solution for Isothermal titration calorimetry. 
Ethidium bromide (0.216 g, 0.548 mmol) was dissolved in various buffers (50 mL) in a 50 
mL conical tube. The concentration of the stock solution was determined spectrophotometrically 
prior to use using ε460 = 5600 M





Isothermal titration calorimetry 
ITC experiments were performed using a Microcal iTC200 microcalorimeter (MicroCal, 
Massachusetts, USA). Prior to ITC experiments, instrument calibrations were conducted using 
water/water, Ca2+/EDTA, and EB/DNA titrations. All experiments were performed at 25 °C with 
a 60 s pre-titration delay and 1000 rpm stirring speed. After optimization, appropriate 
concentration of complex was titrated into the sample cell containing DNA in a total of 20 or 40 
injections. The titrant (1 µL) was delivered over 2 s with an appropriate interval between injections 
to ensure complete equilibration. The heat generated per injection of complex bound to DNA was 
recorded and displayed as differential power (µcal s-1) vs time (min). The area under each injection 
peak was integrated and is presented as kcal mol-1 of injectant vs the molar ratio of 
[Complex]/[DNA]. Reference data was obtained by titrating the same concentration of test 
compound into the corresponding buffer, without DNA, and the value was then subtracted from 
the raw heat of reaction to obtain the effective heat of binding. The resulting data was analyzed 
and fit using a Levenberg-Marquardt non-linear least squares curve fitting algorithm using Origin 
7 software (OriginLabs, Northhampton, MA, USA). Full experimental instrumental parameters 
are listed in supporting tables A1 – A3.   
Cell Culture 
4T1 cells were obtained from American Type Culture Collection (ATCC). 4T1 cells were 
transformed with pGL4.50luc2/CMV/Hygro. 4T1-luc cells were cultured in high glucose RPMI 
1640 or DMEM medium supplemented with 10% fetal bovine serum at 37 °C in a humidified 








Cellular viability after treatment with compounds was evaluated by means of the MTS 
colorometric assay using the CellTiter 96® AQueous One Solution Cell Proliferation Assay kits 
from Promega (Madison, WI, USA). Briefly, cells were seeded at 2.5 x 104 per well for 24 hours 
prior to treatment on a 96 well plate. The following day media supplemented with drug treatment 
was added to each well, ranging from 0 – 70 µM. 24 hours later CellTiter 96® AQueous One 
Solution Reagent (100µL) was added to each well and plates were further incubated for one hour. 
Cellular proliferation was determined spectrophotometrically using an enzyme-linked 
immunosorbent assay (ELISA) plate reader at 490 nm. Percentage viability was calculated relative 
to the DMSO vehicle control (taken as 100% viability). 
 
RESULTS AND DISCUSSION 
 
Scheme 4. Synthesis of [VO(oda)(phen)]·1.5H2O 
 
 
The proposed scheme for the synthesis of [VO(oda)(phen)]•1.5H2O is presented in scheme 
4 and mirrors a literature protocol by Álvarez et al.369 Following this protocol, green crystal 
precipitated from a solution of water after a four day reaction. One noticeable difference was the 





be soluble in DMSO).369 With uncertainties around the purity of the product due to lack of 
spectroscopic characterization of the compound, multiple attempts were made to obtained a 
product with chemical properties similar to literature reports. The first attempt involved utilizing 
freshly prepared phen•HCl•H2O as by Del Rio et al.
370 in order to eliminate any undissolved 
phenanthroline impurity, as this starting material would be more water soluble over the four day 
time period of the reaction. This preparation led to a drastic decrease in the yield of the reaction 
(34 vs 85% yield) when compared with the yield of the reaction utilizing solid o-phenanthroline 
as the starting material as by Álvarez et al.369 Additionally, crystals of a different morphology and 
size were obtained from phen·HCl as opposed to solid o-phenanthroline. In yet another preparation 
of the target compound, a procedure similar to that employed by Holder et al.127 yielded a milky 
green powdery substance as opposed to the crystalline product obtained by the first two preparation 
of the compound. In total all efforts to increase the solubility of the compound in DMSO were 
futile as no obtained product showed full solubility in DMSO as reported by León et al.371 All 
complexes were instead characterized with FT IR spectroscopy with major stretching frequencies 
easily identifiable in all spectra including: 451.28 (V-O, s); 1000.92 (V=O, vs) and 3401.98 (OH, 
s, br) cm-1 (Figure 36). A table of the full assignment of FT IR stretching frequencies for this 
compound is presented below in table 6. Interestingly, an overlay of all FT IR spectra for each 
preparation of the target molecules, is identical despite the obvious physical differences in the 
product obtained (supplemental figure A9). As shown figure 36 and table 6 the compound as 






Figure 36. FT IR Spectrum of [VO(oda)(phen)]·1.5H2O. Prepared utilizing the method as by 





Table 6. Full assignment of the vibrational spectra of [VO(oda)(phen)]·1.5H2O. 
Wavenumbers/cm-1 Assignment Literature
372 
451.28 V-O 452 s 
725.14 CH out of plane (ophen) 724 vs 
783 CH out of plane (ophen) 784 w 
856.28 CH out of plane (ophen) 856 vs 
873.64 C-O-C 875 m 
921.85 C-C 922 vs 
1000.92 V=O 1000 vs 
1072.28 CH in plane (ophen) 1074 s 
1143.64 C-O-C 1143 m 
1213.07 Ring (ophen) 1212 m 
1234.28 Ring (ophen) 1238 m 
1313.35 CH in plane (ophen) 1312 m 
1334.56 CH in plane (ophen) 1335 s 
1369.28 COO- 1365 vs 
1429.06 CH2 1428 m 
1521.64 CH in plane (ophen) 1521 m 
1677.85 COO (asym) 1669 vs 
3058.7 CH2 (ophen) 3058 m 
3401.98 OH 3403 s, br 
 
 
While FT IR is a powerful tool for the identification of function groups present within a 
molecule further in-depth characterization was conducted to ensure the correct product was 
obtained. The procedure by Álvarez et al.369 provided the best crystalline product and while the 
crystal were not readily characterized via conventional spectroscopic techniques (i.e. UV-Vis), the 
crystal were of sufficient quality for X-ray crystallographic studies to be obtained. An ORTEP 
diagram of the crystals of 1 is shown below in figure 37 and confirms the structure as proposed. 
The coordination geometry around the metal center is confirmed to be a distorted octahedron. The 
1.5 H2O solvate lie in channels that run parallel to the c-axis of the unit cell and most likely play a 









Figure 37. ORTEP diagram of [VO(oda)(phen)]·1.5H2O. water molecules of crystallization are 
not shown for clarity. 
Table 7. Selected bond distances (Å) and angles (°) for compound 1. 
 Literature370 Experimental 
V(1)-O(1) 1.585(3) 1.619(9) 
V(1)-O(2) 1.974(2) 1.973(6) 
V(1)-N(1) 2.109(2) 2.123(7) 
V(1)-O(3) 2.297(2) 2.302(7) 
O(1)-V(1)-O(2) 101.32(8) 100.2(3) 
O(1)-V(1)-N(1) 101.91(9) 102.7(4) 
O(1)-V(1)-O(3) 176.09(11) 175.8(4) 







Scheme 5. Synthesis of binuclear Ru(II)-V(IV) complex 
 
The binuclear Ru(II)-V(IV) complex 
[Ru(pbt)2(phen2DTT)VO(oda)](PF6)2•2.0H2O•0.5C2H5OH was synthesized in a method similar to 
previous reports by Holder et al.127 as shown in the above scheme 5. The compound was obtained 
in good yield and was characterized via FT IR and elemental analysis. FT IR characterization again 
shows major stretching frequencies: 3421 (O-H, br, s), 1643 (C=O, s), 973 (V=O, m), 842 (PF6¯, 
vs). There is a significant shift to lower energy for the V=O bond in the binuclear complex when 
compared with the mononuclear complex, a similar effect was previously reported for similar 
compounds.127  Additionally the C,H,N analysis revealed there to be two water and half a methanol 
molecules in the solvation shell of the molecule. Further intensive characterization and 
crystallographic studies are underway to further confirm the structure. 
Previously, calometric approaches have been utilized to characterize Hoechest-DNA 
interaction, and ethidium bromide/propidium iodide–DNA associated.284 Due to incomplete 
solubility in DMSO, [VO(oda)(phen)]·1.5H2O could not be probed for its activity with CT DNA 





Therefore, only the interactions with a related compound, [VO(sal-L-tryp)(phen)]•H2O and the 
binuclear complex [Ru(pbt)2(phen2DTT)VO(oda)](PF6)2•2.0H2O•0.5C2H5OH were conducted.  
Prior to completion of isothermal titrations with metal complexes a known DNA 
intercalator, ethidium bromide, was utilized to optimize many of the protocols for the instrument. 
The resultant isotherms for the interactions of the synthesize complexes are presented in figure 38 
below. It can be observed that the mononuclear [VO(sal-L-tryp)(phen)]•H2O shows little 
interaction with DNA, (lower panel 38A) due to the minimal differences between the heat 
exchanges of the titrations conducted in the present (■) and absence (○) of DNA. Previously, it 
was reported utilizing UV-Visible titration methods, that a Kb value of 0.6 (± 0.1) X 10
5 M-1 exists 
for this complex indicating moderate interaction with DNA.368 While the complex does possess a 
phenanthroline moiety with the potential to intercalate between DNA base pairs, it is likely this π-
π stacking interaction would be quite weak, therefore making it difficult to detect surface binding 
and/or partial groove binding even with this ultra-sensitive technique. Conversely, the novel 
binuclear complex 2, shows significant interaction with CT DNA and the apparent dissociation 
constants for three binding sites were determined using nonlinear curve fitting analysis: K1 = 9.36 
x 104, K2 = 8.36 x 10
4, and K3 = 1.08 x 10
5 M-1. This complex not only possesses the heteroaromatic 
intercalating moieties but also possesses as net positive charge allowing for electrostatic 
interaction with the negatively charged phosphate backbone of DNA. Therefore, the nature of the 
observed interaction most likely stems from both the heteroaromatic ligands and the electrostatic 
interaction between the complex and DNA. Based upon obtained apparent dissociation constants 











Figure 38. ITC profile for the association of [VO(sal-L-tryp)(phen)]·1.5H2O (A) and 2 (B) with CT DNA in PBS buffer. The upper 
panels in the ITC profile show the heat of association for complex/CT DNA interactions. The lower panels show the heat exchanged 
per mole of injectant as a function of molar ratio of complex to DNA (■).The thermograms have been fitted after subtracting appropriate 






To determine the antimetastatic activity of the complexes, 4T1-luc breast cancer cells were 
treated with increasing concentrations of the complexes for 24 hours, and the viability was measure 
by means of the MTS assay. As shown in figure 39, the mononuclear [VO(sal-L-tryp)(phen)]•H2O 
exhibits a concentration-dependent decrease in cellular viability, with an IC50 value of 
approximately 18 µM. Our finding is not staggering as previously it has been reported that this 
compound possess significant cytotoxicity, with IC50 values of 41.6 ± 5.8 and 63.1 ± 28.3 µM in 
A431 and HFF cell lines, respectively.374 Interestingly while high antimeastatic activity is reported 
for this compound our ITC studies indicate the complex shows little to no interaction directly with 
DNA, indicating organelles other the nucleus are a potential target for V(IV) drugs. Due to large 
molar absorptivity values for the binuclear complexes within the range of the assay reading and 
low solubility of the [VO(oda)(phen)]·1.5H2O the in vivo activity could not be assessed utilizing 
colorometric assays. Efforts are being made to optimize luminescent assay protocols and increase 







Figure 39. Cell viability graphs following treatment of 4T1-luc cells with [VO(sal-L-
tryp)(phen)]·1.5H2O. Graphs generated using uncompensated raw data with plate being read 1 h 
post incubation of MTS reagent. Data was fit using an exponential function, using Origin 8 
software. IC50 = 18 µM. 
 
CONCLUSION 
In continuation of the work began by Holder et al.127 we have synthesized a 
oxidovanadium(IV) complex which incorporates an OOO donor group, 
[VO(oda)(phen)]·1.5H2O.
370 Upon initial characterization of the complex following literature 
reports, solubility issue arose forcing us the re-evaluate the purity of this product. One prep by 
Álvarez et al.369 yield crystals suitable to X-ray analysis, which confirmed the target molecule 
despite the solubility issues. Additionally, a binuclear Ru(II)-V(IV) complex was synthesized to 
incorporate the new oxidovanadium(IV) complex into a supramolecular scaffold incorporating a 
Ru(II) photosensitizer as by Holder et al.127 Due to solubility issue of the precursor molecule only 





complexes were able to be tested in vitro for their bioactivity. The novel binuclear complex showed 
moderate interaction with CT DNA via isothermal titration calorimetry experiments, whereas the 
mononuclear vanadium complex showed minimal interaction. Despite minimal interaction with 
CT DNA the mononuclear [VO(sal-L-tryp)(phen)]·H2O, showed significant toxicity to breast 
cancer cells under dark incubation conditions over a twenty-four hour period. While our efforts 
suggest that DNA is not the direct cellular target of oxovanadium compounds, Sasmal et al.375-378 
have reported photoactivated cleavage of DNA with similar compounds. It is thus most likely then 
that these complexes serves as a means to generate reactive oxygen species which cause DNA 
cleavage following irradiation. While currently employed methods have not allowed us to 
quantitatively probe the chemotherapeutic properties and mechanism of the binuclear complex, 
the addition of the intercalating photosensitizing Ru(II) metal center should allow for cancer 
selectivity (via uptake and transport proteins) and enhanced activity, however, future mechanistic 






CHAPTER 4  
DESIGN, SYNTHESIS, AND CHARACTERIZATION OF A NEW SERIES PYRIDINE-




Thioamides are carboxylic acid derivatives that have recently become a very important 
functional group in organic synthesis and medicinal chemistry.379, 380 Thioamides exhibit many 
interesting properties, for example, typically the thioamide-NH is a stronger hydrogen donor and 
the sulfur a weaker hydrogen bond acceptor than the corresponding amide.381 In addition, when 
compared to amides and formamides, thioamides possess different bond-lengths and bond-rotation 
characteristics and these unique properties have been exploited in both medicinal chemistry 
(including peptidomimetics) and polymer chemistry applications.382, 383  
The most utilized metho for the preparation of thioamides is the Willgerodt reaction with 
a Kindler modification, which usually employs aryl ketones as starting materials.380, 384-388 
However, it has also been shown that this reaction can also be applied when 2-methylpyridine it 
utilized as the starting material as opposed to aryl ketones.386, 389 Thus, N-substituted 2-
pyridinecarbothioamides (PCAs) have been prepared by reactions of 2-methylpyridine with 
primary amines,389 nitro compounds,380 or N-substituted formamides as amine sources in the 
presence of sulfur at elevated temperatures.390 Harsh reaction condition and low yield utilizing 
common Willgerodt-Kindler conditions prompted the search for alternative methods and in 2004, 
Kingele and Brooker proposed a modification which included utilizing a catalytic amount of 
Na2S·9H2O.
391 The proposed modification drastically increased yields (>70 %) and allowed for 





considered to be bioactive in particular their utility as gastric mucosal protectants was described 
in in vivo rat models in the early 1990s.392 The inherent bioactivity of these molecules makes them 
an ideal candidate as ligands of potentially active metallodrugs. 
Like Schiff bases, thioamides possess excellent chelating properties and have proven their 
useful as building blocks for the synthesis of numerous biologically relevant molecules which 
often possess a variety of interesting pharmacological properties.393, 394 Specifically, PCAs are 
versatile and easily accessible building blocks for the synthesis of S,N-bidentate ligands for 
organometallic and coordination compounds. When utilized as ligands the molecules have the 
potential to coordinate to metal centers in a variety of different ways as shown in Scheme 6. 
Deprotonation of the ligand may occur prior to coordination and because thioamides have two 
tautomeric forms they may act as either a monoanionic N, N’ (coordination of thioketo tautomer 
1) or S, N (coordination of the thiol form 2) bidentate ligand. Alternatively, the neutral ligand may 
coordinate to the metal center via the pyridyl nitrogen and sulfur atoms, 3. In these cases, five-
membered chelates result. However, coordination via the amide nitrogen and the sulfur (either as 









While the inherent biological activity of PCAs has been known since the early 1990s,392 
there have been sparse reports on the bioactivity of transition metal complexes bearing these 
ligands.395-399 Though several cobalt(III) and ruthenium(II) complexes bearing thiosemicarbazone 
(a seemingly similar class of compounds see scheme 7) ligands have been reported for their 
anticancer applications,102, 103, 109, 400-405 the biological application of these structurally related 
complexes bearing thioamides is not well explored.396, 399, 406 Over the past decade there is a single 
report on the use of a ruthenium(II) thioamide complexes as a potential anticancer agent.396 In this 
study a series of Ru(II) and Os(II) complexes bearing PCAs were synthesized and characterized 
and were shown to have high in vitro toxicity.396 Additionally, the complexes were stabilized by 
an arene system and were stable in highly acidic condition giving the potential to be the first non-






Scheme 7. General Structure of PCAs and TSCs 
 
 
Subscribing to a similar point of view, we have decided to investigate the potential of 
polypyridyl Co(III) and Ru(II) complexes bearing PCAs as anticancer agents. To the best of our 
knowledge the complexes described herein are of novel nature and represent a new series of 
potentially active biomolecules. Additionally, in chapter 2 we reported on the potential antitumor 
mechanism of [Co(phen)2(MeATSC)]·2.5H2O·C2H5OH, and thus we can directly compare the 
activity of our novel compounds to that of an established bioactive complex and gain insight into 
differences in the mechanism of action of the structurally related complexes. It is envisioned that 
the removal of the hydrolysable imine linkage and enlargement of the moiety directly adjacent to 
the coordinating thioketone moiety (referred to as the N3 position on thiosemicarbazone ligands 
see scheme 4) is expected to increase the stability and cytotoxic potential of these complexes when 
compared with Schiff base analogues.   
 
EXPERIMENTAL 
General and Instrumentation  
All reagents used in the syntheses, if not specified, were obtained from either Sigma-
Aldrich (St. Louis, MO) or VWR International (Radnor, PA) and were used without further 





Mark Lawrence (Post-doctoral fellow – ODU) and were used without further purification. 1H, 13C 
and 19F NMR spectra were collected on a Varian Inova 400 MHz NMR Spectrometer. 1H NMR 
spectroscopic samples were standardized relative to sodium 3-(trimethylsilyl)propionate (δ = 0.0 
ppm) or appropriate residual solvent peaks. 13C NMR spectroscopic samples were all standardized 
to residual solvent peaks as indicated by respective compounds. 19F NMR spectroscopic samples 
were standardized relative to the external standard trifluoroacetic acid (δ = -78.5 ppm). FT IR and 
ATR data was obtained using a Nicolet AVATAR 370 DTGS spectrophotometer. The mass 
spectral data was obtained from a Bruker 12 Tesla APEX-Qe FTICR-MS with an Apollo II ion 
source in positive ion mode at a flow rate of 2 µL/min. Ultraviolet absorption spectra was obtained 
using an Agilent 8453 diode array system. Thin-layer chromatography (TLC) was performed using 
TLC aluminum sheets (silica gel 60 F254) from Merck (Darmstadt, Germany) for determination of 
retention factors (Rf). Column chromatography was performed using either high purity grade silica 
gel or Sephadex LH-20 from Sigma-Aldrich. Microanalyses (C, H, N) were performed by Intertek 
Pharmaceutical Services, P.O. Box 470, Salem Industrial Park Bldg. #5, Whitehouse, NJ 08888. 
X-ray crystallographic studies were conducted by Dr. Colin McMillen Director of the Molecular 
Structure Center, Department of Chemistry of the Clemson University (Clemson, SC, USA)  
 
Synthesis of ligands. 
Generation of N-substituted pyridine-2-thiocarboxamide ligand library 
General procedure for synthesis of N-substituted 2-pyridinecarbothioamide. The methods of 
Klingele and Brooker was adapted.391 In brief, a mixture of N-substituted aniline and sulfur (1:3 
mol ratio) and sodium sulfide nonhydrate (2 mol %, 0.24g, 1 mmol) was refluxed in 2-picoline (30 





room temperature and the solvent was evaporated under high vacuum. The residue was dissolved 
in an appropriate solvent (as indicated), purified on a silica gel column (length = 46 cm, inner 
diameter = 14.5 cm) and the solvent was evaporated to yield analytically pure N-substituted 2-
pyridinecarbothioamide. All compounds were synthesized by this procedure unless expressly 
stated.  
N-[3,5-bis(trifluromethyl)phenyl]pyridine-2-thiocarboxamide (TPTA) (1) 
Column solvent: CHCl3/MeOH (20:1). A single crystal suitable for X-ray analysis was 
grown via the slow evaporation technique from chloroform. Yield = 5.90 g (77%), yellow solid. 
IR: 3170 (NH, m); 1380 (C=S, s); 1278 (C-F, vs) cm-1. 1H NMR (CDCl3, 400MHz): ppm 12.38 
- 12.28 (m, 1H), 8.76 (d, J=7.8 Hz, 1H), 8.67 (s, 2H), 8.61 - 8.54 (m, 1H), 7.93 (dt, J=1.6, 7.8 Hz, 
1H), 7.77 (s, 1H), 7.54 (ddd, J=1.2, 4.7, 7.4 Hz, 1H); 13C NMR (101MHz, CDCl3) Cppm 189.36, 
150.69, 146.61, 140.00, 137.84, 132.43, 132.09, 126.66, 124.87, 122.19, 121.66, 119.51 19F NMR 
(376MHz, CDCl3): δF/ppm -62.94 (s, 6F). 
N-(anthracene)pyridine-2-thiocarboxamide (APTA) (2) 
Column solvent: CHCl3. A single crystal suitable for X-ray analysis was grown via the slow 
evaporation of a saturated solution of the compound in chloroform layered with methanol. Yield 
= 0.1353 g (33 %), orange powder. IR: 3216 (NH, m); 1384 (C=S, s) cm-1. 1H NMR (400 MHz, 
DMSO-d6): ppm 12.55 (s, 1H), 8.97-8.98 (m, 1H), 8.70-8.80 (m, 1H), 8.60-8.61 (m, 3H), 8.03-
8.21 (m, 6H), 7.92 (dd, J=2.15, 9.18 Hz, 1H), 7.70 (ddd, J=1.17, 4.69, 7.42 Hz, 1H), 7.49-7.59 (m, 
3H). 13C NMR (CDCl3, 101MHz): Cppm 187.1, 151.4, 146.4, 137.8, 135.5, 132.2, 131.7, 131.3, 







Column solvent: CHCl3. Yield = 4.134 g (83%), golden yellow solid. IR: 3170 (NH, m); 
1380 (C=S, s); 1278 (C-F, vs) cm-1. 1H NMR (CDCl3, 400MHz): ppm 12.14 (s, 1H), 8.71 (d, 
J=7.8 Hz, 1H), 8.55 (d, 2H), 8.06 (td, J = 7.7 Hz 1H), 7.78 (dt, J=1.6, 7.8 Hz, 1H),, 7.30 (d, J = 
8.7 Hz, 1H), 7.01 (dd, J =8.73) ; 13C NMR (101MHz, CDCl3) Cppm 190.8, 160.5, 149.0, 136.7, 
136.1, 123.4, 121.9, 118.7, 117.0 19F NMR (376MHz, CDCl3): δF/ppm -114.9 (s, 1F).  
N-(2,4-difluorphenyl)pyridine-2-thiocarboxamide (4) 
Colum solvent: CHCl3/MeOH (20:1). Yield = 0.5803 g (81%), yellow solid. IR: 3170 (NH, 
m); 1380 (C=S, s); 1278 (C-F, vs) cm-1. 1H NMR (CDCl3, 400MHz): ppm 12.14 (s, 1H), 8.61 
(d, J=7.8 Hz, 1H), 8.55 (d, 2H), 8.06 (td, J = 7.7 Hz 1H), 7.78 (dt, J=1.6, 7.8 Hz, 1H), 7.70 (m, 
1H), 7.43 (td, J=1.2, 4.7, 7.4 Hz, 1H), 7.19 (td, J = 1.64, 8.73) ; 13C NMR (101MHz, CDCl3) 
Cppm 190.3, 162.3, 152.5, 152.0, 149.0, 138.7, 129.9, 129.8, 127.2, 125.3, 112.0, 105.1 
19F NMR 
(376MHz, CDCl3): δF/ppm -110.8 (s, 1F), -115.1 (s, 1F). 
N-(3,4,5-trimethoxyphenyl)pyridine-2-thiocarboxamide (5) 
Column solvent: CHCl3/MeOH (10:1). Yield = 2.01 g (67 %), brown/yellow solid. IR: 
3170 (NH, m); 1380 (C=S, s); 1278 (C-F, vs) cm-1. 1H NMR (CDCl3, 400MHz): ppm 12.22 (s, 
1H), 8.68 (d, J=7.8 Hz, 1H), 8.55 (d, 2H), 8.05 (td, J = 7.7 Hz 1H), 7.67 (dt, J=1.6, 7.8 Hz, 1H), 
7.62 (s, 2H), 3.71 (s, 6H), 3.33 (s, 3H) ; 13C NMR (101MHz, CDCl3) Cppm 188.9, 153.1, 152.9, 







N-(4-Pyridinyl)pyridine-2-thiocarboxamide (PPTA) (6) as by Kingle and Brooker. 107 
A mixture of 4-aminopyridine (9.31 g, 0.10 mol), sulfur (9.62 g, 0.30 mol) and sodium 
sulfide nonahydrate (0.48 g, 2 mol %) in 2-methylpyridine (60 mL) was refluxed for 48 h. After 
cooling and removal of all volatiles in vacuo, the dark solid residue was taken up in 2 M aqueous 
sodium hydroxide (200 mL), and the mixture was filtered. The filtrate was diluted with water (400 
mL) and acidified to pH 5 by dropwise addition of concentrated hydrochloric acid. The resulting 
very voluminous yellow precipitate was filtered off and washed thoroughly with water. Drying in 
vacuo gave pure N-(4-pyridyl)pyridine-2-thiocarboxamide as a yellow powder. Yield = 14.87 g 
(75 %). IR(KBr):3170 (NH, m); 1357 (C=S, s); 1519 and 1357 (ArH, s); 815 (=C-H bend, s) cm-
1. 1H NMR (CDCl3, 400MHz): ppm 12.23 (s, 1H), 8.74 (d, J=8.2 Hz, 1H), 8.65-8.69 (m, 2H), 
8.57 (dd, J=4.7, 0.8 Hz, 1H), 8.14-8.20 (m, 2H), 7.91 (td, J=7.8, 1.6 Hz, 1H), 7.52 (dd, J=7.4, 4.7 
Hz, 1H). 13C NMR (CDCl3, 101MHz): Cppm 189.5, 150.9, 150.8, 146.5, 145.4, 137.7, 126.5, 
124.7, 115.3. 
N-[4-benyzl alcohol]pyridine-2-thiocarboxamide (7). The preparation of this ligand first 
required the reduction of the carboxylic acid moiety present in 4-aminobenzoic acid. Safety 
notes: LAH is extremely water reactive and must be handled with care!  
Lithium aluminum hydride (5.0 g, 0.132 mol) was dissolved in Et2O (500 mL) in a 500 mL 
RBF. 4-aminobenzoic acid (7.54g, 55 mmol) was placed in a cellulose sohxlet thimble and was 
placed in a sohxlet extractor and the reaction mixture was allowed to reflux for 7 days. After 7 day 
the remaining lithium aluminum hydride was neutralized by the addition of H2O (150 mL). Then 
10 % NaOH solution (150 mL) was added and the ether layer was separated. The water layer was 





in vacuo to yield a yellow oil. Yield = 2.56 g (33 %) 4-aminobenzyl alcohol. 1H NMR (400 MHz, 
DMSO-d6): ppm 6.81 (dd, J=0.78, 7.03 Hz, 1H), 6.45-6.50 (m, 1H), 4.27 (s, 1H), 3.99 (s, 1H).             
4-aminobenzyl alcohol (0.5733 g, 4.65 mmol) (oil from above) was combined with sulfur (0.5733 
g, 13.95 mol) sodium sulfide nonahydrate (0.447 g, 2 mol %) in 2-methylpyridine (15 mL) was 
refluxed for 48 h. After cooling and removal of all volatiles in vacuo, the dark brown oil residue 
was taken up in CHCl3 and was purified using column chromatography on silica gel. Fractions 
containing the desired product were combined and the filtrate was evaporated under reduced 
pressure to yield a yellow solid. Yield = 0.7158 g (65 %). 1H NMR (400 MHz, DMSO-d6): ppm 
12.23 (br. s., 1H), 8.67 (qd, J=0.89, 4.73 Hz, 1H), 8.50-8.55 (m, 1H), 8.03 (dt, J=1.95, 7.81 Hz, 
1H), 7.84 (d, J=8.59 Hz, 2H), 7.64 (ddd, J=1.17, 4.69, 7.81 Hz, 1H), 7.25 (d, J=8.20 Hz, 2H), 3.36 
(s, 1H). 13C NMR (101 MHz, DMSO-d6)Cppm 189.3, 152.7, 147.4, 137.8, 136.7, 135.9, 129.0, 
126.4, 124.7, 123.8, 20.8.  
4-[(pyridine-2-ylcarbothioyl)amino]benzoic acid (8) 
N-[4-benyzl alcohol]pyridine-2-thiocarboxamide (0.200 g, 1.02 mmol) was dissolved in 
acetone (18 mL) in a 50 mL RBF and placed under argon at 0 °C. Then to the mechanically stirred 
solution was added a dropwise solution of 2 mL of Jones reagent (2.67 g CrO3, 2.3 mL of H2SO4 
diluted to 10 mL) and acetone (10 mL) over a one hour period (color change from green to orange). 
After the solution persisted at the orange coloration for thirty minutes at 0 °C excess isopropyl 
alcohol was added to destroy excess Jones reagent. The reaction mixture was decanted and 
concentrated to a minimal volume. The desired product was extracted from a brine/CHCl3 (1:1) 
mixture. The organic layer was washed with H2O (20 mL), 20 % sodium bicarbonate (10 mL), and 





(400 MHz, DMSO-d6): ppm 12.23 (br. s., 1H), 8.67 (qd, J=0.89, 4.73 Hz, 1H), 8.50-8.55 (m, 
1H), 8.03 (dt, J=1.95, 7.81 Hz, 1H), 7.84 (d, J=8.59 Hz, 2H), 7.64 (ddd, J=1.17, 4.69, 7.81 Hz, 
1H), 7.25 (d, J=8.20 Hz, 2H), 3.36 (s, 1H). 13C NMR (101 MHz, DMSO-d6)Cppm 190.7, 168.2, 
152.0, 149.1, 136.7, 136.1, 130.3, 123.4, 122.0, 116.9 
 
Synthesis of Complexes. 
Attempted [Co(phen)2(PPTA)](PF6)3 (9) 
[Co(phen)2(OH2)2](NO3)3 (0.16 g, 0.249 mmol) and 1 (0.080 g, 0.3735 mmol) were 
combined in a 250 RBF in EtOH (80 mL) and were refluxed under argon with stirring for 24 hours. 
After 24 hours at reflux the flask was allowed to cool to room temperature and NH4PF6 (0.284 g, 
1.75 mmol) was added. The solvent was removed under reduced pressure and resulting solid was 
suspended in water (20 mL) and collected by vacuum filtration. The crude product was purified 
using column chromatography on Sephadex LH-20 (pre-soaked in acetonitrile) using acetonitrile 
as the mobile phase. Two distinct bands were collected (confirmed via simultaneous collection of 
UV-visible spectra) and the solvents were removed from each to yield brown solids. Yield = 
0.1488 g. 19F NMR (376 MHz, DMSO-d6): Fppm -69.18 (d, 18 F) 
[Ru(phen)2(PPTA)](PF6)2·1.5H2O (10) 
[Ru(phen)2Cl2] (1.00 g, 1.90 mmol) and 1 (0.84 g, 3.90 mmol) were combined in a 1L RBF 
in 2:1 EtOH/H2O (850 mL) and were refluxed with stirring for 24 hours. After 24 hours at reflux 
the flask was allowed to cool to room temperature and NH4PF6 (3.51 g, 21.5 mmol) was added. 
The solvent was removed under reduced pressure and resulting solid was collected by vacuum 





chromatography on Sephadex LH-20 (pre-soaked overnight in acetonitrile) using acetonitrile as 
the mobile phase. Three distinct bands were collected (confirmed via simultaneous collection of 
UV-visible spectra) and the solvents were removed from each to yield brown solids. A single 
crystal for X-ray analysis was grown via the slow evaporation technique from MeCN/Toulene 
(1.5:1) supplemented with an equimolar amount of triphenylphosphine oxide (0.100 mmol). Yield 
= 1.23 g (67%). ESI-MS: m/z 676.0849 [10]+, Elemental Analysis: Calculated: C 43.49; H 2.88; 
N 9.82, Found: C 43.57; H 2.89, N 9.91. 1H NMR (400 MHz, DMSO-d6): ppm 9.73 (dd, J=1.37, 
5.27 Hz, 1H), 8.83 (ddd, J=1.17, 8.40, 9.57 Hz, 3H), 8.72 (dd, J=1.17, 8.20 Hz, 2H), 8.61 (d, 
J=7.03 Hz, 2H), 8.52 (dd, J=0.98, 8.40 Hz, 1H), 8.32-8.44 (m, 7H), 8.24 (d, J=8.98 Hz, 1H), 8.16 
(dd, J=5.47, 8.20 Hz, 2H), 8.05 (dd, J=5.08, 8.20 Hz, 1H), 7.94-8.00 (m, 2H), 7.77 (dd, J=1.17, 
5.08 Hz, 1H), 7.72 (dd, J=5.08, 8.20 Hz, 1H), 7.57 (d, J=7.03 Hz, 3H), 7.49 (dd, J=5.47, 8.20 Hz, 
1H), 7.30 (ddd, J=1.56, 5.86, 7.42 Hz, 1H). 19F NMR (376 MHz, DMSO-d6): Fppm -69.18 (d, 
12 F) 
Attempted [Co(phen)2(TPTA)](PF6)3 (11) 
[Co(phen)2(OH2)2](NO3)3 (1.00 g, 1.56 mmol) and 2 (0.546 g, 1.56 mmol) were combined 
in a 1L RBF with EtOH (850 mL) and were refluxed with stirring for 24 hours under Ar (g). After 
24 hours the contents were concentrated to 200 mL and NH4PF6 was added followed by H2O (100 
mL). The mixture was further concentrated to 50 mL and cooled to room temperature. The mixture 
was filtered through a fine glass frit and air dried. A single crystal for X-ray analysis was grown 
via the slow evaporation technique from MeCN/Toulene (1.5:1) supplemented with an equimolar 
amount of triphenylphosphine oxide (0.100 mmol). Yield = 1.25 g (66%). Elemental Analysis: 
Calculated: C 35.89, H 2.01, N 6.98; Found: C 41.98, H 2.53, N 7.74. ESI-MS: m/z 384.0465 





2H), 9.09 (dd, J=1.17, 8.20 Hz, 1H), 8.84 (dd, J=0.98, 8.40 Hz, 1H), 8.48-8.61 (m, 5H), 8.23-8.41 
(m, 4H), 7.94 (dd, J=5.47, 8.20 Hz, 1H), 7.86-7.90 (m, 1H), 7.74 (d, J=0.78 Hz, 3H), 7.52-7.66 
(m, 3H), 7.23-7.30 (m, 1H) 19F NMR (376 MHz, DMSO-d6):Fppm -61.31 (s, 6 F), -69.19 (d, 18 
F). 
Attempted [Co(phen)2(APTA)](PF6)3 (12) 
[Co(phen)2(OH2)2](NO3)3 (64 mg, 0.1 mmol) and 3 (31 g, 0.1 mmol) were combined in a 
100 mL RBF with EtOH (32 mL) and were refluxed with stirring for 65 hours under Ar (g). After 
65 hours the contents were concentrated to 10 mL and NH4PF6 (0.163 g, 1 mmol) was added 
followed by H2O (32 mL). The flask was placed in an ice bath then filtered through a fine glass 
frit and washed with H2O (2 x 40 mL) and then air dried. Yield = 74.7 mg (64%). Elemental 
Analysis: Calculated: C 45.22, H 2.59, N 7.19; Found: C 55.99, H 3.45, N 8.55.  1H NMR (400 
MHz, DMSO-d6): Hppm 12.55 (s, 1H), 7.51-9.01 (m, 29 H). 
19F NMR (376 MHz, DMSO-






RESULTS AND DISCUSSION 
 
Scheme 8. General synthesis of PCA ligands.a 
 
 
a (i) S, Na2S·9H2O, R-NH2 
 
 The general synthesis of the PCA ligands (1-6) is shown in scheme 8 and was adapted from 
previously reported literature protocols which gives the synthesis of compound 6.107 PCAs were 
generated in a one pot synthetic scheme utilizing a modified Willgerodt-Kindler reaction where 
the substituted aniline and elemental sulfur were refluxed for the specified time period in 2-
picoline in the presence of a catalytic amount of sodium sulfide nonhydrate. TLC analysis during 
the course of the reaction shows almost complete disappearance of the substituted aniline precursor 
with the concurrent appearance of the desired products as indicated by a decrease in the overall 
polarity of the compounds. After column purification the PCA ligands were generally obtained in 
moderate yield (75-77%), except in the case of 2 which may have been inhibited due to steric 





aprotic deutrated solvents, the thioamide proton was detected at ~12 ppm and the thiocarbonyl was 
detected at ~188 ppm (see Supporting figure A8-A11). These values correlate with the previous 
reports in literature for similar compounds.107,120 As shown in figure 40 the 1H and 13C resonance 
for the pyridinyl moieties are well conserved among all derivatives (1-8) allowing for simplified 
assignment of the remaining resonances present. Additionally, the inclusion of other nuclei, such 
as fluorine, allows for further characterization by 19F NMR. Compounds 1, 3, and 4, show 
resonances in their 19F NMR spectra further confirming the purity of these compounds (see figure 
41). Furthermore, the formation of the thioketone moiety is observed by analyzing the FT IR 
spectra of all of the compounds and its shift value of 1380 cm-1 is highly conserved in all cases. 
Despite spectroscopic characterization confirming the purity of the synthesized compounds, no 
comprehendible mechanism exists for a Willgernot-Kindler reaction utilizing methylpyridine as 
the starting material, and therefore further characterization was conducted. In an attempt to prove 
the structure of these novel compounds crystallization experiments were conducted utilizing 
various techniques, i.e. vapor diffusion, slow evaporation, convection, etc. X-ray quality crystals 
of compound 1 were produced by slow evaporation of CHCl3 and the structure was solved (Dr. 
Colin McMillen – Clemson University) unequivocally proving the structure and the utility of the 


















Figure 42. ORTEP diagram of 1. 
 
In the case of compound 7, a modified two-step reaction scheme was utilized which first 
required the reduction of the carboxylic acid moiety present in 4-aminobenzoic acid to a benzyl 
alcohol via lithium aluminum hydride (LAH) due to both the competitive ketone moiety and the 
cost of pure p-aminobenzyl alcohol.407 Following the reduction, the obtained 4-aminobenzyl 
alcohol was reacted by the same scheme as the other PCAs. Interestingly, the methylene protons 
and carbon of 7 do not correlate well to literature or with predicted expectations, with the 
methylene carbons resonance shifted upfield 40 ppm from the predicted values of ~60 ppm. 
However, following oxidation of 7 with Jones’ reagent the desired carboxylic acid containing 
thiocarboxaimde (8) is obtained as confirmed by the appearance of the downfield resonance in the 
13C NMR spectrum attributed to the reformation of the carboxylic acid moiety, with remaining 





Table 8. PCA-containing complexes (9-12) composition. 
Compound Metal Center PCA Ligand 
9  CoIII 6 
10 RuII 6 
11 CoIII 1 
12 CoIII 2 
 
Scheme 9. Synthesis of cyclometallated PCA complexes. 
 
 
Complexes 9-12 are generated via a substitution reaction involving an appropriate amount 
of the purified PCAs (1,2, or 6) with either a Co(III) or Ru(II) precursor as indicated by table 8 
and shown in scheme 9.  Compounds 9, 11, and 12 were generated by refluxing the respective 
PCAs with a previously prepared Co(III) precursor complex. The 1H NMR and FT IR spectra of 
complexes 9 and 11 show upfield shift of the thioamide proton and thioketone, respectively, 





attributed to the hydrazinic proton upon N,S coordination in thiosemicarbazones.108,109,121 The 
conservation of the thioketone moitey in the FT IR spectra also gives indication that ligands eixit 
in the thione form when coordinated to the metal center. Alternatively, in compound 12 similar 
shift in the FT IR spectrum are not observed potentially indicating a difference in the coordination 
made for this ligand. Additionally, the purity of the 11 was confirmed using 19F NMR and ESI-
MS (Supporting figures A11-12). The presence of a singlet, attributed to the equivalent bis-
trifluoromethyl moieties, and a doublet for the hexaflurophosphate counter ion is observed in the 
19F NMR spectrum. As shown in figure 43, a peak of m/z 384.0465 was observed in the mass 
spectrum which was attributed to the [11]2+ species. With the ligand coordinating in the thione 
form (as indicated by 1H NMR and FT IR characterization), it is suggested that the complex 
tautomerizes to the thiol form within the mass spectrometer chamber. Elemental analysis of 
complexes 11 and 12 raised questions on the purity of these complexes due to drastic differences 
in the calculated and found C and N ratios for these complexes. With all resonances in the aromatic 
region of the 1H NMR spectra it is difficult to confirm the purity of the complexes using 
conventional spectroscopic studies due to extensive overlap, however, the shift of the hydrazinic 
proton from 12 ppm to 10 ppm in the 1H NMR spectra does give hope to coordination of the ligand 
in an N,S bidentate fashion. Additionally, spurious peaks were observed in aromatic region of the 















Compound 10 the ruthenium analogue of 9 was generated in a similar reaction scheme. 
Shifts of the thioamide proton and thioketone resonance are observed similar to compounds 9 and 
11 indicating an N,S- bidentate thione coordination mode for this complex. In the ESI-MS 
spectrum of 10, a peak at m/z 676.0849 was observed and is attributed to the [10]+ species 
supporting the proposed structure (figure 44). Elemental analysis of this complex indicated the 
structure as proposed and also shows there are 1.75 H2O molecules coordinated within the inner 
coordination sphere of the complex. During the purification step of the complex a second high 
molecular weight band was identified by UV-visible spectroscopy and it is hypothesized that this 
secondary band is due to the formation of a binuclear species following the coordination of the 



















Figure 45. Potential binuclear product obtained from reaction of [Ru(phen)2Cl2] and PPTA. 
 
These PCA ligands can coordinate in multiple bidentate manners to the metal center, 
despite spectroscopic evidence of coordination in the thione N,S-fashion more detailed 
conformation was sought. Triclinc crystals obtained from a diffusion of Et2O into a saturated 
solution of 12 in MeCN provided a structure of [CoII(phen)3](PF6)2 with 2 high disordered MeCN 
molecules within the crystallization sphere (Figure 46). Due to the previously discussed 
characterizations of these compounds it is likely the [CoII(phen)3]
2+ is a trace byproduct present in 
the precursor, [Co(phen)2(OH2)2](NO3)3, utilized in the preparation of these compounds. This 
byproduct can also be observed in the ESI MS of compound 11 with an m/z of 299.56 attributed 
to the species [CoII(phen)3]
2+ (supporting figure A12). The presence of this byproduct in the all 
Co(III) samples has halted the ability of these complexes to be utilized in any cell free or cell based 






Figure 46. Trace impurity, [CoII(phen)3]
2+, present in all prepared Co(III) complexes.  
 
CONCLUSION 
The design, synthesis and characterization of a new series of PCA ligands (1-8) and PCA-
containing complexes (9-12) are present. While the definitive mechanism of the employed 
Willgernot-Kindler reaction employed remains elusive, characterizations of the 1-8 indicate high 
yield and purity of synthesized PCAs. In one case X-ray crystallographic studies confirmed the 
structure as proposed thereby corroborating the employed scheme. Compound 8 in this series 
represent a PCA which will be future functionalized in the future for not only biological 
applications but for it use in bridging ligands potentially capable of facilitating election transport 
(See chapter 6). Characterization of the cyclometallated complexes 9-12 proved more difficult, 
however, it was confirmed by FT-IR analysis in most cases that the PCAs coordinate in an N,S 





the proposed complexes were synthesized, X-ray crystallographic studies show a trace impurity, 
[Co(phen)3]
2+, to be present in all samples. This fact was further confirmed by EA and MS data 
(Supporting Figure A12). This impurity restricts the ability of in-depth characterization to be 
performed as well as negates the usage of these compounds in bioassays. Alternatively, the Ru(II) 
complex (10) was obtained in moderate yield with high purity confirming the utility of the 
employed reaction scheme. These PCAs represent a new series of compounds synthesized by a 
clean, versatile, process that potentially allows for rapid generation of a library of functionalize 
PCAs in the future. Furthermore, these PCA ligands and PCA-containing complexes represent a 
series of complexes which can be evaluated for their biological activity, specifically their ability 
to induce apoptosis in mammary breast cancer cell lines. The relative ease of preparation should 
allow for future SAR studies to be conducted and allow for easy comparison with 
thiosemicarbazone data. A solid understanding of the structure of the complexes, mechanism of 
action, and bioactivity with various cell markers is necessary for developing more active and 






SYNTHESIS AND CHARACTERIZATION OF A SERIES OF THIADIAZOLE- AND 




Heterocyclic compounds have attracted much attention in the field of medicinal chemistry 
given their unique chemical properties and wide ranging biological activities. Despite the 
widespread success of these systems, a recent upheaval in research progress on these systems has 
begun to identify novel heterocyclic compounds with potent bioactivities.408 Of the various 
heterocylces often five member systems, such as imidazole, oxaxole, thiazol, oxadiazole and 
thiadiazole are typically the most studies as they often possess biological activity. In particular, 
the thiadiazole ring has been extensively studied and has been linked to drugs which possess 
antiparasitic and antimicrobial properties, with some of the resultant drugs still in clinical use 
today.409 More recently, research has indicated that the thiadaizole ring is an increasingly important 
framework, with broad spectrum bioactivity. As shown in figure 47 there are four major types of 
thiadiazole rings: 1,2,4-, 1,3,4-, 1,2,3- , and 1,2,5-thiadiazole, with the most investigated being the 
1,2,4- and 1,3,4-thiadiazoles. It has been widely reported that compounds which bear the 
thiadiazole ring exhibit anticancer, anti-inflammatory, antibacterial, antifungal, antiviral, 






Figure 47. A) Core structures of thiadiazoles. B) A side by side comparison of the basic structures 
of pyrimidine and 1,2,4-thiadiazole scaffolds. 
  
There are a variety of thiadiazole-containing drugs currently on the market with a variety 
of activities (figure 48). For example, methazolamide and acetazolamide are diuretics which 
inhibit carbonic anhydrase.412 While the main mechanism of action of these drug is the inhibition 
on carbonic anhydrase closely related derivatives have found applications as anticonvulsants and 
cerebral vasodilators.411, 413 Perhaps the most important thiadiazole containing drugs are: cefazolin 
sodium and cefazedone which are first generation cephalosporins that possess broad spectrum 
activity against gram-negative and gram-positive bacteria;414 and timolol which is a blocker 
used for treatment of hypertension and migraine headaches.413 All are listed on the World Health 
Organizations List of Essential Medicine needed for basic health systems. Additionally, megazol 
is a nitroimidazole based drug which is has been found to be more effective than the standard 






Figure 48. Some thiadiazole-containing drugs currently on the market. 
 
The widespread activity of thiadiazole compounds is ascribed to the idea that 1,2,4-
thiadizoles are bioisosteres to pyrimidines based upon the theory of ring equivalents proposed by 
Burger (shown in figure 48). With the pyrimidine ring playing a prominent role in nucleobases 
found in DNA and RNA, specifically, cytosine, uracil, and thymine it is predicted that these 
compounds many interfere with normal metabolism of nucleic acids.417 Cellular uptake of 
compounds which incorporate the thiadiazole moiety is often aided leading to enhanced activity 
due to the sulfur atom imparting improved liposolubility.418 Additionally, the 1,3,4-thiadiazoles 
are mesoionic - with conjugated p and electrons and regions of positive and negative charges.419 
This unique property may give ligands incorporating these systems the ability to facilitate electron 
transfer reactions, a property which has been exploited in many other applications.420-423   
While the thiadiazole moiety is independently powerful,424-427 current trends are focused 





utility of these molecules. Another moiety, 1,2,4-triazoles have been reported to possess similar 
widespread activity similar to thiadiazoles.428, 429 Commonly, triazoles are combined with 
thiadiazoles or thiazdiazines to create triazolothiadiazoles and triazolothiadiazines, respectively. 
These multiple heterocylic compound have been reported to have broad spectrum therapeutic 
activity from antiviral and antitumoral activity to CNS-stimulants and phosphodiesterase-4 
inhibitors.430-437 
Our design strategy was to generate a library of these thiadiazole and triazolothiadiazole 
ligands to conduct SAR studies on their biological activity. Several protocols exist for the 
preparing of both thiadiazole- and triazolothiadiazole-containing compounds, however we have 
chosen to follow recent literature examples on the preparation of both systems.438, 439  The use of 
4-amino-5-(pyridine-2-yl)-1,2,4-triazol-3-thiol (4) in the preparations of our triazolothiadiazole 
systems (5-11) allows for the incorporation of a third heterocycle for future coordination to metal 
centers. The amino and mercapto groups present also serve as ready-made nucleophilic center for 
the synthesis of condensed heterocyclic rings.440, 441 Herein we report the synthesis and 
characterization of a series of thiadiazole and triazolothiadiazole compounds, as shown in schemes 
7 and 8, respectively. These compounds represent proof of concept model and are the beginning 
stages of a library of heterocyclic compounds which can complexed to various metal centers and 




All reagents used in the syntheses, if not specified, were obtained from either Sigma-





purification. 1H, 13C and 19F NMR spectra were collected on a Varian Inova 400 MHz NMR 
Spectrometer. 1H NMR spectroscopic samples were standardized relative to sodium 3-
(trimethylsilyl)propionate (δ = 0.0 ppm) or appropriate residual solvent peaks. 13C NMR 
spectroscopic samples were all standardized to residual solvent peaks as indicated by respective 
compounds. FT IR and ATR data was obtained using a Nicolet AVATAR 370 DTGS 
spectrophotometer. X-ray crystallography studies were conducted by Dr. Colin McMillen, 
Director of the Molecular Structure Center, Department of Chemistry of the Clemson University 
(Clemson, SC, USA). 
Synthesis of N-phenyl-1,3,4-thiadiazole-2-amine ligands 
5-(2-pyridinyl)-N-phneyl-1,3,4-thiadiazole-2-amine (1) 
N-phenylthiosemicarbazide (1.67 g, 0.01mol) and 2-picolinc acid (1.23 g, 0.01mol) in 
DMF (25ml) were combined in a 100 mL RBF. A few drops of concentrated HCl were added to 
the reaction and the reaction flask was placed in a silicon oil bath to reflux for 72 hours at 95 °C.  
After 72 hours the blue/green reaction mixture was slowly poured into crushed ice forming an 
immediate yellow precipitate. The separated solid was filtered, washed with water, dried and 
purified by recrystallization from methanol. A single crystal suitable for X-ray analysis was grown 
via slow evaporation technique by dissolving 50 mg of the obtained yellow solid in a 2 M HCl 
solution and allowing the solvent to evaporate. Yield = 0.346 g (13.7 %), yellow solid. FT IR 
(KBr) cm-1 = 3230 (NH, m); 3006 (CH, m); 1600 (C=N, s); 1554 (C=C, vs), 746 (ArH, s), 694 
(ArH, s). 1H NMR (400 MHz, DMSO-d6): Hppm 6.93 (t, J=7.22 Hz, 1 H) 7.30 (t, J=8.01 Hz, 3 
H) 7.55 (d, J=7.81 Hz, 3 H) 8.71 (s, 1 H) 9.85 (s, 1 H).  13C NMR (100 MHz, DMSO-d6 ): Cppm 






N-phenylthiosemicarbazide (1.67 g, 0.01mol) and 3,4-dimethoxybenzoic acid (1.82 g, 
0.01mol) in DMF (25ml) were combined in a 100 mL RBF. A few drops of concentrated HCl were 
added to the reaction and the reaction flask was placed in a silicon oil bath to reflux for 72 hours 
at 95 °C.  After 72 hours the blue/green reaction mixture was slowly poured into crushed ice 
forming an immediate white precipitate. The separated solid was filtered, washed with water, dried 
and purified by recrystallization from methanol. Yield = 0.880 g (28 %), white powder. FT IR 
(KBr) cm-1: 3230 (NH, m); 2966 (CH, m); 1677 (C=N, s); 1598 (C=C, vs); 1483 and 1268 (ArH, 
vs); 746 and 630 ArH, m). 1H NMR (400 MHz, DMSO-d6): Hppm 9.88 (s, 1H), 7.57 (dd, J=2.15, 
8.40 Hz, 2H), 7.44 (d, J=1.95 Hz, 1H), 7.31 (s, 1H), 7.26-7.36 (m, 1H), 7.04 (d, J=8.59 Hz, 1H), 
6.94 (s, 1H), 6.94 (d, J=14.84 Hz, 1H), 3.81 (d, J=10.54 Hz, 6H). 13C NMR (100 MHz, DMSO-
d6): Cppm 163.9, 162.9, 161.9, 139.1, 131.0, 129.1, 124.7, 117.9, 111.0, 101.3, 55.5. 
2-(dithiocarboxy)hydrazide-4-pyridinecarboxylic acid (potassium salt) (3) 
Isonicotinic hydrazine (5.00 g, 36.5 mmol) was treated with a solution of potassium 
hydroxide (2.16 g, 54.75 mmol) dissolved in ethanol (100 mL) in a 250 mL RBF. The flask was 
cooled to 0 °C, then CS2 (3273 µL, 54.75 mmol) was slowly added with constant stirring resulting 
in a clear yellow solution. After 24 hour of stirring at room temperature, the opaque yellow solution 
was filtered through a fine glass frit to yield a yellow powder. The product was washed with chilled 
ethanol and air dried. Yield = 9.01 g (96 %). FT IR (KBr): 3311 (-NH, s); 3081 (-CH, s); 1677 
(C=O, vs); 1508 and 1473 (ArH, m); C=S (1093, m); 692 (C-S, m). 1H NMR (400 MHz, DMSO-







2-(dithiocarboxy)hydrazide-4-pyridinecarboxylic acid (2.0 g, 7.95 mmol) was dissolved in 
H2O (63 mL) in a 250 mL RBF with a stir bar resulting in a yellow solution. Then hydrazine 
hydrate (4952 µL, 159 mmol) was added dropwise to the flask and it was allowed to reflux for 24 
h. During the progress of the reaction, the reaction mixture turned green with the evolution of 
hydrogen sulfide gas and became homogeneous. After 24 hours at reflux the flask was cooled to 
room temperature and evaporated to a minimum volume (~ 20 mL). Then HCl (conc.) was added 
dropwise to the flask resulting in the formation of a white precipitate. The solid was collected by 
filtration through a glass frit. The HCl addition process was repeated on the filtrate until no further 
product was obtained. The crude product was washed with water and air dried to yield an off white 
powder. Yield = 1.47 g (96 %). FT IR (KBr, cm-1): 3320 (NH, m), 2598 (SH, s), 1610 (C=N, m), 
1572(C–H, m). 1H NMR (400 MHz, DMSO-d6): Hppm 5.85 (s, 1 H) 7.82 (br. s., 2 H) 8.03 (br. 
s., 2 H) 8.81 (d, J=3.51 Hz, 2 H) 
Generation of 6-substituted-1-2,4-triazolo-[3,4-b]-1,3,4-thiadiazole library 
General procedure for synthesis of 6-substituted-1-2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles was 
adapted from the methods of Gilani et al.438 In brief, an equimolar mixture 4-amino-5-(pyridine-
2-yl)-4H-1,2,4-triazole-3-thiol (4) and aromatic acids in phosphorus oxychloride (20 mL) were 
refluxed for five hours. The reaction mixture was cooled to room temperature and then gradually 
poured on to crushed ice with stirring. The mixture was allowed to stand overnight and the solid 
separated out, was filtered, treated with dilute sodium hydroxide solution and washed thoroughly 







Yield = 0.5312 g (73 %). 1H NMR (400 MHz, CDCl3): Hppm 8.84-8.89 (m, 2H), 8.31-
8.34 (m, 2H), 7.96-8.03 (m, 2H), 7.56-7.71 (m, 3H). 13C NMR (100 MHz, DMSO-d6): Cppm 
175.7, 158.1, 149.9, 149.7, 132.8, 130.4, 129.2, 128.9, 125.9, 121.5. 
6-(3,4-dimethoxyphenyl)-3-(4-pyridyl)-1,2,4-triazolo-[3,4-b][1,3,4-]thiadiazole (6) 
Yield = 0.3787 g (72 %). 1H NMR (400 MHz, CDCl3): Hppm 8.85 (d, J=5.08 Hz, 2H), 
8.30 (d, J=5.47 Hz, 2H), 7.50-7.55 (m, 1H), 7.46 (d, J=1.56 Hz, 1H), 7.02 (d, J=8.20 Hz, 1H), 4.04 
(s, 3H), 4.00 (s, 3H). 13C NMR (100 MHz, DMSO-d6): Cppm 175.7, 158.1, 149.8, 149.7, 148.3, 
132.8, 130.4, 129.2, 128.9, 125.9, 121.5. 
5-hydroxyl-2-[3-(4-pyridinyl)-1,2,4-triazolo-[3,4-b][1,3,4]-thiadiazole-6-yl]-phenol (7) 
Yield = 1.18 g (74 %). 1H NMR (400 MHz, CDCl3): Hppm 8.81 (s, 1H), 8.63 (m, 2H), 
7.74 (m, 2H), 7.23 (d, J=8.44 Hz, 1H), 6.48 (s,1H), 6.32 (d,, J=8.44, 3H), 3.96 (s, 2H). 
2-[3-(4-pyridinyl)-1,2,4-triazolo-[3,4-b][1,3,4]-thiadiazole-6-yl]-benzamine (8) 
Yield = 27 mg (45 %). 1H NMR (400 MHz, CDCl3): Hppm 8.67-8.75 (m, 2H), 8.04-8.09 
(m, 2H), 7.95 (dd, J=1.71, 7.81 Hz, 1H), 7.57 (dt, J=1.71, 7.94 Hz, 1H), 7.42 (dt, J=0.98, 7.81 Hz, 
1H), 6.68 (dd, J=1.22, 8.06 Hz, 1H) 
6-(anthracen-1-yl)-3-(pyridin-4-yl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole (9) 
            Yield = 52 mg (52 %). 1H NMR (400 MHz, CDCl3): Hppm 9.15 (m, 1H), 8.84 (dd, 2H), 





13C NMR (100 MHz, DMSO-d6): Cppm 158.1, 156.2, 150.4 149.6, 136.7, 132.8, 131.9, 131.3, 
130.7, 130.6, 128.2,127.8, 126.5, 121.5, 120.4. 
4-[3-(pyridin-4-yl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole-6-yl]benzene-1,2-diamine (10). 
            Yield = 30 mg (55 %). 1H NMR (400 MHz, CDCl3): Hppm 8.64 (dd, 2H), 8.13 (d, 1H), 
8.04 (dd, 2H), 7.02 (t, 1 H), 6.66 (dd, 1H). 13C NMR (100 MHz, DMSO-d6): Cppm 158.1, 156.7, 
150.1, 149.6, 141.0, 137.9, 132.6, 130.1, 127.4, 121.5, 115.2. 
4-[3-(pyridin-4-yl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole-6-yl]phenol (11) 
Yield = 27 mg (45 %). 1H NMR (400 MHz, CDCl3): Hppm 8.67-8.75 (m, 2H), 8.04-8.09 
(m, 2H), 7.95 (dd, J=1.71, 7.81 Hz, 1H), 7.57 (dt, J=1.71, 7.94 Hz, 1H), 7.42 (dt, J=0.98, 7.81 Hz, 
1H), 6.68 (dd, J=1.22, 8.06 Hz, 1H) 
 
RESULTS AND DISCUSSION 
 
Scheme 10. Synthetic route for preparation of thiadiazole-containing compounds.439, 442 
 
 
a (i) RCOOH, DMF, HCl 
 
The synthesis of compounds 1 and 2 are shown in Scheme 10. The preparation involves 
the cyclization of 4-phenylthiosemicarbazide to a 1,3,4-thiadiazole in the presence of various 
aromatic carboxylic acids. Typically, reactions of this type are carried out under microwave 
conditions in order to reduce the reaction time and to afford a cleaner product,439, 442 however, 





The 1H NMR spectrum of 1 indicates high conversion and it consistent with reported literature 
values for the compound as shown in figure 49.442 The 13C NMR spectrum shows the losses of the 
resonances at ≈180 and ≈160 ppm attributed to thiourea and carboxylic acid moieties in the starting 
materials, respectively. In addition, a similar pattern is observed in compound 2, a 3,4-dimethoxy 
derivative. Despite the confirmation of 1 by NMR spectroscopic studies, a crystal of 1 was shown 
to have a unit cell dimension matching N,N-diphenyl-[1,3,4]thiadiazole-2,5-diamine, a 
symmetrical 1,3,4-thiadiazole compound with 2 equivalent phenyl rings.443 Interestingly, the 1H 
NMR resonances are similar for the two structures,443 however, the 13C resonances show 
significant differences. This formation of N,N-diphenyl-[1,3,4]thiadiazole-2,5-diamine was further 
confirmed with ESI-MS where the molecular ion peak can be observed at an m/z of 269.08 
(supporting figure A21). Interestingly, no such symmetrical compound was obtained when 
utilizing the same reaction scheme and a substituted (3,4-dimethoxy) carboxylic acid as the starting 
material. An alternative route for the preparation of the target molecule has been proposed starting 













Scheme 11. Route for preparation of triazolothiadiazole-containing compounds.438 
 
 
a (i) KOH, EtOH, CS2; (ii) NH2NH2·H2O, H2O, HCl; (iii) RCOOH, POCl3 
 
 Compounds 3 and 4 serve as the synthetic precursors to forming 6-substituted-1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazoles 5-11 and the synthesis is shown in scheme 11. The key step in 
the synthesis of these systems is the acid catalyzed condensation, where, for example, benzoic acid 
is reacted with 4 in the presence of POCl3 to generate 5 in high yields. The required 
dithiocarbazinate 3 was synthesized by reacting isonicotinic acid hydrazide with carbon disulfide 
and potassium hydroxide in ethanol. This salt underwent ring closure with an excess of 99% 
hydrazine hydrate to afford 4, in high yields. Full caution (closed hood, lab coats and gloves) must 
be taken when working with hydrazine hydrate as it is extremely flammable and during the work 





(4) matches well with literature characterization for the compound (Figure 50);438 and ring closure 
can be confirmed by the appearance of the stretching frequency at 2598 cm-1 in the FT IR spectrum, 
indicative of the formed thiol moiety. 
 
 
Figure 50. 1H NMR spectrum of 4-amino-5-(pyridine-2-yl)-4H-1,2,4-triazole-3-thiol (4) in 
DMSO-d6. 
  
The triazole containing precursor (4) was converted to the desired 6-substituted-1,2,4-triazolo[3,4-
b]-1,3,4-thiadiazoles 5-9  in a one-pot reaction by condensation with various aromatic acids in the 
presence of POCl3 utilizing the protocol by Gilani et al.
438 For example, 5 was prepared in high 
yield and high purity as indicated by 1H NMR data (Figure 51), which is consistent with previous 





reaction was completed using 4 and 2-picolinic acid. Unfortunately, FT IR characterization 
indicated no conversion to the desired product due the conservation of the broad stretching 
frequency at 3200 cm-1 attributed to the carboxylic acid.  
 
 
Figure 51. 1H NMR spectrum of 5 in CDCl3.  Inset shows blow up of peaks present in the aromatic 
region. 
 
In order to further determine the utility of this reaction scheme and rapidly generate a 
library of compounds, various substituted aromatic acids were condensed in POCl3 in the presence 
4. As shown in scheme 10, we have synthesized a variety of compounds which include common 
functional groups such as amines, alcohols, methoxy, and aryl. Spectroscopic characterization of 





heterocylic compound failed to produce a compound for characterization. This small library of 
compounds shows the widespread utility of the employed reaction scheme which can further be 
utilized to quickly and efficiently generate a large library of compounds for SAR studies.  
 
CONCLUSION 
The synthesis and characterization data of various thiadiazole or triazole-thiadiazole 
containing compounds is discussed in this chapter. First, using conventional methods similar to 
those employed by Sahoo et al.439 we have prepared or attempted to prepare two thiadiazole 
containing compounds 1 and 2. Similar to reports by Efirmova et al.442 conventional methods 
proved unsuccessful at preparing 1; instead X-ray crystallographic data suggests N,N-
diphenyl[1,3,4]thiadiazole-2,5-diamine was prepared. A scheme starting from 2-picolinc acid has 
been proposed as a possible alternative route to preparing the compound without employing 
microwave conditions. Additionally, a series of triazole-thiadiazole containing compound were 
created 5-9 via a condensation reaction of the precursor 4 with various aromatic acids. We have 
utilized mono- and di-substituted aromatic acids with some success and a small of compounds has 
been prepared. Future studies will focus on coordination of these compound to various metal 
centers (notably Ru(II) and Co(III)) as well as studying the in vitro bioactivities, most notably anti-
microbial and anti-cancer. As both triazole and thiadiazole rings are often found in drug molecules 
both series of prepared compounds are predicted to have high biological activity and therefore 






CHAPTER 6  
CONCLUSIONS AND FUTURE WORKS 
 
The primary focuses of the studies outlined in this thesis were to design, synthesize and 
characterize novel ligands and transition metal complexes for biomedical applications and to 
provide enhanced knowledge on the mechanism of action of transition metal complexes and nsPEF 
technology in breast cancer cell lines. Transition metal complexes remain to be one of the largest 
and most studies class of compounds as they relate to medicinal chemistry owing to the success of 
cisplatin.97 Despite significant research progress on a variety of these metal complex systems, there 
are ongoing efforts to discover novel compounds with potent bioactivities and elucidate their 
mechanism of action.  
 
Mechanistic investigations 
To investigate the mechanism of action of a new drug molecule is to fully describe the 
functional or anatomical changes of a living organism elicited by the introduction of the substance 
at the molecular level. In chapter 2, we investigated the mechanism of action of 
[Co(phen)2(MeATSC)](NO3)3·2.5H2O·C2H5OH,
273 via various cell-free and cell based assays. It 
was revealed through fluorescence and UV-visible titration experiments that the complex interacts 
with DNA in an intercalative manner, most likely stemming from the inclusion of polypyridyl 
heteroaromatic phenanthroline ligands. The complex demonstrated moderate toxicity in the model 
aggressive metastatic breast cancer cell line with an IC50 = 34 µM. Additionally, it was established 
that the complex induced autophagy, apoptosis, and dissipation of the m in breast cancer cells 





was activated in a caspase-dependent manner and was this signaling pathway was most involved 
in cell death. Given other observations of the molecular target of the complex, it is most likely that 
the caspase cascade is activated via the intrinsic pathway following initial DNA damage. Initial 
studies conducted involving a novel dual treatment strategy involving nsPEF technology and 
Co(III) chemotherapeutic agents were also described. It was observed that dual treatment resulted 
in an increase in cellular viability, the opposite of the hypothesized synergistic killing effect. The 
nature of the “protective” event occurring was further investigated by the inhibition of the 
autophagic pathway, however, inhibition of this signaling pathway yield no significant change in 
observed effect.  
While the assays conducted here have provided interesting preliminary information on the 
punitive mechanism of action of [Co(phen)2(MeATSC)](NO3)3·2.5H2O·C2H5OH, there is much 
room for improvement on current studies and future work. One of the biggest unanswered 
questions for our studies is: what is the effect of typsin-EDTA on our cells? Trypsin is a prolytic 
enzyme utilized to remove adherent cells from culture flasks prior to many assays. We have some 
preliminary results which suggest that this harsh method of removing cells could cloud some of 
the results but have yet to determine its overall effect. Other protocols could be optimized to further 
validate our hypotheses moving forward for instance, in the Enzo autophagy assay only a small 
shift in the fluorescence signal via flow cytometric analysis is observed. To further confirm the 
activation of this pathway staining and imagining using confocal microscopy could greatly aid in 
the visualization of the formed autophagosomes. Viability assays conducted were heavily reliant 
on the MTS assay which monitors NADPH production (which occurs in the mitochondria) to 
detect viable cells, however, our studies have shown that the complex affect the mitochondria in 





confirm the activity of the complex perhaps monitoring ATP levels or luminescence signals from 
viable cells following exposure to luciferase, as the cells contain a plasmid for luciferin.  
The studies conducted within this thesis can be considered preliminary in nature and in 
order to fully discern the mechanism of action of [Co(phen)2(MeATSC)](NO3)3·2.5H2O·C2H5OH 
much more intensive mechanistic studies will be required. Initial efforts will focus on studying the 
uptake and trafficking of the compound using ICP-AES, confocal fluorescence microscopy, and 
flow cytometry coupled with tracking dyes such as Lyso-tracker DND-99 (Sigma-Aldrich), Mito-
tracker Red CMXRos (Sigma Aldrich), and DAPI. Additionally, monitoring the activity of various 
endocytosis pathways such as: clathrin-mediated, lipid-raft, dynamin-mediated lipid raft, and 
transferrin-mediated will be important to determine an uptake mechanism and various inhibitors 
such as: sodium azide/2-deoxy-D-glucose, sucrose, nystatin, and dynasore will be utilized to study 
these pathways in detail.  
From our studies we have proposed the activation of the intrinsic apoptotic pathway is 
necessary to facilitate cell death based upon caspase 3 activation, dissipation of the m and 
spectroscopic evidence, however, this hypothesis should be investigated in greater detail. While 
caspase 3 was investigated in these studies, an increase in its’ activity is implicated in both the 
intrinsic and extrinsic apoptotic pathways. Mitochondrial signaling leading to m collapse, 
results in cytoplasmic release of effectors (cytochrome c, pro-caspase 9, etc.) constituting the 
apoptosome, which promotes caspase-9 and then caspase-3 activation, and the intracellular levels 
of these effectors should be monitored to validate the hypothsized caspase-dependent cell death 
mechanism proposed. Studies should also be conducted monitoring the activation of the extrinsic 
death receptor pathway by monitoring caspase 8, apoptosis inducing factor (AIF), Fas ligand and 





role of apoptosis related the caspase cascade including APAF-1, Bax, Bid, Bcl-2. Perhaps the most 
important information will come from monitoring the trafficking and cellular distribution of p53, 
which is stabilized by post-translational modifications following stress. Phosphorylation of Ser15 
and Thr18 and upregulation leading to either nuclear or mitochondrial accumulation of this protein 
could be telling of the transcriptional events activated.  
All current studies have only been conducted in one TNBC cell line (due in part to time 
and available resources), however, it would be in the best interest of future researchers to 
conducted all studies in other cancerous cell lines such as: HeLa (adenocarcinoma), HEK-293 
(kidney), A2780cis (cisplatin resistant ovarian), and MDA-MD-435 (melanoma) as well as 
“normal” control cell lines such as: MCF-10A (mammary) and HFF-1 (fibroblasts) to determine 
the specificity of this particular compound for certain cell types and cancerous vs noncancerous 
cells. Additionally, it is also required that an appropriate control drug such cisplatin or doxorubicin 
be utilized in order for comparison to known anticancer chemotherapeutics. The inclusion of 
multiple cell line while a daunting task in terms of labor will provide essential information on the 
complexes activity. For instance, NAMI-A has very low cytotoxic potential but has shown 
remarkable antimetastatic potential.   
The activation of the autophagic signaling pathway provided an interesting phenomenon 
upon addition of the test compound and it would be of interest to further study the activation of 
this signaling pathway, by monitoring cellular ATP levels. While the molecular event which 
provoke autophagic cell death or post-autophagic cell death are highly and intensively debated, 
drastic oxidative stress has been shown to lead to autophagic or necrotic cell death, thus modulation 





involved in both the autophagic and apoptotic pathways and therefore it would be of interest to 
further investigate and probe for potential crosstalk between these two RCD pathways.  
Finally, the nature of the “protective” event observed in the synergistic dual treatment 
studies must be further investigated. First it is imperative that the stability of the complex following 
exposure to nsPEF be established utilizing a combination of HRMS, 1H, 13C and 59Co NMR 
spectroscopic studies be conducted. Transients formed during the nsPEF exposure process may be 
ultimately detected using a modified pulse radiolytic technique to provide information on whether 
reduction and therefore potential “activation” of the CoIII metal center is occurring. Alternatively, 
if localized and selective uptake of the compound is observed and a reduction can be achieved 
following nsPEF exposure, an interesting, localized treatment therapy may be developed.   
 
ITC studies  
In chapter 3, we utilized isothermal titration calorimetry to probe the interaction of 
mononuclear V(IV) and binuclear Ru(II)-V(IV) complexes with CT DNA. Following the work 
conducted by Holder et al.127 we have synthesized a new oxidovanadium(IV) complex which 
incorporates an OOO donor group. This complex, [VO(oda)(phen)]·1.5H2O was characterized via 
conventional spectroscopic techniques and X-ray crystallography. Despite a crystal structure 
confirming the target molecule, solubility issues, not previously reported in literature, inhibited 
our ability to conduct bio-physical and bio-chemical studies on the complex.370, 445 The complex 
was however, successfully incorporated into a supramolecular scaffold to generate a binuclear 
Ru(II)-V(IV) complex. Isothermal titration calorimetry experiments revealed that this novel 
binuclear Ru(II)-V(IV) complex showed significant binding interactions with DNA with three 





with the mononuclear Ru(II) precursor molecule as well as complementing this studies using 
alternative techniques such as UV-Vis or fluorescence spectroscopy. We were unable to assess the 
chemotherapeutic activity of this binuclear complex due to complications with background 
absorbance, however, optimization of protocols utilizing different assays (i.e. luminescence or 
flow cytometric) methods are underway to circumvent this problem. Future studies will also focus 
on further characterization of the interactions of these supramolecular complexes with DNA and 
their chemotherapeutic activity in the absence/presence of light irradiation. Following initial 
studies on these complexes studies similar to those described in Chapter 2 will be conducted to 
fully describe their mechanism of action.  
 
Synthesis of Ligands and Complexes  
Despite significant research progress on heterocyclic ring systems, there are ongoing 
efforts to discover novel compounds with potent bioactivities. The goal of this research was to 
design a series of sulfur containing molecules as they are bioisosteres of common functionalities 
found within many drug molecules and often have enhanced liposolubility owing to the sulfur 
component.418 The approaches utilized throughout this thesis open the door for the synthesis of 
entire libraries of compounds with clean, versatile, and relatively simple reactions.  
In chapter 4 our efforts focused on generating a series of N-substituted pyridine-2-
carbothioamides due to their structural similarity to thiosemicarbazones.102, 103, 399, 446, 447 Due to 
minimal reports on the application of metal complexes incorporating N-substituted PCAs,392, 395, 
397, 399, 448 the work described in this thesis seeks to developed a series of these PCAs and PCA-
containing complexes which may possess anticancer bioactivity. Several PCA ligands were 





techniques as well as X-ray crystallography, where appropriate. One derivative required an 
alternative path due to a competitive ketone moiety, however, following a simple reduction with 
LAH the desired PCA was obtained in high yield similar to others prepared. Successful 
complexation a transition metal precursor, [Ru(phen)2Cl2], was achieved, however, impurities in 
the [Co(phen)2(OH2)2](NO3)3 precursor limited success of these analogues. While ESI MS, FT IR, 
and 19F NMR spectroscopic studies exhibit peaks and shifts from the proposed complexes 
crystallographic studies indicate the presence of a byproduct, [Co(phen)3]
2+. Future studies will 
focus on purifying the synthesized Co(III) complexes and generating a larger library of PCAs for 
complexation. Despite only sparse reports on the application of this class of ligands we envision 
these complexes to exhibit enhanced anticancer activity and stability when compared with Schiff 
base containing thiosemicarbzaone complexes. Following initial screening of the bioactivity of the 
complexes structure-activity relationship studies will be conducted to allow for rational design of 
future ligands. Furthermore, mechanistic studies will be carried out these complexes and compared 
with current and any future data on the mechanism of complexes similar to those in Chapter 2 for 
direct comparison of the mechanisms of these related structures.   
Finally in chapter 5, a series of thiadiazol and triazolothiadiazol compounds were 
synthesized via simple reactions involving either N-phenylthiosemicarbazide or isonicotinc 
hydrazine hydrate. Similar to previous reports on the synthesis of thiadiazol compound we were 
unsuccessful at preparing the proposed compounds via conventional methods, however a modified 
scheme has been proposed for their synthesis in an attempt to continue to avoid the adjuvant of a 
microwave reactor. Additionally, a series of triazolothiadiazol compound were synthesized via a 
condensation reaction of the prepared precursor 4-amino-5-(pyridine-2-yl)-1,2,4-triazol-3-thiol 





utilized of the employed reaction scheme in rapidly generating a library of related compounds. As 
both triazole and thiadiazole rings are often found in drug molecules of many drug classes both 
series of prepared compounds are predicted to have high biological activity and therefore have 
merit in their continued exploration. Future studies will seek to study the bioactivities of the free 
ligands as well as of transition metal complexes which incorporate them.  
Additionally, in a cross over between the major projects of our lab a novel bridging ligand 
has been conceptualized from the two major reaction schemes in this thesis (schemes found in 
chapters 4 and 5). The proposed ligand and complex shown below incorporate both a bidentate 
PCA moiety and a pendent pyridine allowing for complexation with multiple metal centers. It is 
hypothesized that the electron withdrawing nature of the centralized electron deficient thiadiazol 
ring present may facilitate electron transfer processes from the Ru(II) photosensitizing unit to the 





In summary, designing, synthesizing and fully discerning the mechanism of action of even 
a single compound is an extremely complex, arduous, and time consuming endeavor. Cisplatin, 
arguably the most famous transition metal anticancer drug, was first described in 1845, but it 





now, almost 40 years after its FDA approval questions are still swirling around its utilization as a 
chemotherapeutic agent given the rise of cisplatin-resistant cancers. Given the challenges faced 
with this famous and widely prescribed drug, it seems the real question remaining is: will we ever 
fully understand exactly what pathways in the interconnected signaling web are the most important 
to effect to obtain only our desired result? Looking forward from an evolutionary perspective, what 
can we as scientists learn from the evolution of cisplatin resistance and how can we apply that 
knowledge to non-platinum based chemotherapeutics? With near infinite design possibilities of 
transition metal complexes and rapidly advancing scientific methods we may never fully 
understand the complete mechanisms of many of the drugs but that should not stop one from 
investigating in detail. As targeted therapies involving small interfering technology move towards 
clinical application, infinite opportunities to target specific genes may offer some complementary 
way forward on a patient-by patient basis for these drugs. Considering the emergence of these new 
targeted treatment options, it would appear that the days of serendipitous discoveries are behind 
us, but like all hypothesis-driven science, in some cases requires a bit of serendipity, is always 
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Figure A 1. Fluorescence spectra of Ethidium bromide in the absence (black) and presence (red) 










Figure A 2. Contour plots of fluorescence resulting from m after four hours (FL2-H, Y-axis) and FSC-H (Y-axis). A) 0 µM; B) 5 µM; 












Figure A 3. Contour plots are shown of fluorescence resulting from m after six hours (FL2-H, Y-axis) and FSC-H (Y-axis). A) 0 µM; 












Figure A 4. Contour plots of fluorescence resulting from m after delayed TMRE stain addition (FL2-H, Y-axis) and FSC-H (Y-axis) 
after 24 h exposure to 5 µM [Co(phen)2(MeATSC)](NO3)3·2.5H2O·C2H5OH . A) 0 min; B) 15 min; C) 30 min; D) 1 hour delay. Data 






Figure A 5. Cell viability graphs following treatment of 4T1-luc cells with 
[Co(phen)2(MeATSC)](NO3)3·2.5H2O·C2H5OH for various time periods. Cells were seeded at 2.5 
X 104 cells per well for 24 h prior to addition to treatment. Graphs represent n = 3 replicates of 










Figure A 6. Contour plots of fluorescence resulting from propidium iodide staining (FSC-H, Y-axis) and (FL1-A X-axis) after 3 h 
exposure to [Co(phen)2(MeATSC)](NO3)3·2.5H2O·C2H5OH. A) 0 µM; B) 5 µM; C) 20 µM; D) 40 µM; E) 60 µM; F) 80 µM 









Figure A 7. Contour plots of fluorescence resulting from propidium iodide staining (FSC-H, Y-axis) and (FL1-A X-axis) after 3 h 
exposure to [Co(phen)2(MeATSC)](NO3)3·2.5H2O·C2H5OH. A) 0 µM; B) 5 µM; C) 20 µM; D) 40 µM; E) 60 µM; F) 80 µM 






Figure A 8. Determination of inhibition of autophagy after exposure to 
[Co(phen)2(MeATSC)](NO3)3·2.5H2O·C2H5OH and necrostatin-1 (600 µM). Plot of the mean 
fluorescent intensity vs [Complex]. Black drug treated cells, red positive control (starvation). Data 





















Table A 1. Injections parameter for Microcal ITC200 for Ethidium Bromide with CT DNA in PBS 
(pH = 7.0) for protocol optimization and instrument calibration.  









Total injections 40 Injection Volume Duration Spacing Filter 
Cell Temp. (°C) 25 1 0.4 0.8 280 2 
Reference Power (µcal/sec) 10 2 1 2 280 2 
Initial Delay (s) 60 3 1 2 280 2 
[Syringe] (mM) 1.1 … … … … 2 
[Cell] (mM) 0.102 39 1 2 280 2 







Table A 2. Injections parameter for Microcal ITC200 for [VO(phen)(sal-L-tryp)]·H2O with CT 
DNA in PBS (pH = 7.2). 
Experimental Parameters   Edit Mode 







Injection Volume Duration Spacing Filter 
Cell Temp. (°C) 25 1 0.4 0.8 180 2 
Reference Power (µcal/sec) 10 2 1 2 180 2 
Initial Delay (s) 60 3 1 2 180 2 
[Syringe] (mM) 0.1 … … … … … 
[Cell] (mM) 0.042 19 1 2 180 2 







Table A 3. Injections parameter for Microcal ITC200 for 
[Ru(pbt)2(phen2DTT)VO(oda)](PF6)2•2.0H2O•0.5C2H5OH with CT DNA in PBS (pH = 7.2). 
Experimental Parameters   Edit Mode 







Injection Volume Duration Spacing Filter 
Cell Temp. (°C) 25 1 0.4 0.8 280 2 
Reference Power (µcal/sec) 10 2 1 2 280 2 
Initial Delay (s) 60 3 1 2 280 2 
[Syringe] (mM) 0.1 … … … … … 
[Cell] (mM) 0.01 39 1 2 280 2 















Figure A 11. 13C NMR spectrum of N-[3,5-bis(trifluromethyl)phenyl]pyridine-2-















































Figure A 16. Separation process of [Co(phen)2(APTA)](PF6)3  as monitored by 














































Figure A 20. 1H NMR spectra of the species obtained during the separation process of [Ru(phen)2(PPTA)](PF6)2 all in DMSO-d6. F1 
represents the complex fraction and contains the desired [Ru(phen)2(PPTA)](PF6)2. F2 is a mixture of the metal complex 
[Ru(phen)2(PPTA)](PF6)2 and free ligand PPTA. F3 represents the third band collected and is labelled as the ligand fraction and contains 
















CRYSTALLOGRAPHIC STRUCTURAL DATA FOR N-[3,5-
BIS(TRIFLUROMETHYL)PHENYL]PYRIDINE-2-THIOCARBOXAMIDE 
Table A 4. Crystal data and structural refinement  
Empirical formula C14 H8 F6 N2 S 
Formula weight 350.28 
Temperature 293(2) K 
Wavelength 0.71073 A 
Crystal system space group Monoclinic,  C2/c 
Unit cell dimensions a = 14.326(3) A 
b = 8.5708(17) A                                             
c = 24.713(5) A 
beta = 103.10(3) deg. 
Volume 2955.4(10) A^3 
Z, Calculated density 8 , 1.575 Mg/m^3 
Absorption coefficient 0.283 mm^-1 
F(000) 1408 
Crystal size 0.50 x 0.33 x 0.26 mm 
Theta range for data collection 2.79 to 25.14 deg. 
Limiting indices -17<=h<=17, -9<=k<=10, -29<=l<=29 
  
Reflections collected / unique 11020 / 2619 [R(int) = 0.0276] 
  
Completeness to theta = 25.14 99.4 % 
  
Absorption correction Semi-empirical from equivalents 
  
Max. and min. transmission 1.0000 and 0.8638 
  
Refinement method Full-matrix least-squares on F^2 
  
Data / restraints / parameters 2619 / 0 / 236 
  
Goodness-of-fit on F^2 1.043 
  
Final R indices [I>2sigma(I)] R1 = 0.0576, wR2 = 0.1401 
  
R indices (all data) R1 = 0.0656, wR2 = 0.1478 
  
Extinction coefficient 0.0049(10) 
  






Table A 5. Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 
x 10^3) for c2c. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
 
 x y z U(eq) 
S(1) 3382(1) 6467(1) -246(1) 76(1) 
F(1) 4054(2) 9681(3) 1789(1) 146(1) 
F(2) 4512(2) 10194(2) 1068(1) 122(1) 
F(3) 5495(2) 10261(3) 1838(1) 145(1) 
F(4) 6509(9) 5318(16) 2810(3) 136(5) 
F(5) 6437(15) 3249(10) 2354(8) 187(8) 
N(1) 3879(2) 1977(3) -69(1) 70(1) 
N(2) 4285(2) 4442(3) 523(1) 61(1) 
C(1) 3664(3) 635(4) -339(1) 85(1) 
C(2) 3044(3) 532(4) -850(2) 84(1) 
C(3) 2636(2) 1857(4) -1096(1) 85(1) 
C(4) 2853(2) 3279(4) -824(1) 70(1) 
C(5) 3478(2) 3279(3) -311(1) 56(1) 
C(6) 3740(2) 4758(3) 17(1) 55(1) 
C(7) 4709(2) 5392(3) 976(1) 56(1) 
C(8) 4518(2) 6961(3) 1024(1) 62(1) 
C(9) 4988(2) 7784(3) 1491(1) 62(1) 
C(10) 5644(2) 7057(4) 1913(1) 67(1) 
C(11) 5816(2) 5490(4) 1865(1) 66(1) 
C(12) 5361(2) 4657(3) 1405(1) 63(1) 
C(13) 4773(3) 9466(4) 1543(1) 81(1) 
C(14) 6520(3) 4682(5) 2323(2) 95(1) 
F(6) 7408(5) 5000(20) 2279(5) 149(4) 
F(5A) 7083(11) 3740(20) 2130(4) 163(4) 
F(6A) 7043(16) 5473(11) 2676(9) 212(9) 


















































































































































   
Symmetry transformations used to generate equivalent atoms:  











Table A 7. Anisotropic displacement parameters (A^2 x 10^3) for c2c. The anisotropic 
displacement factor exponent takes the form: -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
 
 U11 U22 U33 U23 U13 U12 
       
S(1) 96(1) 61(1) 64(1) 3(1) -1(1) 17(1) 
F(1) 188(3) 117(2) 158(2) 3(2) 92(2) 57(2) 
F(2) 209(3) 70(1) 76(1) 6(1) 8(1) 35(1) 
F(3) 155(2) 81(2) 159(2) -34(2) -47(2) 9(1) 
F(4) 180(9) 162(11) 49(2) 18(3) -9(4) 74(9) 
F(5) 220(16) 67(3) 193(14) 21(7) -123(11) 0(8) 
N(1) 84(2) 54(1) 68(1) 6(1) 9(1) -5(1) 
N(2) 69(1) 54(1) 56(1) 4(1) 2(1) 4(1) 
C(1) 110(2) 57(2) 85(2) 2(2) 16(2) -12(2) 
C(2) 100(2) 72(2) 82(2) -13(2) 23(2) -19(2) 
C(3) 89(2) 94(2) 66(2) -15(2) 6(2) -14(2) 
C(4) 71(2) 74(2) 61(2) -2(1) 5(1) 3(1) 
C(5) 54(1) 60(2) 54(1) 3(1) 12(1) -2(1) 
C(6) 52(1) 60(2) 54(1) 2(1) 11(1) 2(1) 
C(7) 54(1) 63(2) 50(1) 4(1) 7(1) 2(1) 
C(8) 62(1) 65(2) 53(1) 3(1) 5(1) 9(1) 
C(9) 67(2) 65(2) 52(1) 1(1) 9(1) 5(1) 
C(10) 70(2) 75(2) 52(1) 2(1) 4(1) 1(1) 
C(11) 66(2) 72(2) 55(2) 13(1) 1(1) 2(1) 
C(12) 67(2) 59(2) 60(2) 10(1) 7(1) 4(1) 
C(13) 99(2) 76(2) 59(2) -9(1) 2(2) 14(2) 
C(14) 97(3) 91(3) 79(2) 12(2) -16(2) 16(2) 
F(6) 75(3) 224(12) 127(6) 27(7) -17(4) 34(5) 
F(5A) 137(8) 190(11) 140(6) 36(8) -17(6) 80(8) 
F(6A) 226(15) 97(5) 213(15) 5(9) -159(12) -12(9) 







Table A 8. Hydrogen coordinates ( x 10^4) and isotropic displacement parameters (A^2 x 10^3) 
for c2c. 
     
 x y z U(eq) 
H(2A) 4397 3463 582 74 
H(1B) 3947 -276 -174 101 
H(2B) 2905 -429 -1025 101 
H(3A) 2215 1816 -1443 102 
H(4A) 2584 4203 -985 84 
H(8A) 4076 7464 745 74 
H(10A) 5963 7617 2222 81 
H(12A) 5489 3599 1380 76 
 












































































































































   







CRYSTALLOGRAPHIC STRUCTURAL DATA FOR [VO(ODA)(PHEN)]·1.5H2O 
   
Table A 10. Crystal data and structural refinement for [VO(oda)(phen)]·1.5H2O 
Identification code c2 
Empirical formula C16 H15 N2 O7.50 V 
Formula weight 406.24 
Temperature 293(2) K 
Wavelength 0.71073 A 
Crystal system space group Monoclinic,  C2/m 
Unit cell dimensions a = 18.214(4) A 
b = 12.857(3) A                                             
c = 7.1924(14) A 
beta = 90.10(3) deg. 
Volume 1684.3(6) A^3 
Z Calculated density 4,  1.602 Mg/m^3 
Absorption coefficient 0.636 mm^-1 
F(000) 832 
Crystal size 0.31 x 0.04 x 0.04 mm 
Theta range for data collection 3.17 to 25.02 deg. 
Limiting indices -21<=h<=21, -15<=k<=15, -8<=l<=7 
  
Reflections collected / unique 7112 / 1572 [R(int) = 0.0595] 
  
Completeness to theta = 25.02 99.7 % 
  
Max. and min. transmission 0.9750 and 0.8273 
  
Refinement method Full-matrix least-squares on F^2 
  
Data / restraints / parameters 1572 / 0 / 129 
  
Goodness-of-fit on F^2 1.036 
  
Final R indices [I>2sigma(I)] R1 = 0.0787, wR2 = 0.1588 
  
R indices (all data) R1 = 0.1055, wR2 = 0.1882 
  
Extinction coefficient 0.0039(9) 
  
Largest diff. peak and hole 0.456 and -0.751 e.A^-3 





Table A 11. Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters (A^2 
x 10^3) for c2. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor 
 x y z U(eq) 
V(1) 2275(1) 0 4058(3) 59(1) 
O(3) 2319(4) 0 860(10) 47(2) 
O(2) 2993(3) -1105(5) 3502(10) 66(2) 
O(1) 2309(6) 0 6307(12) 95(3) 
O(4) 3461(4) -2236(5) 1424(12) 93(3) 
N(1) 1399(3) 1043(6) 3492(10) 58(2) 
C(1) 1401(5) 2072(8) 3601(15) 75(3) 
C(2) 785(5) 2682(8) 3149(16) 79(3) 
C(3) 141(4) 2194(7) 2685(14) 73(3) 
C(4) 115(4) 1099(6) 2586(12) 53(2) 
C(5) 755(4) 553(7) 2992(11) 53(2) 
C(6) -539(4) 529(7) 2094(14) 69(3) 
C(7) 3080(4) -1461(7) 1798(14) 59(2) 
C(8) 2664(5) -946(6) 233(13) 63(2) 
O(7W) 422(6) 5000 6580(20) 120(5) 






























































































Table A 13. Anisotropic displacement parameters (A^2 x 10^3) for c2. The anisotropic 
displacement factor exponent takes the form: -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
 
 U11 U22 U33 U23 U13 U12 
V(1) 37(1) 80(1) 61(1) 0 -7(1) 0 
O(3) 44(4) 32(3) 63(4) 0 11(5) 0 
O(2) 41(3) 70(4) 87(5) 20(4) -9(3) 7(3) 
O(1) 71(6) 170(11) 44(5) 0 -13(5) 0 
O(4) 77(4) 73(4) 128(7) -23(4) -31(5) 36(4) 
N(1) 40(3) 71(5) 63(5) -17(4) -4(3) 7(3) 
C(1) 53(5) 76(6) 95(8) -31(6) -6(5) 0(5) 
C(2) 68(6) 67(6) 101(8) -28(6) -5(5) 17(5) 
C(3) 53(5) 85(6) 80(6) -12(6) 12(5) 26(5) 
C(4) 32(3) 78(5) 49(4) -4(5) 6(4) 7(3) 
C(5) 34(3) 75(5) 51(5) -2(4) 1(3) 3(4) 
C(6) 33(3) 101(7) 72(6) 3(5) 13(4) 11(4) 
C(7) 42(4) 56(5) 78(6) -1(4) -13(4) -3(4) 
C(8) 66(5) 45(4) 77(6) -11(4) 1(5) 17(4) 






























Table A 14. Hydrogen coordinates ( x 10^4) and isotropic displacement parameters (A^2 x 10^3) 
for c2. 
 x y z U(eq) 
H(1) 1828 2405 3991 90 
H(2) 813 3404 3165 94 
H(3) -278 2584 2436 87 
H(6) -964 887 1775 83 
H(8A) 3000 -789 -775 75 
H(8B) 2293 -1419 -236 75 
H(7W) 38 4435 6225 215 
H(8W) 292 4374 9995 200 
 


























































   











CRYSTALLOGRAPHIC STRUCTURAL DATA FOR [Co(PHEN)3]2+ OBTAINED 
FROM ATTEMPTED CRYSTALLIZATION OF [Co(PHEN)2(APTA)](PF6)3 
Table A 16. Crystal data and structural refinement for [Co(phen)3]
2+ 
Empirical formula C40 H30 Co F12 N8 P2 
Formula weight 971.59 
Temperature 293(2) K 
Wavelength 0.71073 A 
Crystal system space group Triclinic  P-1 
Unit cell dimensions a = 13.019(3) A 
b = 13.276(3) A 
c = 14.573(3) A 
alpha = 69.16(3) deg. 
beta = 70.78(3) deg. 
gamma = 68.86(3) deg. 
Volume 2136.3(7) A^3 
Z, Calculated density 2,  1.510 Mg/m^3 
Absorption coefficient 0.570 mm^-1 
F(000) 982 
Crystal size 0.43 x 0.32 x 0.24 mm 
Theta range for data collection 1.72 to 25.15 deg. 
Limiting indices -15<=h<=15, -15<=k<=14, -17<=l<=15 
Reflections collected / unique 18249 / 7578 [R(int) = 0.0374] 
Completeness to theta = 25.15 99.0 % 
  
Max. and min. transmission 0.8754 and 0.7918 
  
Refinement method Full-matrix least-squares on F^2 
  
Data / restraints / parameters 7578 / 0 / 515 
  
Goodness-of-fit on F^2 1.174 
  
Final R indices [I>2sigma(I)] R1 = 0.1072, wR2 = 0.2604 
  
R indices (all data) R1 = 0.1291, wR2 = 0.2782 
  
Extinction coefficient 0.0034(15) 
  
Largest diff. peak and hole 1.192 and -0.717 e.A^-3 
 2 highly disordered MeCN molecules per formula unit modeled by SQUEEZE, corresponding to 
88 electrons per unit cell.  PLATON identified 87 electrons located in solvent accessible voids in 





Table A 17. Atomic coordinates ( x 10^4) and equivalent isotropic displacement parameters 
(A^2 x 10^3) for p-1_sqd. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor.  
   
 x y z U(eq) 
Co(1) 3099(1) 3081(1) 3020(1) 57(1) 
N(1) 4236(4) 4062(4) 2099(4) 59(1) 
N(2) 4109(4) 2145(4) 1968(4) 59(1) 
N(3) 4125(4) 2159(4) 4091(4) 59(1) 
N(4) 2195(4) 1911(4) 4015(4) 56(1) 
N(5) 2110(4) 4272(4) 3874(4) 67(1) 
N(6) 1862(4) 4102(4) 2172(4) 63(1) 
C(1) 4276(6) 5028(5) 2153(5) 71(2) 
C(2) 5120(6) 5541(6) 1555(6) 76(2) 
C(3) 5974(7) 5024(7) 890(6) 84(2) 
C(4) 5972(5) 4010(6) 784(5) 69(2) 
C(5) 5075(5) 3573(5) 1410(4) 58(1) 
C(6) 6809(6) 3435(7) 91(6) 84(2) 
C(7) 6746(6) 2472(7) 31(6) 81(2) 
C(8) 5841(6) 1992(6) 635(5) 69(2) 
C(9) 5010(5) 2535(5) 1333(5) 59(1) 
C(10) 5713(6) 1021(6) 566(6) 78(2) 
C(11) 4813(7) 641(6) 1174(6) 81(2) 
C(12) 4032(6) 1206(5) 1882(5) 65(2) 
C(13) 5085(5) 2270(6) 4132(6) 70(2) 
C(14) 5594(6) 1737(6) 4946(6) 77(2) 
C(15) 5067(6) 1057(6) 5769(6) 79(2) 
C(16) 4052(6) 897(5) 5778(5) 68(2) 
C(17) 3620(5) 1459(5) 4915(4) 57(1) 
C(18) 3447(7) 185(6) 6619(5) 82(2) 
C(19) 2482(7) 46(6) 6561(5) 79(2) 
C(20) 2039(6) 609(5) 5687(5) 65(2) 
C(21) 2584(5) 1317(5) 4866(4) 54(1) 
C(22) 1024(6) 520(6) 5601(6) 72(2) 
C(23) 655(6) 1096(6) 4757(6) 72(2) 
C(24) 1249(5) 1796(5) 3968(5) 64(2) 
C(25) 2214(7) 4358(7) 4718(6) 85(2) 
C(26) 1605(9) 5240(9) 5140(8) 111(3) 
C(27) 865(10) 6091(9) 4655(10) 125(4) 
C(28) 684(7) 6071(6) 3771(9) 100(3) 
C(29) 1331(5) 5121(5) 3404(6) 74(2) 
C(30) 1202(5) 5040(5) 2488(6) 75(2) 





C(32) 370(8) 5759(9) 1069(9) 119(4) 
C(33) 995(8) 4838(9) 769(7) 103(3) 
C(34) 1751(6) 3996(7) 1326(6) 81(2) 
P(1) 2660(2) 8449(2) 2830(2) 84(1) 
F(1) 2558(13) 7667(11) 3898(8) 271(7) 
F(2) 2744(9) 9275(9) 1789(6) 220(5) 
F(3) 2786(11) 7476(10) 2506(10) 272(6) 
F(4) 3880(8) 8290(11) 2705(12) 286(7) 
F(5) 2556(14) 9415(10) 3206(9) 293(8) 
F(6) 1430(6) 8658(9) 3069(10) 253(6) 
P(2) 8402(2) 3233(2) 2606(2) 83(1) 
F(7) 9104(8) 3677(7) 2950(7) 180(3) 
F(8) 7680(16) 3162(17) 3532(13) 427(14) 
F(10) 9084(12) 2062(7) 2906(10) 260(6) 
F(12) 9067(16) 3410(13) 1590(8) 341(10) 
F(9) 7676(12) 2753(10) 2345(11) 286(7) 
C(35) -204(9) 6843(9) 2352(12) 126(5) 
C(36) -91(9) 6939(8) 3137(13) 132(5) 
F(11) 7851(15) 4429(9) 2196(17) 359(11) 
































































































































































































































































































   
Symmetry transformations used to generate equivalent atoms:  














Table A 19. Anisotropic displacement parameters (A^2 x 10^3) for p-1_sqd. The anisotropic 
displacement factor exponent takes the form: -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
 
 U11 U22 U33 U23 U13 U12 
Co(1) 52(1) 55(1) 60(1) -13(1) -12(1) -15(1) 
N(1) 61(3) 55(3) 62(3) -12(2) -14(2) -20(2) 
N(2) 53(3) 61(3) 61(3) -12(2) -13(2) -18(2) 
N(3) 54(3) 59(3) 66(3) -16(2) -15(2) -16(2) 
N(4) 52(3) 55(3) 61(3) -18(2) -11(2) -16(2) 
N(5) 60(3) 67(3) 69(3) -24(3) -4(2) -17(2) 
N(6) 56(3) 63(3) 69(3) -2(2) -20(2) -24(2) 
C(1) 70(4) 60(4) 81(4) -17(3) -15(3) -22(3) 
C(2) 81(5) 67(4) 85(5) -3(4) -23(4) -39(4) 
C(3) 74(5) 88(5) 97(5) -7(4) -20(4) -47(4) 
C(4) 57(4) 76(4) 70(4) -9(3) -15(3) -23(3) 
C(5) 49(3) 63(3) 60(3) -7(3) -19(3) -18(3) 
C(6) 58(4) 111(6) 77(5) -19(4) 1(3) -38(4) 
C(7) 62(4) 104(6) 76(5) -34(4) 0(3) -26(4) 
C(8) 62(4) 74(4) 65(4) -20(3) -10(3) -14(3) 
C(9) 52(3) 64(3) 59(3) -14(3) -16(3) -12(3) 
C(10) 74(4) 84(5) 77(5) -39(4) -12(4) -11(4) 
C(11) 94(5) 74(4) 77(5) -30(4) -9(4) -25(4) 
C(12) 72(4) 63(4) 66(4) -21(3) -18(3) -21(3) 
C(13) 56(3) 72(4) 87(5) -21(3) -20(3) -20(3) 
C(14) 64(4) 92(5) 81(5) -23(4) -28(3) -17(4) 
C(15) 75(4) 83(5) 84(5) -24(4) -38(4) -9(4) 
C(16) 76(4) 60(3) 67(4) -18(3) -27(3) -8(3) 
C(17) 54(3) 56(3) 59(3) -20(3) -13(3) -7(3) 
C(18) 97(5) 76(4) 64(4) -10(3) -28(4) -14(4) 
C(19) 89(5) 76(4) 63(4) -7(3) -16(4) -28(4) 
C(20) 72(4) 53(3) 63(4) -18(3) -5(3) -16(3) 
C(21) 50(3) 51(3) 58(3) -20(3) -8(2) -10(2) 
C(22) 71(4) 66(4) 79(4) -19(3) -4(3) -31(3) 
C(23) 64(4) 76(4) 89(5) -26(4) -12(3) -34(3) 
C(24) 58(3) 65(4) 72(4) -18(3) -18(3) -21(3) 
C(25) 96(5) 86(5) 79(5) -33(4) -4(4) -36(4) 
C(26) 120(8) 94(6) 123(8) -66(6) 22(6) -43(6) 
C(27) 117(8) 100(7) 170(11) -94(8) 42(8) -53(6) 
C(28) 67(5) 54(4) 153(9) -31(5) 9(5) -14(3) 
C(29) 56(4) 58(4) 97(5) -21(3) 2(3) -22(3) 
C(30) 51(3) 56(4) 99(5) 2(3) -11(3) -20(3) 
C(31) 61(4) 69(5) 140(8) 18(5) -35(5) -21(4) 
C(32) 79(6) 107(7) 136(9) 47(7) -55(6) -39(5) 





C(34) 74(4) 91(5) 76(5) 7(4) -26(4) -42(4) 
P(1) 82(1) 93(1) 87(1) -30(1) -5(1) -41(1) 
F(1) 397(17) 282(12) 173(9) 87(9) -125(10) -232(13) 
F(2) 255(10) 288(11) 115(6) 53(7) -59(6) -162(9) 
F(3) 320(14) 238(10) 325(14) -210(11) 58(11) -140(10) 
F(4) 136(7) 281(13) 412(18) 21(13) -110(10) -95(8) 
F(5) 423(19) 248(11) 279(13) -171(10) 93(12) -232(13) 
F(6) 76(4) 224(9) 374(15) -29(10) 4(6) -45(5) 
P(2) 80(1) 84(1) 87(1) -8(1) -30(1) -31(1) 
F(7) 205(8) 196(7) 213(8) -75(6) -101(7) -70(6) 
F(8) 470(20) 500(30) 370(18) -302(19) 324(18) -390(20) 
F(10) 355(15) 111(5) 345(15) -42(7) -243(13) 29(7) 
F(12) 550(20) 319(16) 157(8) -114(9) 169(12) -299(18) 
F(9) 348(15) 279(12) 366(15) 13(11) -240(14) -195(12) 
C(35) 85(7) 77(6) 195(14) -6(7) -51(8) -11(5) 
C(36) 73(6) 60(5) 221(15) -36(8) 6(8) -11(4) 







Table A 20. Hydrogen coordinates ( x 10^4) and isotropic displacement parameters (A^2 x 10^3) 
for p-1_sqd.   
 x y z U(eq) 
H(1A) 3707 5376 2616 85 
H(2A) 5105 6225 1606 92 
H(3A) 6564 5343 503 101 
H(6A) 7407 3727 -327 101 
H(7A) 7315 2106 -421 97 
H(10A) 6241 639 107 93 
H(11A) 4713 6 1122 97 
H(12A) 3437 915 2309 77 
H(13A) 5441 2740 3573 84 
H(14A) 6269 1840 4931 92 
H(15A) 5381 695 6329 95 
H(18A) 3717 -181 7203 99 
H(19A) 2110 -425 7103 94 
H(22A) 619 64 6128 86 
H(23A) -5 1031 4692 87 
H(24A) 969 2193 3392 76 
H(25A) 2738 3778 5049 102 
H(26A) 1704 5244 5741 133 
H(27A) 465 6707 4914 150 
H(32A) -118 6319 686 142 
H(33A) 928 4753 187 124 
H(34A) 2182 3357 1109 97 
H(35) -727 7413 2013 152 






















Table A 21. Torsion angles [deg] for p-1_sqd.   
 
N(2)-Co(1)-N(1)-C(1)                                178.0(6)  
N(4)-Co(1)-N(1)-C(1)                               -113.2(12)  
N(6)-Co(1)-N(1)-C(1)                                 82.3(6)  
N(3)-Co(1)-N(1)-C(1)                                -88.5(6)  
N(5)-Co(1)-N(1)-C(1)                                  3.7(6)  
N(2)-Co(1)-N(1)-C(5)                                 -6.7(4)  
N(4)-Co(1)-N(1)-C(5)                                 62.0(13)  
N(6)-Co(1)-N(1)-C(5)                               -102.5(4)  
N(3)-Co(1)-N(1)-C(5)                                 86.7(4)  
N(5)-Co(1)-N(1)-C(5)                                178.9(4)  
N(4)-Co(1)-N(2)-C(12)                                10.5(5)  
N(6)-Co(1)-N(2)-C(12)                               -87.9(5)  
N(1)-Co(1)-N(2)-C(12)                              -178.1(5)  
N(3)-Co(1)-N(2)-C(12)                                89.4(5)  
N(5)-Co(1)-N(2)-C(12)                              -142.6(11)  
N(4)-Co(1)-N(2)-C(9)                               -164.9(4)  
N(6)-Co(1)-N(2)-C(9)                                 96.7(4)  
N(1)-Co(1)-N(2)-C(9)                                  6.6(4)  
N(3)-Co(1)-N(2)-C(9)                                -85.9(4)  
N(5)-Co(1)-N(2)-C(9)                                 42.1(13)  
N(2)-Co(1)-N(3)-C(13)                                82.1(6)  
N(4)-Co(1)-N(3)-C(13)                               179.5(6)  
N(6)-Co(1)-N(3)-C(13)                              -112.8(11)  
N(1)-Co(1)-N(3)-C(13)                                 3.4(6)  
N(5)-Co(1)-N(3)-C(13)                               -90.2(6)  
N(2)-Co(1)-N(3)-C(17)                              -107.3(4)  
N(4)-Co(1)-N(3)-C(17)                                -9.9(4)  
N(6)-Co(1)-N(3)-C(17)                                57.8(12)  
N(1)-Co(1)-N(3)-C(17)                               174.0(4)  
N(5)-Co(1)-N(3)-C(17)                                80.4(4)  
N(2)-Co(1)-N(4)-C(24)                               -87.3(5)  
N(6)-Co(1)-N(4)-C(24)                                 9.8(5)  
N(1)-Co(1)-N(4)-C(24)                              -154.5(11)  
N(3)-Co(1)-N(4)-C(24)                              -179.8(5)  
N(5)-Co(1)-N(4)-C(24)                                88.3(5)  
N(2)-Co(1)-N(4)-C(21)                               101.8(4)  
N(6)-Co(1)-N(4)-C(21)                              -161.2(4)  
N(1)-Co(1)-N(4)-C(21)                                34.5(14)  
N(3)-Co(1)-N(4)-C(21)                                 9.3(4)  
N(5)-Co(1)-N(4)-C(21)                               -82.6(4)  
N(2)-Co(1)-N(5)-C(25)                              -125.0(11)  
N(4)-Co(1)-N(5)-C(25)                                81.6(6)  
N(6)-Co(1)-N(5)-C(25)                               179.1(6)  





N(3)-Co(1)-N(5)-C(25)                                 3.1(6)  
N(2)-Co(1)-N(5)-C(29)                                47.9(13)  
N(4)-Co(1)-N(5)-C(29)                              -105.4(4)  
N(6)-Co(1)-N(5)-C(29)                                -7.9(4)  
N(1)-Co(1)-N(5)-C(29)                                82.7(4)  
N(3)-Co(1)-N(5)-C(29)                               176.1(4)  
N(2)-Co(1)-N(6)-C(34)                                 8.5(5)  
N(4)-Co(1)-N(6)-C(34)                               -90.4(5)  
N(1)-Co(1)-N(6)-C(34)                                87.1(5)  
N(3)-Co(1)-N(6)-C(34)                              -156.5(9)  
N(5)-Co(1)-N(6)-C(34)                              -179.6(5)  
N(2)-Co(1)-N(6)-C(30)                              -163.4(4)  
N(4)-Co(1)-N(6)-C(30)                                97.7(4)  
N(1)-Co(1)-N(6)-C(30)                               -84.8(4)  
N(3)-Co(1)-N(6)-C(30)                                31.6(12)  
N(5)-Co(1)-N(6)-C(30)                                 8.5(4)  
C(5)-N(1)-C(1)-C(2)                                  -0.4(10)  
Co(1)-N(1)-C(1)-C(2)                                174.6(5)  
N(1)-C(1)-C(2)-C(3)                                  -1.6(11)  
C(1)-C(2)-C(3)-C(4)                                   2.6(11)  
C(2)-C(3)-C(4)-C(5)                                  -1.7(10)  
C(2)-C(3)-C(4)-C(6)                                 178.1(7)  
C(1)-N(1)-C(5)-C(4)                                   1.5(9)  
Co(1)-N(1)-C(5)-C(4)                               -174.4(5)  
C(1)-N(1)-C(5)-C(9)                                -178.2(5)  
Co(1)-N(1)-C(5)-C(9)                                  6.0(6)  
C(3)-C(4)-C(5)-N(1)                                  -0.4(9)  
C(6)-C(4)-C(5)-N(1)                                 179.8(6)  
C(3)-C(4)-C(5)-C(9)                                 179.2(6)  
C(6)-C(4)-C(5)-C(9)                                  -0.6(9)  
C(5)-C(4)-C(6)-C(7)                                   0.0(11)  
C(3)-C(4)-C(6)-C(7)                                -179.7(7)  
C(4)-C(6)-C(7)-C(8)                                   1.2(12)  
C(6)-C(7)-C(8)-C(10)                                177.0(7)  
C(6)-C(7)-C(8)-C(9)                                  -1.9(11)  
C(12)-N(2)-C(9)-C(8)                                 -1.4(9)  
Co(1)-N(2)-C(9)-C(8)                                174.6(5)  
C(12)-N(2)-C(9)-C(5)                                178.5(5)  
Co(1)-N(2)-C(9)-C(5)                                 -5.5(6)  
C(10)-C(8)-C(9)-N(2)                                  2.2(10)  
C(7)-C(8)-C(9)-N(2)                                -178.8(6)  
C(10)-C(8)-C(9)-C(5)                               -177.7(6)  
C(7)-C(8)-C(9)-C(5)                                   1.3(9)  
N(1)-C(5)-C(9)-N(2)                                  -0.3(8)  
C(4)-C(5)-C(9)-N(2)                                180.0(5)  





C(4)-C(5)-C(9)-C(8)                                  -0.1(9)  
C(9)-C(8)-C(10)-C(11)                                -0.7(11)  
C(7)-C(8)-C(10)-C(11)                              -179.6(7)  
C(8)-C(10)-C(11)-C(12)                               -1.5(12)  
C(9)-N(2)-C(12)-C(11)                                -0.9(9)  
Co(1)-N(2)-C(12)-C(11)                             -176.2(5)  
C(10)-C(11)-C(12)-N(2)                                2.4(11)  
C(17)-N(3)-C(13)-C(14)                               -0.6(10)  
Co(1)-N(3)-C(13)-C(14)                              169.8(5)  
N(3)-C(13)-C(14)-C(15)                               -0.6(11)  
C(13)-C(14)-C(15)-C(16)                               0.8(11)  
C(14)-C(15)-C(16)-C(17)                               0.1(10)  
C(14)-C(15)-C(16)-C(18)                             179.7(7)  
C(13)-N(3)-C(17)-C(16)                                1.6(9)  
Co(1)-N(3)-C(17)-C(16)                             -170.4(5)  
C(13)-N(3)-C(17)-C(21)                             -178.8(5)  
Co(1)-N(3)-C(17)-C(21)                                9.2(6)  
C(15)-C(16)-C(17)-N(3)                               -1.4(9)  
C(18)-C(16)-C(17)-N(3)                              179.0(6)  
C(15)-C(16)-C(17)-C(21)                             179.0(6)  
C(18)-C(16)-C(17)-C(21)                              -0.5(9)  
C(17)-C(16)-C(18)-C(19)                               1.4(10)  
C(15)-C(16)-C(18)-C(19)                            -178.1(7)  
C(16)-C(18)-C(19)-C(20)                              -1.2(11)  
C(18)-C(19)-C(20)-C(21)                               0.1(11)  
C(18)-C(19)-C(20)-C(22)                            -178.1(7)  
C(24)-N(4)-C(21)-C(20)                               -0.7(8)  
Co(1)-N(4)-C(21)-C(20)                              171.3(4)  
C(24)-N(4)-C(21)-C(17)                             -179.4(5)  
Co(1)-N(4)-C(21)-C(17)                               -7.4(6)  
C(22)-C(20)-C(21)-N(4)                                0.3(9)  
C(19)-C(20)-C(21)-N(4)                             -178.0(6)  
C(22)-C(20)-C(21)-C(17)                             179.0(5)  
C(19)-C(20)-C(21)-C(17)                               0.8(9)  
N(3)-C(17)-C(21)-N(4)                                -1.3(8)  
C(16)-C(17)-C(21)-N(4)                              178.3(5)  
N(3)-C(17)-C(21)-C(20)                              179.9(5)  
C(16)-C(17)-C(21)-C(20)                              -0.5(8)  
C(21)-C(20)-C(22)-C(23)                               0.5(9)  
C(19)-C(20)-C(22)-C(23)                             178.8(7)  
C(20)-C(22)-C(23)-C(24)                              -1.0(10)  
C(21)-N(4)-C(24)-C(23)                                0.2(9)  
Co(1)-N(4)-C(24)-C(23)                             -170.4(5)  
C(22)-C(23)-C(24)-N(4)                                0.6(10)  
C(29)-N(5)-C(25)-C(26)                               -0.7(11)  





N(5)-C(25)-C(26)-C(27)                               -1.4(14)  
C(25)-C(26)-C(27)-C(28)                               2.3(14)  
C(26)-C(27)-C(28)-C(29)                              -1.1(13)  
C(26)-C(27)-C(28)-C(36)                            -179.5(9)  
C(25)-N(5)-C(29)-C(28)                                1.9(10)  
Co(1)-N(5)-C(29)-C(28)                             -172.0(5)  
C(25)-N(5)-C(29)-C(30)                             -179.7(6)  
Co(1)-N(5)-C(29)-C(30)                                6.3(7)  
C(27)-C(28)-C(29)-N(5)                               -1.1(11)  
C(36)-C(28)-C(29)-N(5)                              177.5(7)  
C(27)-C(28)-C(29)-C(30)                            -179.4(7)  
C(36)-C(28)-C(29)-C(30)                              -0.8(10)  
C(34)-N(6)-C(30)-C(31)                               -1.2(9)  
Co(1)-N(6)-C(30)-C(31)                              171.6(5)  
C(34)-N(6)-C(30)-C(29)                              179.2(6)  
Co(1)-N(6)-C(30)-C(29)                               -8.0(7)  
N(5)-C(29)-C(30)-N(6)                                 1.1(9)  
C(28)-C(29)-C(30)-N(6)                              179.5(6)  
N(5)-C(29)-C(30)-C(31)                             -178.5(6)  
C(28)-C(29)-C(30)-C(31)                              -0.1(10)  
N(6)-C(30)-C(31)-C(32)                               -0.1(10)  
C(29)-C(30)-C(31)-C(32)                             179.4(7)  
N(6)-C(30)-C(31)-C(35)                             -179.6(7)  
C(29)-C(30)-C(31)-C(35)                               0.0(11)  
C(30)-C(31)-C(32)-C(33)                               1.4(12)  
C(35)-C(31)-C(32)-C(33)                            -179.2(9)  
C(31)-C(32)-C(33)-C(34)                              -1.3(13)  
C(30)-N(6)-C(34)-C(33)                                1.3(9)  
Co(1)-N(6)-C(34)-C(33)                             -170.2(5)  
C(32)-C(33)-C(34)-N(6)                                0.0(12)  
C(30)-C(31)-C(35)-C(36)                               1.2(17)  
C(32)-C(31)-C(35)-C(36)                            -178.1(11)  
C(31)-C(35)-C(36)-C(28)                              -2(2)  
C(27)-C(28)-C(36)-C(35)                            -179.5(12)  
C(29)-C(28)-C(36)-C(35)                               2.1(16)  
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